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A B S T R A C T
Background
Psoriasis is a common skin disease that can also involve the nails. All parts of the nail and surrounding structures can become affected.
The incidence of nail involvement increases with duration of psoriasis. Although it is difficult to treat psoriatic nails, the condition may
respond to therapy.
Objectives
To assess evidence for the efficacy and safety of the treatments for nail psoriasis.
Search methods
We searched the following databases up to March 2012: the Cochrane Skin Group Specialised Register, CENTRAL in The Cochrane
Library, MEDLINE (from 1946), EMBASE (from 1974), and LILACS (from 1982). We also searched trials databases and checked
the reference lists of retrieved studies for further references to relevant randomised controlled trials (RCTs).
Selection criteria
All RCTs of any design concerning interventions for nail psoriasis.
Data collection and analysis
Two authors independently assessed trial risk of bias and extracted the data. We collected adverse effects from the included studies.
Main results
We included 18 studies involving 1266 participants. We were not able to pool due to the heterogeneity of many of the studies.
Our primary outcomes were ’Global improvement of nail psoriasis as rated by a clinician’, ’Improvement of nail psoriasis scores (NAS,
NAPSI)’, ’Improvement of nail psoriasis in the participant’s opinion’. Our secondary outcomes were ’Adverse effects (and serious adverse
effects)’; ’Effects on quality of life’; and ’Improvement in nail features, pain score, nail thickness, thickness of subungual hyperkeratosis,
number of affected nails, and nail growth’. We assessed short-term (3 to 6 months), medium-term (6 to 12 months), and long-term (>
12 months) treatments separately if possible.
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Two systemic biologic studies and three radiotherapy studies reported significant results for our first two primary outcomes. Infliximab
5 mg/kg showed 57.2% nail score improvement versus -4.1% for placebo (P < 0.001); golimumab 50 mg and 100 mg showed 33%
and 54% improvement, respectively, versus 0% for placebo (P < 0.001), both after medium-term treatment. Infliximab and golimumab
also showed significant results after short-term treatment. From the 3 radiotherapy studies, only the superficial radiotherapy (SRT)
study showed 20% versus 0% nail score improvement (P = 0.03) after short-term treatment.
Studies with ciclosporin, methotrexate, and ustekinumab were not significantly better than their respective comparators: etretinate,
ciclosporin, and placebo. Nor were studies with topical interventions (5-fluorouracil 1% in Belanyx® lotion, tazarotene 0.1% cream,
calcipotriol 50 ug/g, calcipotriol 0.005%) better than their respective comparators: Belanyx® lotion, clobetasol propionate, betametha-
sone dipropionate with salicylic acid, or betamethasone dipropionate.
Of our secondary outcomes, not all included studies reported adverse events; those that did only reported mild adverse effects, and
there were more in studies with systemic interventions. Only one study reported the effect on quality of life, and two studies reported
nail improvement only per feature.
Authors’ conclusions
Infliximab, golimumab, SRT, grenz rays, and electron beam caused significant nail improvement compared to the comparative treatment.
Although the quality of trials was generally poor, this review may have some implications for clinical practice.
Although powerful systemic treatments have been shown to be beneficial, they may have serious adverse effects. So they are not a
realistic option for people troubled with nail psoriasis, unless the patient is prescribed these systemic treatments because of cutaneous
psoriasis or psoriatic arthritis or the nail psoriasis is severe, refractory to other treatments, or has a major impact on the person’s quality
of life. Because of their design and timescale, RCTs generally do not pick up serious side-effects. This review reported only mild adverse
effects, recorded mainly for systemic treatments. Radiotherapy for psoriasis is not used in common practice. The evidence for the use
of topical treatments is inconclusive and of poor quality; however, this does not imply that they do not work.
Future trials need to be rigorous in design, with adequate reporting. Trials should correctly describe the participants’ characteristics and
diagnostic features, use standard validated nail scores and participant-reported outcomes, be long enough to report efficacy and safety,
and include details of effects on nail features.
P L A I N L A N G U A G E S U M M A R Y
Treatments for nail psoriasis
Psoriasis is a common chronic skin disease with a prevalence in 2% to 3%of the population, according to European studies. Involvement
of the nails occurs in about 50%. Nail psoriasis is difficult to treat, but may respond to some treatments. We aimed to review the
efficacy and safety of the treatments used for nail psoriasis.
We included 18 randomised controlled clinical trials (RCTs), which involved 1266 participants and were mostly based on a single study
per treatment. Ten studies assessed topical treatments, i.e. applied to the surface of the skin (clobetasol, ciclosporin inmaize oil, hyaluronic
acid with chondroitin sulphates, 5-fluorouracil, a combination of dithranol with salicylic and UVB, tazarotene, and calcipotriol); 5
studies assessed systemic treatments, i.e. taken orally (golimumab, infliximab, ustekinumab, ciclosporin, and methotrexate); and 3
studies assessed radiotherapy (electron beam, grenz ray, and superficial radiotherapy). With regard to other treatments that are used for
nail psoriasis, no RCTs had been carried out.
It was not possible to pool and compare the results because the studies were all so different.
In 5 studies, we found significant improvement of nail psoriasis compared to placebo: with infliximab (5 mg/kg), golimumab (50 mg
and 100 mg), superficial radiotherapy, electron beam, and grenz rays.
Although powerful systemic treatments have been shown to be beneficial, they may have serious adverse effects. So they are not a
realistic option for people troubled with nail psoriasis, unless the patient is a candidate for these systemic treatments because of skin
psoriasis or psoriatic arthritis. Because of their design and timescale, RCTs generally do not pick up serious side-effects. This review
reported only mild adverse effects, recorded mainly for systemic treatments.
Radiotherapy for psoriasis is not used in common practice. The evidence for the use of topical treatments is inconclusive and of poor
quality; however, this does not imply that they do not work. Topical treatment options could be beneficial and need to be further
investigated.
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Clinical trials on nail psoriasis need to be rigorous in design, with clear reporting to enable readers to better interpret the results. Trials
should accurately describe the participants’ characteristics and diagnostic features of nail psoriasis; use standard validated nail scores
and patient-reported outcomes; be long enough to report efficacy and safety; and include more details of effects on nail features.
B A C K G R O U N D
Description of the condition
Psoriasis is a common chronic skin disease with a prevalence in
2% to 3% of the population, according to population-based Eu-
ropean studies (Schafer 2006). The disease of the skin and joints
is an autoimmune disorder mediated by T-cell interactions with
keratinocytes and other skin cells; this condition can also include
nail involvement, ranging from mild to severe. There is a sub-
group of people who have only nail psoriasis or whose nail psori-
asis is the main manifestation that drives them to seek treatment.
Of those with psoriasis, 40% were found to have nail psoriasis
when questioned (van de Kerkhof 1998). Salomon et al examined
106 individuals with psoriasis in which nail changes were present
in about 78%. Men and women were equally affected (Salomon
2003; Tham 1988). There is a higher prevalence of nail psoriasis
in those with psoriatic arthritis (Sadek 2007), a type of inflamma-
tory arthritis that affects around 10% to 30% of people suffering
from psoriasis. The incidence of nail involvement increases with
duration of psoriasis (de Jong 1996).
Some details about the cause(s) and pathogenesis of psoriasis and
psoriatic nails are known. A major susceptibility gene is known,
located in the major histocompatibility complex class I region
on chromosome six near to the HLA-Cw6 gene. People with the
HLA-Cw*0602positive gene have a higher incidence of the guttate
type and the eruptive type of psoriasis, a younger age of onset,
more exacerbations with throat infections, higher appearance of
the Koebner phenomenon, and more extensive disease. However,
all variations of nail changes are more frequent in people who
are Cw*0602-negative (Gudjonsson 2006). Furthermore, minor
trauma to the nails may play a role in the onset of nail psoriasis.
Fingernails are more affected than toenails (Dawber 1992; Farber
1992; Scher 1990; Tham 1988). Psoriasis may affect both the nail
matrix and the nail bed. Clinical observations that aid the diag-
nosis of nail psoriasis include irregular pitting, salmon patches of
the nail bed, and separation of the nail from the nail bed with red-
dening of the border (paronychia). Furthermore, splinter haemor-
rhages, subungual hyperkeratosis, nail plate thickening, and crum-
bling may be seen (Bolognia 2003; Kaur 2001). The most com-
mon nail abnormalities are pitting and subungual hyperkeratosis.
Pitting of the nail is caused by small parakeratotic foci in the distal
portion of the nail matrix. The salmon patches or ’oil spots’ reflect
exocytosis of leukocytes beneath the nail plate. Increased capillary
fragility leads to splinter haemorrhages. Subungual hyperkeratosis
and distal onycholysis are the result of parakeratosis of the distal
nail bed (Bolognia 2003).
Differential diagnoses include onychomycosis, lichen planus,
parakeratosis pustulosa, acropustulosis keratotica, acrodermatitis
continua of Hallopeau, and eczema. Because onychomycosis is
more prevalent in people with nail psoriasis, it is important to rule
out fungal infection of the nails in those with nail psoriasis.
It is known that more severe psoriasis is associated with poorer
quality of life (de Korte 2004). De Jong et al (de Jong 1996) inves-
tigated the influence of nail involvement on quality of life. Half
of those with psoriasis of the nails are limited in their profession,
housekeeping, and daily activities, or both. More than 90% have
cosmetic problems that cause social embarrassment. Over 50% of
those with nail psoriasis suffer from pain due to nail changes.
A glossary of the terms and abbreviations we have used throughout
this review are shown in Table 1 and Table 2, respectively.
Description of the intervention
Although it is difficult to treat psoriatic nails, the condition may
respond to therapy.Where there is a response to treatment, there is
often no permanent nail plate damage, and marked improvement
can be achieved. However, treatment response may be slow, the
result is sometimes disappointing, and relapse is common. Thera-
peutic options include, for example, topical and intralesional corti-
costeroids and topical calcipotriol, ciclosporin (Cannavo 2003), 5-
fluorouracil, and tazarotene. In a review published by Forleo et al,
it is mentioned that topical calcipotriol is a promising treatment,
especially for subungual hyperkeratosis and onycholysis (Forleo
1999). Systemic, mostly oral, treatments, such as methotrexate
and ciclosporin, may be very efficacious, but until now they
have only been recommended in people with additionally dif-
fuse skin or joint involvement because of the side-effects of these
drugs. Other therapeutic approaches used are oral retinoids, dif-
ferent kinds of photo- and radiotherapy (Kwang 1995; Yu 1992),
grenz ray (Lindelof 1989), ultraviolet B phototherapy, and pho-
tochemotherapy (de Berker 2000).
Biologics are relatively new therapeutic agents for the treatment of
psoriasis, which are now being used as routine therapy for those
with chronicmoderate to severe plaque type psoriasis and psoriatic
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arthritis unresponsive to conventional systemic treatments or with
contraindications for these. As a result of their proven efficacy and
relative safety, the biologics are considered a valuable supplement
for treating moderate to severe psoriasis, and the effects of some
have been investigated for nail psoriasis (Reich 2005). Currently,
the following are registered for psoriasis treatment: the tumour
necrosis factor-α (TNF-α) inhibitors etanercept, infliximab, and
adalimumab; and the T-cell blocker, alefacept. Etanercept is a fully
human receptor p75 fusion protein. Infliximab and adalimumab
are monoclonal antibodies, of which adalimumab is fully human,
and infliximab is chimeric, which means 75% human and 25%
mouse. Alefacept is a totally human fusion protein of the recep-
tor LFA3 and human IgG1. Ustekinumab, a human monoclonal
anti-p40 antibody that blocks the IL 12/23 receptor, has also been
approved recently for psoriasis, and it is the subject of a Cochrane
review that is in progress (Roberts 2010). Another fully human
monoclonal antibody, golimumab, has been approved for treat-
ment of psoriatic arthritis, but also improves skin lesions of psori-
asis. Anti-CD11a efalizumab has been removed from the market
because several cases of progressive multifocal leukoencephalopa-
thy have been reported.
Assessment of nail psoriasis severity
Different outcomemeasures have been developed for nail psoriasis
compared to the disease of the skin and joints. Besides a clinical
description of improvement or worsening of nail psoriasis features,
there are severity scoring systems. There is no consensus on core
outcomes to be used.
In 1994, Jones et al used a scoring system later referred to as the
Psoriasis Nail Severity Score (PNSS). In this system, fingernails
are assessed for pitting, onycholysis, hyperkeratosis, and severe
nail deformity with involvement of both sides of the nail. Each
of these nail features scores 1 point with a possible maximum
nail score of 40 for all finger nails (Jones 1994). Subsequently,
Williamson extended this score by also including toenails to a
possible maximum score of 80 (Williamson 2004).
Another score is the total Nail Area Severity (NAS) score including
parameters for the number of nail pitting areas, number of nail
pits, amount of subungual keratoses, onycholysis, and oil spots (de
Jong 1999).
Rich et al developed a more complex scoring system, the Nail
Psoriasis Severity Index (NAPSI). This index is formed by the sum
of a score for each nail per quadrant, distinguishing nail bed, and
nail matrix. Nail matrix psoriasis includes one of the following
nail features: pitting, leuconychia, red spots in the lunula, and
crumbling. For nail bed psoriasis, the existence of onycholysis, oil
drop, splinter haemorrhages, and nail bed hyperkeratosis will be
scored (Rich 2003).
Because of its complexity, Parrish et al concluded that the exist-
ing NAPSI system is probably not sensitive enough to reflect sig-
nificant clinical improvement. Therefore, they proposed a modi-
fied score with a classification for each parameter of zero to three
(Parrish 2005).
Baran et al suggested that the signs of nail psoriasis should be
scored from zero to three, with a standardised legend for each fea-
ture separately. However, splinter haemorrhages, which are often
of traumatic origin, should not be taken into account in their
opinion, nor should onychomadesis or nail loss (Baran 2004).
Why it is important to do this review
Although nail psoriasis is a common disorder that causes pain and
restrictions in daily activities in half of those affected, and cosmetic
problems in almost all, a summary of the evidence of possible
treatments is missing. There is no uniform therapeutic regimen
and no nail psoriasis treatment algorithm available in textbooks
or reviews. However, although many available treatments are not
well documented and comparative studies are scarce, marked im-
provement can be achieved with some treatments.
Cassell and Kavanaugh published a review of 20 studies (including
clinical trials, case series’, and observational studies) on the treat-
ment of nail psoriasis, and they also presented a list of treatment
recommendations (Cassell 2006). Some elements of this system-
atic review may be improved: searching more databases, not ap-
plying a language restriction, reviewing all treatments, assessing
the validity of the studies, extracting the data independently, and
drawing conclusions concerning all of the objectives of the review
(also ’symptoms’, ’quality of life’, and ’toxicity of therapies’ as out-
come measures) based on the level of evidence.
The goal of this Cochrane systematic review was to summarise the
best available evidence, in order to inform both physicians and
those with nail psoriasis and to identify future research areas about
treatment possibilities.
O B J E C T I V E S
To assess evidence for the efficacy and safety of the treatments for
nail psoriasis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials.
We included studies if nail psoriasis was the main clinical feature
as well as studies where nail psoriasis was just one of several com-
ponents of the disease besides arthritis or plaque type psoriasis.
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Types of participants
All participants diagnosed with nail psoriasis and no other nail
disorder.
We excluded studies concerning mainly participants with pustular
psoriasis of the nails, acropustulosis keratotica, and acrodermatitis
continua of Hallopeau.
Types of interventions
Any type of intervention used, either alone or in combination, to
treat nail psoriasis.
We included comparison studies with placebo or active treatment.
Types of outcome measures
Because there is no consensus on core outcome measures for nail
psoriasis, we included all possible outcome measures.
We dichotomised results in participants with less, equal, or more
than 50% improvement, regardless of which score measurement
was used.
To calculate the number of participants with at least 50% nail
score improvement, we proportionally converted point scores to
percentage improvement. For example, a 5-point scale of ’no im-
provement’, ’slight improvement’, ’moderate improvement’, ’al-
most complete resolution’, and ’complete resolution’ was con-
verted to 0%, 25%, 50%, 75%, and 100%, respectively. For exam-
ple, a 4-point scale of ’worsened’, ’failure’, ’improved’, and ’cured’
was converted to 0%, 25%, 50%, and 100%, respectively. The
reverse situation, as in ’absence of lesions’, ’mild lesions’, ’moderate
lesions’, and ’severe lesions’, was converted to 100%, 75%, 50%,
and 25% improvement, respectively.
The participants with the converted 50% or more nail score im-
provement, according to the point scales, were calculated for the
following primary and secondary outcome parameters.
Primary outcomes
(a) Global improvement of nail psoriasis as rated by a clinician
(ordinal scale).
(b) Improvement of nail psoriasis scores (NAS, NAPSI) (ordinal
scales).
(c) Improvement of nail psoriasis in the participant’s opinion (or-
dinal scale).
Secondary outcomes
(a) Adverse effects (and serious adverse effects, i.e. serious enough
to require withdrawal of the treatment).
(b) Effects on quality of life.
(c) Improvement in nail features, pain score, nail thickness, thick-
ness of subungual hyperkeratosis, number of affected nails, and
nail growth.
Additional: nail features
The effects of interventions on specific nail features were evaluated
separately for nail matrix and nail bed features. In this way, the
outcomes of research are applicable for daily practice.
Timing of outcome assessment
If possible, we assessed separately the outcomes in the short-term
(3 to 6 months, closest to 3 months), medium-term (6 to 12
months, closest to 6months), and long-term (> 12months, closest
to 1 year).
Search methods for identification of studies
We aimed to identify all relevant randomised controlled trials
(RCTs) regardless of language or publication status (published,
unpublished, in press, or in progress).
Electronic searches
We searched the following databases up to 22 March 2012:
• the Cochrane Skin Group Specialised Register using the
following terms: psoria* and (nail* or toenail* or onycholysis or
ungu* or paronychia or (subungu* AND hyperkerato*) or
pitting or pitted or leukonychia);
• the Cochrane Central Register of Controlled Trials
(CENTRAL) in The Cochrane Library using the strategy in
Appendix 1;
• MEDLINE via OVID (from 1946) using the strategy in
Appendix 2;
• EMBASE via OVID (from 1974) using the strategy in
Appendix 3; and
• LILACS (Latin American and Caribbean Health Science
Information database, from 1982) using the strategy in
Appendix 4.
Trials registers
We searched the following trials registers on 22March 2012 using
the terms ’nail’ and ’psoriasis’:
• The metaRegister of Controlled Trials (www.controlled-
trials.com).
• The US National Institutes of Health ongoing trials register
(www.clinicaltrials.gov).
• The Australian New Zealand Clinical Trials Registry (
www.anzctr.org.au).
• The World Health Organisation International Clinical
Trials Registry platform (www.who.int/trialsearch).
• The EU Clinical Trials Register (https://
www.clinicaltrialsregister.eu/).
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Searching other resources
Reference lists
We checked the bibliographies of the included studies and of gen-
eral articles about nail psoriasis for further references to relevant
RCTs.
Adverse effects
We summarised adverse effects described in the included RCTs
and gave the percentage of participants with adverse effects and
the type of adverse effects.
Data collection and analysis
Selection of studies
Two review authors (AV andNB) independently checked the titles
and abstracts identified from the searches, taking into account the
inclusion and exclusion criteria. We also independently assessed
those initially selected studies to determine whether they met the
predefined eligibility criteria. We discussed differences in selection
with a third review author (PS).We also described excluded studies
and the reasons for exclusion. If necessary, we asked the Dutch
Cochrane Centre or the Cochrane SkinGroup for assistance in the
translation of articles that were not published in English, Dutch,
or German.
Data extraction and management
Two review authors (AV and NB) independently extracted the
data. A third review author (PS or LH) resolved any differences.
We adapted a data extraction form template from the Cochrane
Skin Group in order to summarise the trials. This form addressed
the following issues: baseline characteristics of the participants for
age, sex, duration, and severity of nail psoriasis; aims; description
of the intervention (including drug doses and duration of treat-
ment); the methods and methodological quality of the study; out-
come measures; and results. We contacted trial authors requesting
that they provide missing data where possible. Two reviewers (AV
and NB) checked and entered the data into Review Manager. We
reviewed data from studies with nails as the main diagnosis and
studies where nail psoriasis was one of several components of dis-
ease in the results separately.
Assessment of risk of bias in included studies
Two review authors (AV and NB) independently assessed risk of
bias in the included studies following the domain-based evaluation
described in Chapter 8 in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).
We compared the evaluations and discussed and resolved any in-
consistencies between the review authors. We evaluated the fol-
lowing components for each included study (Juni 2001) as ’low
risk of bias’, ’high risk of bias’, and ’unclear’ if the risk of bias was
uncertain or unknown:
(a) the method of generation of the randomisation sequence;
(b) the method of allocation concealment - it was considered ’ad-
equate’ if the assignment could not be foreseen;
(c)whowas blinded/not blinded (participants, clinicians, outcome
assessors);
(d) how many participants were lost to follow up in each arm, and
whether participants were analysed in the groups to which they
were originally randomised (intention-to-treat);
(e) if there was selective outcome reporting (assessed by comparing
the outcomes in the methods section with the reported outcomes
in the results section); and
(f ) if the studies were free of other bias.
We recorded the information in a ’Risk of bias’ table for each
included study as part of the Characteristics of included studies
section.
Measures of treatment effect
It was impossible to extract or calculate all relevant data, like the
95% confidence interval (CI) and standard deviation (SD). The
diversity of design and study outcomes made it impossible to do
so. We did not contact the original authors when we encountered
missing data. Therefore, we described data with qualitative de-
scriptions, if available in the original studies.
Unit of analysis issues
Internally-controlled studies
Internally-controlled studies are statistically analogous to cross-
over studies, and results should be adjusted by the correlation co-
efficient (Cochrane Handbook for Systematic Reviews of Interven-
tions, section 16.4.6 (Higgins 2011)). No study included in this
review reported these statistical data to impute, and we did not
have access to patient-level data.
We considered whether in each study individuals (also for inter-
nally-controlled studies) underwent more than one intervention
(e.g. in a cross-over trial) and if there were multiple observations
for the same outcome (e.g. repeated measurements).
Cross-over trials
Whenwe consideredno carry-over effect to be present, we analysed
the trial as a parallel-group trial. If carry-over effect was present,
we included only data from the first period.
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Repeated measurements
Outcomeswere given for the following treatment durations: short-
term (3 to 6 months, closest to 3 months), medium-term (6 to
12 months, closest to 6 months), and long-term (> 12 months,
closest to 1 year) treatment.
Itwas not possible to pool data because of clinical andmethodolog-
ical heterogeneity and limited reporting of statistical data. Con-
sidering the differences, we tried to make homogeneous groups
based on three interventions types (topical, systemic, and radio-
therapy). We decided to describe all the data presented in these
groups in accordance with the primary and secondary outcomes,
as we believe that this will be useful in clinical practice.
Dealing with missing data
In the case of participant dropout and continuous outcomes, we
analysed only the available data. We contacted trial authors re-
questing that they provide missing data where possible.
Assessment of heterogeneity
We assessed statistical heterogeneity using I² statistic. In the case of
mild heterogeneity (I² statistic = < 30%), we used the fixed-effect
model (FEM). In the case of moderate heterogeneity (I² statistic =
30% to 60%), we used the random-effects model (REM) instead
of the FEM. In the case of notable heterogeneity (I² statistic = >
60%), we identified subgroups to explain the heterogeneity.
In the case of severe methodological and clinical heterogeneity,
we did not perform meta-analyses using either a FEM or REM.
Instead, we described the data per intervention group (topical,
systemic, and radiotherapy). In the analyses, we reported the par-
ticipants with at least 50% nail score improvement.
Assessment of reporting biases
If possible, we would have used funnel plots to test publication
bias. However, since performing a meta-analysis was not possible
due to heterogeneity, we did not use funnel plots (this is only infor-
mative when there are at least 10 homogeneous studies included
in the meta-analysis (Higgins 2011)).
Data synthesis
For studies with similar types of intervention, we performed a
meta-analysis when possible; we only carried out a meta-analysis
of all outcomes (primary and secondary) if we were able to iden-
tify an adequate number of studies that were investigating similar
interventions and reporting data that exhibited not less thanmod-
erate heterogeneity. In that case, we used a fixed-effect or random-
effects model to pool the data into a meta-analysis.
We dichotomised outcomes for nail score improvement and calcu-
lated and analysed the available data, reporting participants with
at least 50% nail score improvement, regardless of which score
measurementwas used, and differentiated between short-term and
medium-term treatment.
If possible, we analysed the ’mean nail score improvement per
intervention after short andmedium term treatment duration’ and
used the outcome as a continuous variable.
When it was not possible to perform a meta-analysis, we presented
the extracted data qualitatively.
Subgroup analysis and investigation of heterogeneity
Where there was substantial clinical heterogeneity, we performed
subgroup analyses when sufficient information was given to ex-
plore the reasons for heterogeneity, such as disease severity, type of
nail psoriasis (isolated nail psoriasis or with skin involvement), the
extensiveness (different groups based on number of nails affected),
and the dosage and duration of treatment.
Sensitivity analysis
We carried out sensitivity analyses to assess the robustness of the
results of this review; thus, we repeated all fixed-effect meta-anal-
yses using random-effects models. With these sensitivity analyses
we wanted to show that the overall results were not affected by
differences caused by the following methodological items:
1. concealment of allocation;
2. blinding of the participant;
3. blinding of care provider; and
4. interparticipant comparison (versus intraparticipant
comparison).
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies.
Results of the search
We retrieved 212 references from the electronic searches and 8
ongoing studies when we searched the websites of trials registers
(Characteristics of ongoing studies).
Of these 220 references, we obtained the full text for 49. Twenty-
six references related to our 18 included studies (see Characteristics
of included studies). One single reference referred to two separate
trials, which we counted as two included studies. Eleven other
references referred to 3 of the included studies; in the latter, we
have marked the primary publication.
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Of the remaining 23 references, we excluded 7 (see Characteristics
of excluded studies); 8 are in Studies awaiting classification (see
Characteristics of studies awaiting classification); and 8 are ongo-
ing trials (see Characteristics of ongoing studies).
We summarised our process for screening and selecting studies in
Figure 1.
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Figure 1. Study flow diagram
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We checked the bibliographies of the included studies and other
general papers about nail psoriasis for possible references to RCTs,
but found no additional studies.
Included studies
We included 18 trials, with a total of 1266 participants. Twenty-
six references, including abstracts and full text, represented the
included studies. The data were extracted from 17 primary ref-
erences. The study by Baran 1999 reported two independent tri-
als; this review reported these trials separately (Baran 1999; Baran
1999a), so counted them as two included studies. There were two
references referring to the trial by Cannavo 2003, six references
referring to the trial by Rich 2008, and three references referring
to the trial by Scher 2001.
These 18 trials include 6 with topical therapies versus placebo, 3
trials comparing 2 topicals, 1 topical therapy versus conventional
systemic therapy, 2 studies comparing conventional systemic ther-
apies, 3 with biologics versus placebo, and 3 with radiotherapy
versus placebo.
The basic characteristics of the included studies are reported in
Table 3. Further information, together with the ’Risk of bias’ in-
formation, are reported in the ’Characteristics of included studies’
tables. These tables show clinical and methodological heterogene-
ity for all outcomes, so we were not able to pool data and perform
sensitivity analyses, except the 50% nail score improvement.
Design
Twelve trials adopted a parallel-group design and 6 (Baran 1999;
Baran 1999a; de Jong 1999; Kwang 1995; Lindelof 1989; Yu
1992), an internally-controlled design.
Therewere four trials (Igarashi 2012; Lindelof 1989;Mahrle 1995;
Rich 2008) with a cross-over design.
In Mahrle 1995 after 10 weeks, there was cross-over to another
treatment (phase 2). Because nowash-out was required, there was a
possibility of a carry-over effect in the second phase. Therefore, we
only analysed the first 10 weeks (phase 1), representing a parallel-
group trial.
The studies by Igarashi 2012, Lindelof 1989, and Rich 2008 per-
formed a cross-over design fromplacebo to active treatment.How-
ever, this cross-over hadno carry-over effect; therefore, we included
both phases.
The methods and study design of Rich 2008 originated from the
EXPRESS study (Reich 2005); however, the Rich 2008 study re-
ported the nail results. Reich 2010 reported the results of a retro-
spective analysis of the EXPRESS study.
Ten trials included participants with skin psoriasis and nail in-
volvement (Cannavo 2003; Flori 1994; Igarashi 2012; G m el
2011; Kavanaugh 2009; Levell 1995; Mahrle 1995; Rich 2008;
Rigopoulos 2007; Scher 2001). Another eight trials were unclear
about the coexistence of the skin psoriasis (Baran 1999; Baran
1999a; de Jong 1999; Kwang 1995; Lindelof 1989; Tosti 1998;
Tzung 2008; Yu 1992), so it is probable none of the trials included
participants with ’only nail psoriasis’.
The treatment duration ranged from 2weeks to 64 weeks (Igarashi
2012).
The studies originated from 12 different countries (The Nether-
lands, France, Singapore, Sweden, Germany, Greece, Turkey, Tai-
wan, Japan, United Kingdom (2), USA (3), Italy (3)). One study
was written in Italian (Flori 1994).
The included studies were published between 1989 and 2012.
Sample sizes
The number of participants included in the individual studies
varied widely, from 10 to 305 participants (1 had 102 participants
(Igarashi 2012); 1 had 137 participants (Mahrle 1995); and 1 trial
by Rich 2008 studied 305 participants), but with between 10 and
60 representing the most common sample size.
Participants
Participants were adults (> 18 years), of either sex, with nail pso-
riasis.
Interventions
We evaluated a wide range of interventions. Therefore, the study
results are presented in the three intervention groups (topical, sys-
temic, and radiotherapy).
Ten trials examined topical treatments: calcipotriol monotherapy
versus calcipotriol in combination with betamethasone dipropi-
onate (Tzung 2008), calcipotriol monotherapy versus calcipotriol
with betamethasone and salicylic acid (Tosti 1998), hyaluronic
acid with chondroitin sulphates (Flori 1994), tazarotene 0.1% gel
(Scher 2001) and tazarotene cream (Rigopoulos 2007), dithranol
with salicylic acid and additional UVB (Levell 1995), ciclosporin
dissolved maize oil solution (Cannavo 2003), 5-fluorouracil (5-
FU) in a penetration-enhancing vehicle (de Jong 1999), and clo-
betasol propionate cream (Baran 1999; Baran 1999a).
Six trials examined systemic therapies: ciclosporin (G m el
2011; Levell 1995; Mahrle 1995), methotrexate (G m el
2011), etretinate (Mahrle 1995), golimumab (Kavanaugh 2009),
ustekinumab (Igarashi 2012), and infliximab (Rich 2008). Levell
1995 was included in the topical intervention and the systemic
intervention group.
Three trials examined radiotherapy treatments: superficial radio-
therapy (Yu 1992), grenz rays (Lindelof 1989), and electron beam
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(Kwang 1995). In the trial with superficial radiotherapy, they used
150 centiGray (cGy (1/100 of a Gray)) (90 kV, 5 mA, 1.00 mm
aluminium filter). The amount of grenz rays used was 5 Gray (Gy)
(10 kV, 10 mA, half-value layer 0.02 mm Al, half-value depth
in tissue 0.5 mm, focus skin distance 10 cm). Kwang 1995 used
electron beam of 7 mega-electron volts.
Outcomes
The NAPSI, an ordinal scale of nail psoriasis severity, was scored
in five studies (G m el 2011; Igarashi 2012; Kavanaugh 2009;
Rich 2008;Tzung 2008); Rigopoulos 2007 used theNAPSI partly;
and de Jong 1999 applied the ordinal NAS score. de Jong 1999,
G m el 2011, Kavanaugh 2009, and Tzung 2008 also used a
point scale next to the NAPSI or NAS. Ten studies utilised only
an ordinal 3-, 4-, or 5-point scale for assessing the nails during
treatment. This scale was assessed by the investigator or physician,
and in some studies, not adequately defined. One study (Tosti
1998) assessed the nail thickness, not using a NAPSI or point
scale. The categories from the point scores (absent, slight, mild,
moderate, severe, cured) are described as mentioned in the original
text.
An ordinal scale for ’Improvement of nail psoriasis in the partic-
ipant’s opinion’ was used in five studies (Cannavo 2003; de Jong
1999; G m el 2011; Tosti 1998; Tzung 2008).
All studies, except Baran 1999 and Baran 1999a, assessed adverse
effects.
Only Cannavo 2003 reported ’Effects on quality of life’.
Eleven studies assessed ’Improvement in nail features, pain score,
nail thickness, thickness of subungual hyperkeratosis, number
of affected nails, and nail growth’ (Baran 1999; Baran 1999a;
Cannavo 2003; de Jong 1999; Flori 1994; Kwang 1995; Rich
2008; Rigopoulos 2007; Scher 2001; Tzung 2008; Yu 1992).
Excluded studies
Of the 49 initially eligible references, we included 26. Of the re-
maining 23 references, we excluded 7, details of which and the rea-
sons for exclusion are described in the ’Characteristics of excluded
studies’ tables.
Studies awaiting assessment
There were eight studies that were only published in abstract form
(poster or conference publication), so we were unable to assess
them for this review, but details are given in the ’Characteristics
of studies awaiting classification’ tables. This includes the study
abstract by Baerveldt 2010, which was retrieved from a national
source.
Ongoing studies
We give details of the eight ongoing studies in theOngoing studies
tables.
Risk of bias in included studies
We assessed and presented the risk of bias of each study as part of
the ’Characteristics of included studies’ tables.
Figure 2 presents the review authors’ judgements on the method-
ological quality of the included studies. Figure 3 presents the re-
view authors’ judgements on the methodological quality as per-
centages across all included studies.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study
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Figure 3. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
Allocation
’Adequate sequence generation’ and ’allocation of concealment’
are the two most important indicators that can minimise bias in
trials.
Five studies (G m el 2011; Kavanaugh 2009; Levell 1995; Rich
2008; Rigopoulos 2007) had adequate sequence generation and
allocation of concealment. Without knowledge of the underlying
allocation criteria, these studies used either a dice, centralised in-
teractive voice responses (IVR), or a code of randomisation avail-
able to an uninvolved pharmacist or a computer.
The randomisation methods and allocation of concealment were
unclear in 5 of the 18 included trials. Eight studies reported an
adequate sequence generation and an unclear allocation of con-
cealment.
Blinding
Twelve trials had a double-blind design, of which 11 trials blinded
the investigator and participant and 1 trial (Yu 1992) blinded the
participant and outcome assessor. Yu 1992 was unclear about the
investigator/physician blinding.
Two trials were single-blind (G m el 2011; Tzung 2008),
and their comparisons were active-controlled. Tzung 2008 had
a blinded investigator. G m el 2011 had unclear blinding for
physician and observer; the initials of the blinded observer were
the same as the initials of the probably unblinded physician.
Levell 1995 was an open study (active-controlled) so was judged
at high risk of bias for these three domains.
The studies by Cannavo 2003, Kwang 1995, and Mahrle 1995
reported insufficient information to permit a clear judgment of
the risk of bias for these three domains.
Incomplete outcome data
Five studies were ’unclear’ for the risk of bias in reporting incom-
plete outcome data: Igarashi 2012, Kavanaugh 2009, and Mahrle
1995 described data about the dropouts and withdrawals of all
randomised participants, but there were no separate data available
about participants with nail psoriasis. Cannavo 2003 and Rich
2008 did not mention dropouts or withdrawals.
We judged the following studies at low risk of bias for this domain:
Flori 1994, Kwang 1995, and Scher 2001. These studies reported
that therewere nodropouts orwithdrawals in the trial; Baran1999,
Baran 1999a, G m el 2011, Lindelof 1989, Tzung 2008, and
Yu 1992 reported less than 20% dropouts of the study population,
mostly unrelated to treatment (for example, lost to follow up); and
de Jong 1999, which reported intention-to-treat (ITT) analysis.
We judged three studies that had more than 20% dropouts per
group at high risk of bias: Levell 1995, Rigopoulos 2007, and
Tosti 1998. Levell 1995 and Tosti 1998 reported dropouts mostly
because of participants failing to attend the visits. Rigopoulos 2007
reported dropouts because of the need for another treatment and
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had two participants with incomplete outcome data.
Kavanaugh 2009 reported intention-to-treat (ITT) analysis.
G m el 2011, Igarashi 2012, and Rich 2008 used no ITT anal-
ysis. The other trials mentioned no dropouts or reported unclear
data about the ITT analysis.
Not all the included studies assessed nail improvement compared
to the control group.
Selective reporting
The studies by Flori 1994, Levell 1995, and Lindelof 1989 were
not free of selective reporting, so we judged them at high risk of
bias. Flori 1994 did not report the results of the assessed toenails
in the placebo group. Levell 1995 did not describe data from
the group using dithranol in Lassar’s paste, and there was also a
discrepancy in the article between the improvement score shown
in the figure and the text. Lindelof 1989 did not separately discuss
nail signs in the results.
The other trials reported all the outcomes mentioned in their
methods, so we judged these studies at low risk of bias.
Other potential sources of bias
Pharmaceutical industries supported 8 of the 18 included trials
(Flori 1994; Igarashi 2012; Kavanaugh 2009; Levell 1995;Mahrle
1995; Rich 2008; Scher 2001; Tosti 1998). Because the influence
of the pharmaceutical industries was unclear, we could not exclude
a potential source of bias.
Kavanaugh 2009, Levell 1995, Mahrle 1995, and Tosti 1998 had,
regardless of the unclear bias by the pharmaceutical industries,
other potential sources of bias, which could cause high risk of bias.
In Kavanaugh 2009, a stable dose of methotrexate, non-steroidal
anti-inflammatory drugs (NSAIDs), and corticosteroids were al-
lowed as co-medication. Mahrle 1995 allowed salicylic acid-con-
taining emollients for all participants during the study. Levell 1995
applied ciclosporin until two weeks after the psoriasis of the skin
had cleared. This was not allowed for the dithranol group. The ex-
tra two weeks of ciclosporin were applied in the follow-up weeks.
In Tosti 1998 at 3 months, treatment was continued for another 2
months if participants treated with calcipotriol or betamethasone
had more than 50% reduction of the subungual hyperkeratotic
thickness in at least 1 nail (responders). The baseline hyperker-
atoses of these two treatment groups were not homogeneous.
Four trials (Kwang 1995; Lindelof 1989; Rigopoulos 2007; Yu
1992) reported no baseline characteristics of the participants. It
was unclear if the groups were comparable at baseline. We could
not exclude bias.
Effects of interventions
Because of the diversity of study designs, the outcomes, and severe
clinical and methodological heterogeneity, it was impossible to
calculate confidence intervals and pool the data from the studies.
To make the results more concise, we have presented forest plots
of participants with at least 50% nail score improvement only for
individual parallel-group studies. For internally-controlled studies,
we have presented the P values for the randomised comparison
when these were available.
The outcomes of this review were as follows.
Primary outcomes
1. Global improvement of nail psoriasis as rated by a clinician.
2. Improvement of nail psoriasis scores (NAS, NAPSI).
3. Improvement of nail psoriasis in the participant’s opinion.
Two biologic (Kavanaugh 2009; Rich 2008) and three radiother-
apy studies (Kwang 1995; Lindelof 1989; Yu 1992) reported sig-
nificant improvement of nail psoriasis from nail scores and rating
from a clinician. Infliximab 5 mg/kg showed 26.8% and 57.2%
nail score improvement versus -7.7% and -4.1% for placebo, re-
spectively, after short- and medium-term treatment (Rich 2008).
Golimumab 50 mg showed 25% and 33% nail score improve-
ment, and 100 mg showed 43% and 54% nail score improvement,
respectively, after short- and medium-term treatment versus 0%
in the placebo group for both durations (Kavanaugh 2009). From
the 3 radiotherapy studies, only the superficial radiotherapy study
showed underlying data: 20% versus 0% score improvement after
short-term treatment (Yu 1992).
Seven studies showed no significant results in the primary out-
comes compared to each other (de Jong 1999; G m el 2011;
Igarashi 2012;Mahrle 1995; Rigopoulos 2007; Tosti 1998; Tzung
2008). Four studies did not present comparative data (Baran 1999;
Baran 1999a; Cannavo 2003; Levell 1995).
Two studies reported nail improvement only per feature (sec-
ondary outcome), and they did not show primary outcome on nail
improvement (Flori 1994; Scher 2001).
In Table 4, we present the mean percentage score improvement of
fingernail severity over time. Toenails were not assessed in all trials;
therefore, they were not all included. We presented the outcomes
as “moderate” (in accordance with NAPSI: 25% to 75% improve-
ment, mild/moderate, medium) and “good” (in accordance with
NAPSI:≥ 75% improvement, no lesions, almost complete recov-
ery), independent of the outcome measure used. Where possible,
we shared data on nail improvement and significance compared
to the other treatment. If this was not reported in the studies, we
shared the improvement and significance compared to baseline.
The outcome “no/worse” (in accordance with NAPSI: < 25% im-
provement, no improvement, or worsening) is not shown in this
table. The column ’Time to assessment’ shows the exact treatment
weeks associated with the score improvement. We could not give
an overview of the onset of response because of missing data. The
improvement is shown for 2 treatment periods: short-term (stud-
ies with < 12 weeks of treatment) and medium-term (studies with
12 to 24 weeks of treatment). Rich 2008 and Igarashi 2012 were
the only studies with > 24 weeks, for which results are mentioned
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in the text only. These groups were necessary because no trials
used a standard outcome measurement. We explained the exact
definitions of the groups in the footnotes below the table.
In Figure 4, we gave data on short-term treatment with > 50%
improvement (n = 5) and data on medium-term treatment with >
25% improvement (n = 6).
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Figure 4.
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Secondary outcomes
1. Adverse effects (and serious adverse effects, i.e. serious
enough to require withdrawal of the treatment).
2. Effects on quality of life.
3. Improvement in nail features, pain score, nail thickness,
thickness of subungual hyperkeratosis, number of affected nails,
and nail growth.
In Table 5, we present the adverse effects (the percentage of par-
ticipants and the type of adverse effects).
Only one trial (Cannavo 2003) assessed effects on quality of life.
Table 6 shows nail features with at least 50% improvement. The
duration of treatment is divided into two groups: short- and
medium-term. If specified, the improvement is shown per inter-
vention regardless of the outcome parameter used. Not all trials
assessed the same features; therefore, it was impossible to compare
the results. One study reported the percentage of participants with
nail feature improvement. In this study, all eight features of the
’NAPSI’ score were presented.
Eleven studies showed separate data on nail features, of which
three (Flori 1994; Scher 2001; Tzung 2008) showed significance
compared to placebo in some features. One study (Rich 2008)
showed a significant decrease in the occurrence of individual fea-
tures over time, and three (de Jong 1999; Rigopoulos 2007; Tosti
1998) showed no significance between the treatments. Four stud-
ies reported no compared data.
Additional: nail features
We evaluated and separately reported the effects of interventions
on specific nail features per nail feature instead of per interven-
tion. In this way, the outcomes of research are applicable for daily
practice.
We assess our outcomes under the three following headings: Topi-
cal therapy, Systemic therapy, and Radiotherapy. Finally, under an
additional heading, we discuss nail features.
Topical therapy (10 studies)
Ten trials studied the effect of topical treatment on nail psoriasis
(Baran 1999; Baran 1999a; Cannavo 2003; de Jong 1999; Flori
1994; Levell 1995; Rigopoulos 2007; Scher 2001; Tosti 1998;
Tzung 2008).
Flori 1994 compared hyaluronic acid and chondroitin sulphate
versus placebo for 90 days. Levell 1995 compared the topical com-
bination of dithranol with salicylic acid and UVB, with systemic
ciclosporin, while Cannavo 2003 compared 70% ciclosporin in
maize oil as a topical therapy versus maize oil only. Tosti 1998
and Tzung 2008 both used calcipotriol: Tosti 1998 compared
calcipotriol with betamethasone dipropionate plus salicylic acid,
and Tzung 2008 compared calcipotriol alone with calcipotriol in
combination with betamethasone dipropionate. Baran 1999 and
Baran 1999a both studied topical 8% clobetasol versus a placebo
lacquer. de Jong 1999 reported 1% 5-fluorouracil in Belanyx®
lotion versus Belanyx® lotion alone. Scher 2001 and Rigopoulos
2007 both used tazarotene 0.1%, versus, respectively, a vehicle gel
and clobetasol propionate 0.05%.
Primary outcomes addressed by the topical studies
(a) Global improvement of nail psoriasis as rated by a
clinician
Six trials with 189 participants assessed nail psoriasis by clinicians.
Levell 1995 compared topical dithranol with salicylic acid and
UVB with oral ciclosporin for 16 weeks until clearance of psori-
asis. Of the 15 participants treated with dithranol, salicylic acid,
and UVB, 8 participants had improved nail psoriasis; 2 were un-
changed; and 5 worsened (the median nail severity score at base-
line was 5; after treatment, the median score change was 0 (95.2%
CI -3 to 2.5)).
Follow-up
In Levell 1995, all participants in the study with cleared skin psori-
asis were followed until relapse or until eight months had elapsed.
Ten participants whose psoriasis cleared with dithranol, salicylic
acid, and UVB also had nail involvement. These 10 participants
were assessed on their nails after treatment discontinuation, of
which 1 had unchanged nail psoriasis, 7 improved, and 2 wors-
ened; the median score improvement at the end of follow up was
4 (95.8% CI 0 to 8)). For further details and data on ciclosporin
treatment, please see the section ’Systemic therapy’.
Analysis 1.1 shows participants with at least 50% nail score im-
provement after a short-term treatment duration. There was no
significant improvement when systemic ciclosporin was compared
to topical dithranol with salicylic acid and UVB (RR 1.50, 95%
CI 0.85 to 2.64; Levell 1995).
Cannavo 2003 studied a topical oil solution of 70% oral ci-
closporin versus maize oil alone. In the active group, 3 out of 8
participants came to a complete resolution of nail lesions com-
pared to baseline, and 5 out of 8 showed a substantial improve-
ment (between 55% and 70%) of the overall severity score. In the
placebo group, there was an improvement of 44% in 1 of the 8
participants, a minimal improvement (between 10 and 25%) in
3 of the 8 participants, and no changes in 4 of the 8 participants,
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all compared to baseline. There were no data available about the
comparison between the active and control group in this study.
The mean improvement was 77% in the active group (initial me-
dian score = 8, final score = 3, significant P < 0.0005) and 12% in
the placebo group (initial median score = 8, final score = 6.5; this
was not significant).
Follow-up
After an eight-week follow-up, the study observed a relapse (not
defined) in one case of the active group.
Analysis 2.1 showed participants with at least 50% nail score im-
provement after the short-term period. The study by Cannavo
2003 showed a significant improvement for topical ciclosporin
70% in maize oil versus maize oil (RR 17.00, 95% CI 1.14 to
252.54).
After a short-term treatment period with calcipotriol in combi-
nation with betamethasone dipropionate versus calcipotriol alone
(Tzung 2008), 53% of the participants of both treatments showed
at least a moderate improvement. There was no significant dif-
ference between the treatments using the Investigator’s Global
Assessment (IGA) (P = 0.071). Once-daily combination therapy
was as efficacious as, but not better than, twice-daily calcipotriol
monotherapy. Once-daily did have an advantage in terms of com-
pliance.
Analysis 3.1 showed participants with at least 50% nail score im-
provement after a short-term period. Tzung 2008 showed no sig-
nificant outcome for calcipotriol versus calcipotriol + betametha-
sone dipropionate (RR 0.99, 95% CI 0.52 to 1.91).
Baran 1999 and Baran 1999a studied clobetasol-17-propionate
8% in a colourless nail lacquer vehicle versus a placebo lacquer.
No participants in the group receiving 8%clobetasol experienced a
complete disappearance (cured) of their nail lesions (Baran 1999).
Eighteen participants (69%) reported a clear reduction after ther-
apy: 16 (61.5%) in the active group and 2 (7.7%) in the compari-
son group. In 7 participants (27%), no efficacy of the therapy was
observed. Only 1 participant (3.8%) reported impairment of the
nails.
Twelve participants (80%) in the group receiving 8% clobetasol
experienced a complete recovery or improvement (Baran 1999a).
Four participants (26.7%) had a complete disappearance of the
nail lesions: 3 in the active group and 1 in the placebo group.
Eight participants (53.3%) showed an improvement: 5 (33.3%)
in the active group and 3 (20.0%) in the placebo group. In 2
participants (13.3%), no difference was reported after treatment.
Only 1 participant (6.7%) showed impairment of the nails.
A therapeutic response was directly related to the duration of
the treatment. Healing could be reached when participants were
treated long enough.NoP values were available in these internally-
controlled studies (Baran 1999; Baran 1999a).
When Belanyx® lotion with 1% 5-fluorouracil (5-FU) was com-
pared to Belanyx® lotion alone (de Jong 1999), the clinician rated
the overall improvement from baseline by 1% 5-FU in Belanyx®
lotion as significant (P = 0.001) at week 12 of treatment.
(b) Improvement of nail psoriasis scores (NAS, NAPSI)
Three trials with 143 participants assessed nail psoriasis by NAS
or NAPSI.
Tzung 2008 used the topical therapy calcipotriol as monotherapy
compared to a combination with betamethasone dipropionate.
Both treatments noted a significant reduction of total NAPSI score
(P < 0.045). However, there was no significant difference between
treatments (P = 0.649).
de Jong 1999 reported a change from baseline severity of 32%
(score = 7.1 to 4.8) and 39% (score = 7.1 to 4.3) for the total NAS
score (5 parameters) after 12 weeks, and 40% (score = 7.1 to 4.2)
and 46% (score = 7.1 to 3.8) after 16 weeks (4 weeks’ follow up),
for, respectively, 1% 5-fluorouracil (5-FU) in Belanyx® lotion and
Belanyx® lotion alone. These findings were in agreement with
improvements recorded for the mean baseline severity of the total
of the five individual assessed parameters. The nail parameters
were shown to be similarly suppressed by 5-FU in Belanyx® lotion
and Belanyx® lotion alone at the end of treatment (P = 0.063) or
follow up (P = 0.130).
Follow-up
After 4 weeks of follow up, 5-FU in Belanyx® lotion and Be-
lanyx® lotion alone showed a further significant improvement for
all assessed parameters (P < 0.05), with total mean score changes
of 10% (score = 7.1 (28%) to 6.1 (38%)) and 8% (score = 6.1
(38%) to 5.3 (46%)), respectively.
In conclusion, administering 1% 5-FU to Belanyx® does not en-
hance the efficacy in psoriatic nail dystrophy.
Rigopoulos 2007 compared tazarotene 0.1% cream with clobe-
tasol propionate 0.05% cream. The results showed a significant
time-effect improvement with both agents after 12 weeks of treat-
ment (P < 0.001). Comparison of the improvement between the
two agents did not reach statistical significance.
Follow-up
Discontinuation of therapy resulted in significant regression of the
nail signs for both groups, with the exception of hyperkeratosis
treated with tazarotene, which seemed to retain significant im-
provement 12 weeks after the end of treatment. The baseline score
of 1.80 changed to 0.36 after treatment and to 0.97 at the end of
follow up (P < 0.001).
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(c) Improvement of nail psoriasis in the participant’s opinion
Four trials with 171 participants assessed nail psoriasis through
the participant’s opinion.
Cannavo 2003 studied ciclosporin 70% in maize oil as a topical
therapy versus maize oil alone. All the participants of the active
group treated with 70% ciclosporin were positive about the results
of the therapy (significant), while in the placebo group only 1
participant reported a moderate improvement.
In the study by Tosti 1998, where the participants’ opinion of the
acceptability of the treatment in the calcipotriol groupwas assessed
at 3months, 44% of the participants judged it as ’good’, and 16%,
as ’excellent’. In the betamethasone group at 3 months, 58% of
the participants judged it as ’good’, and 19%, as ’excellent’. After
5 months, 50% of the responders assessed the acceptability of cal-
cipotriol as ’good’, and 22%, as ’excellent’ (these participants had
more then 50% improvement in hyperkeratosis in at least 1 nail
at 3 months). The corresponding figures for the betamethasone
responders were 57% ’good’ and 24% ’excellent’ at 5 months.
The result of participants’ self-evaluation after treatment with cal-
cipotriol monotherapy or combined with betamethasone showed
a similar trend to the Investigators’ Global Assessment, which
showed that for 53% of the participants there was at least a mod-
erate improvement after 12 weeks (Tzung 2008).
The overall nail improvement according to the participants treated
with 5-FU in Belanyx® lotion or Belanyx® lotion alone was
shown to be significant (P = 0.001) at week 12 (de Jong 1999).
Secondary outcomes addressed by the topical studies
(a) Adverse effects (and serious adverse effects, i.e. serious
enough to require withdrawal of the treatment)
Eight trials with 307 participants assessed adverse effects. Two
trials with 45 participants did not assess adverse effects (Baran
1999; Baran 1999a).
In the studies by Flori 1994, Cannavo 2003, and Tzung 2008,
participants reported no adverse effects during the study. Levell
1995 reported an increase of serum urate and burning sensation
with dithranol, salicylic acid, andUVB treatment (see belowunder
’Systemic therapy’ for further discussion). Tosti 1998 reported four
adverse effects in three participants with calcipotriol treatment:
one with erythema, one with irritation around the nail, one with a
burning sensation at the place of application, and one participant
with urticaria. Three participants with betamethasone (control)
treatment reported erythema.
Six participants in de Jong 1999 reported possible treatment-re-
lated adverse effects, showing inflammation and infection or dis-
colourations; three participants on 5-fluorouracil lotion showed
onycholysis. For those given the vehicle lotion, none of the adverse
effects were reported.
Five of 21 tazarotene-treated participants (Scher 2001) reported
treatment-related adverse effects (all mild ormoderate) - peeling of
proximal nail fold skin, irritation of skin on the finger, periungual
irritation, paronychia, and erythema of the proximal nail fold - but
the control group reported no adverse effects. However, tazarotene
generally was well tolerated in the treatment of nail psoriasis.
Rigopoulos 2007 reported that 3 of 16 participants receiving
tazarotene experienced desquamation and erythema of nail fold
skin, periungual irritation, paronychia, and irritation of the skin
of the toe or finger. One of the 14 participants in the control group
who was treated with clobetasol had a sensation of burning on the
nail fold skin. All adverse events were mild, with the symptoms
ameliorating after a few days.
Table 5 shows the weighted average of adverse effects for all topical
therapies: 10.7% for the intervention group and 2.9% for the
comparison group.
Analysis 4.1 (see Analysis 4.1.1) shows the numbers of participants
who experienced adverse effects with topical therapy compared to
the control group. In the studies by de Jong 1999, Rigopoulos
2007, Scher 2001, and Tosti 1998, there was no significant dif-
ference in the adverse effects experienced by the participants in
the intervention and control groups. We were unable to estimate
results for the other three studies.
(b) Effects on quality of life
One trial with 16 participants assessed the quality of life during
treatment (Cannavo 2003). Eight participants treated with topical
ciclosporin 70% in maize oil reported significant improvement,
ranging frommoderate to excellent (3 = ’excellent’, 4 = ’good’, and
1= ’moderate’) compared to only 1 participant who had received
maize oil alone who reported ’moderate’ improvement.
(c) Improvement in nail features, pain score, nail thickness,
thickness of subungual hyperkeratosis, number of affected
nails, and nail growth
Eight trials with 265 participants separately assessed nail features
(Baran 1999; Baran 1999a; Cannavo 2003; de Jong 1999; Flori
1994; Rigopoulos 2007; Scher 2001; Tzung 2008).
Two trials with 89 participants assessed nail growth and nail thick-
ness (Tosti 1998; Scher 2001).
Nail signs for those treated with 8% clobetasol responded in the
same sequence as the incidence rate observed in the studies: “ony-
cholysis, pitting, subungual hyperkeratosis, salmon patches, splin-
ter haemorrhages, ridging, transverse grooves, onychomadesis and
periungual lesions, but with an exceptional response for onychol-
ysis” (Baran 1999; Baran 1999a). There were no data available
for the comparison between the active and control group in these
studies.
Cannavo 2003 studied topical oil solution of 70% oral ciclosporin
in maize oil versus maize oil alone. The best results for clinical nail
response in the active group were obtained on onycholysis (score
reduction from 3 to 0) and hyperkeratosis (score reduction from
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3 to 0.50), which were both significant compared to baseline (P <
0.001 and P < 0.005, respectively). Pitting (P = 0.086), crumbling
(P < 0.05), and oil drop (P = 0.07) had minor significant results
on therapy.
In de Jong 1999 after 12weeks of 1%5-FU treatment in Belanyx®
lotion, participants showed a significant improvement compared
to baseline in ’nail pitting area’ (P = 0.004), subungual hyperk-
eratosis (P = 0 .001), and oil spots (P = 0.001). There was no
significant change in the number of pits or onycholysis (P > 0.05).
The Belanyx® lotion alone showed significant improvement of all
assessed nail parameters at the end of treatment (P < 0.05). There
was no statistically-significant difference between the treatment
groups.
Hyaluronic acid with chondroitin sulphate (Flori 1994) showed
a significant improvement of 30% to 70% compared to baseline
in all reported parameters (P < 0.001 to P = 0.018). Pitting im-
proved by 24.1% (score of 1.9 to 1.5) compared to baseline (P
= 0.018) after 60 days of treatment. After 90 days of treatment,
pitting, Beau’s lines, and onycholysis improved compared to base-
line: 41.4% (score = 1.9 to 1.1, P = 0.003), 31.8% (score = 1.5 to
1.0, P = 0.018), and 68.8% (score = 2.1 to 0.7, P < 0.001), respec-
tively. For onychorrhexis, there was a significant improvement of
25% (score = 1.3 to 1.0, P = 0.043) compared to baseline after
30 days of treatment and an improvement of 65% (score = 1.3 to
0.5, P = 0.018) after 90 days. Hyperkeratosis showed a significant
improvement of 70% (score = 1.3 to 0.4, P = 0.005) compared to
baseline, after 60 days of treatment.
There was a significant difference between the hyaluronic acid +
chondroitin sulphate group and the placebo group after 90 days
for onychorrhexis (improvement of 65% (score = 1.3 to 0.5) versus
15% (score = 1.3 to 1.1), respectively; P = 0.039), onycholysis
(68.8% (score = 2.1 to 0.7) versus 35.5% (score = 2.1 to 1.3),
respectively; P = 0.041), and hyperkeratosis (70% (score = 1.3 to
0.4) versus 23.8% (score = 1.4 to 1.1), respectively; P = 0.041).
The placebo group showed a significant improvement of 24%
compared to baseline for pitting (after 90 days, score = 1.7 to
1.3; P = 0.028), 19.4% and 35.5% for onycholysis after 60 days
(score = 2.1 to 1.7, P = 0.028) and after 90 days (score = 2.1
to 1.3, P = 0.005), respectively, and of 23.8% for hyperkeratosis
after 90 days (score = 1.4 to 1.1, P = 0.043). A total improvement
of all parameters was between 15% to 35.5% after 90 days. The
median total improvement was 55% for the participants treated
with hyaluronic acid and chondroitin sulphates versus 24% for
the participants in the placebo group.
The treatment group was clinically more improved (30% to 70%)
compared to the placebo group (15% to 35.5%) after 90 days.
Rigopoulos 2007 compared tazarotene 0.1% cream with clobe-
tasol propionate 0.05% cream. The results showed a significant
time-effect improvement for pitting, onycholysis, hyperkeratosis,
and salmon patches, with both agents after 12 weeks of treatment
(P < 0.001) (not significant between treatments).
Follow-up
Twelve weeks after discontinuation of treatment, the signs resulted
in significant regression for both groups, with the exception of
hyperkeratosis, which seemed to retain significant improvement
(P < 0.001).
Scher 2001 studied tazarotene 0.1% gel versus a vehicle gel.
Tazarotene gel was significantly more efficacious than the vehicle
in reducing onycholysis in occluded nails (P≤ 0.05 at weeks 4 and
12) and non-occluded nails (P≤ 0.05 at week 24). The tazarotene
gel also resulted in a significantly greater reduction of pitting in
occluded nails (P≤ 0.05 at week 24). There were no other signifi-
cant improvements between the two groups with regard to pitting
(non-occluded), subungual hyperkeratosis, leuconychia, nail plate
crumbling/loss, splinter haemorrhage, or nail growth rate.
Tzung 2008 studied calcipotriol in combination with betametha-
sone dipropionate versus calcipotriol alone. Both treatments were
efficacious in improving oil drop discolourations (P ≤ 0.039).
Other nail bed features, as well as nail matrix features, failed
to show significant improvement regardless of the treatment (P
> 0.131). Nail crumbling even worsened during the treatment
course.
Tosti 1998 studied the improvement of finger and toenail thick-
ness. After 3 months, subungual hyperkeratosis of the fingernails
reduced by 26.5% (score = 2.3 to 1.5 mm) and by 30.4% (score
= 2.3 to 1.6 mm), respectively for calcipotriol and betamethasone
(not significant compared to the other treatment). Eight out of
13 calcipotriol-treated participants and 10 out of 16 betametha-
sone-treated participants showed more than 50% improvement
of the hyperkeratosis in at least 1 fingernail (this was defined as
responders), and these responders continued treatment for 2 more
months. There was no homogeneity regarding the baseline thick-
ness for these 2 subgroups (the thickness was 2.8 mm for the cal-
cipotriol group and 2.1 mm for the betamethasone group). After
5 months of treatment, responders reported a score reduction of
49.2% in hyperkeratosis treated with calcipotriol (score = 2.8 to
1.4 mm) and a reduction of 51.7% (score = 2.1 to 1.0 mm) for
the group treated with betamethasone (significant from baseline
(P < 0.001), but not significant between treatments).
Follow-up
Participants who were treated for five months were evaluated one
month after discontinuation. The improvements persisted at the
six-month visit.
After 3 months, the hyperkeratosis of the toenail treated with
calcipotriol reduced by 20.1% (score = 2.6 to 2.1 mm) and by
22.9% (score = 3.0 to 2.3mm) for the participants treated with be-
tamethasone. This improvement was statistically significant com-
pared to baseline hyperkeratosis (P < 0.001), but it was not signifi-
cant between the 2 treatments. Seven out of 20 of the calcipotriol-
treated participants and 12 out of 24 of the betamethasone-treated
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participants were responders. These two subgroups were heteroge-
neous regarding hyperkeratosis at baseline. After 5 months, con-
sidering the responders from baseline to 5 months of treatment,
there was a further reduction of 40.7% (score = 1.2 ± 0.1 mm) in
the calcipotriol group and 51.9% (score = 1.3 ± 0.1 mm) in the
betamethasone group (P < 0.0001 from baseline). Unfortunately,
the five-month data of the non-responders were not reported.
Follow-up
The improvement of the toenails persisted after follow up of one
month.
There was no significant difference between the calcipotriol and
betamethasone groups (RR 0.98, 95% CI 0.55 to 1.75; Analysis
5.1) for the outcome ’Participants with at least 50% nail score im-
provement after short-term treatment duration’, and there was also
no significant difference in ’nail score improvement after short-
term treatment duration’ between the calcipotriol and betametha-
sone groups (standardised mean differences (MD) 0.30, 95% CI
-0.14 to 0.74; Analysis 5.2)
Systemic therapy (six studies)
Six trials studied the effect of systemic treatment on nail dys-
trophy (G m el 2011; Igarashi 2012; Kavanaugh 2009; Levell
1995; Mahrle 1995; Rich 2008). The studies by G m el 2011,
Mahrle 1995, and Levell 1995 compared treatment with systemic
ciclosporin to methotrexate (for 24 weeks), to etretinate (for 22
weeks), and to topical dithranol with salicylic acid and UVB (up
to 16 weeks), respectively.
Igarashi 2012, Kavanaugh 2009, and Rich 2008 studied biologi-
cals. Igarashi 2012 studied ustekinumab 45 and 90 mg compared
to placebo for 64 weeks. Kavanaugh 2009 compared golimumab
to placebo for 20 weeks. Rich 2008 reported data on nail psoriasis
involvement from the original skin psoriasis study by Reich 2005
(EXPRESS Study), which compared infliximab to placebo for 46
weeks.
Primary outcomes addressed by the systemic studies
(a) Global improvement of nail psoriasis as rated by a
clinician
Four trials with 490 participants assessed nail psoriasis by a clini-
cian.
In the study with methotrexate 15 mg/week versus ciclosporin 5
mg/kg/day by G m el 2011, the physician performed a general
evaluation of the nail at each visit. Both treatment groups showed
no significant difference in the mean physicians’ global score (P =
0.28).
Mahrle 1995 reported non-significant nail score reductions of
17.5% and 9.2% in 90 participants treated with ciclosporin 2.5
mg/kg and in 47 participants treated with etretinate 0.5 mg/kg,
respectively, during the first 10 weeks (phase 1) of the trial. This
internally-controlled study had no available P values.
In Levell 1995 after a median of 6 weeks’ treatment, the global
improvement of nail psoriasis, as rated by a clinician, to ciclosporin
2.5 mg/kg (with a median baseline score of 5.5) was improved for
8 participants; 1 had no change; and it was worse for 1 participant
(median decrease in severity score of 4.5; 95.1% CI 0 to 8). The
median nail score improvement was 82% at the end of treatment.
After a median of 8 weeks’ treatment, the global response of nail
psoriasis, as rated by a clinician, to dithranol with salicylic acid and
UVB treatment (with a median baseline score of 5) was improved
for 8 participants, unchanged for 2, and worsened for 5 (the me-
dian decrease in severity score was 0, 95.2% CI -3 to 2.5). The
median nail score improvement was 0% at the end of treatment.
Follow-up
All participants whose psoriasis cleared were followed up until
relapse (return of psoriasis to 50%) or until 8 months had elapsed.
For 8 participants on ciclosporin treatment and 10 participants on
dithranol with salicylic acid and UVB, their psoriatic nail involve-
ment cleared. Of these eight ciclosporin participants, one showed
no change, and seven worsened after stopping treatment. The me-
dian increase of the nail severity score by the end of the follow up
was 5 (96.1% CI 2 to 9.5). Of the 10 dithranol with salicylic acid
and UVB participants, 1 showed no changes, 7 improved, and 2
worsened. The median improvement in score at the end of the
follow-up period was 4 (95.8% CI 0 to 8). Overall, psoriatic nail
disease improved during ciclosporin treatment but deteriorated
to more severe disease after treatment was stopped. No compari-
son was reported between the two treatment groups. No follow-
up data were reported for the participants with nail involvement
whose psoriasis had not cleared. This study showed participants
with at least 50% nail score improvement after a short-termperiod
of systemic therapy with ciclosporin, which was not significantly
better than topical dithranol (RR 1.50, 95% CI 0.85 to 2.64;
Analysis 1.1).
In the study by Kavanaugh 2009, the baseline physician global
assessment in the golimumab (50 mg and 100 mg) and placebo
group was reported for 40% to 50% of the participants’ nails as
’mild’ (41/146 participants with golimumab 50 mg, 50/146 par-
ticipants with golimumab 100 mg, and 52/113 participants with
placebo) and for 30% to 40% as ’moderate’ (39/146 participants
with golimumab 50mg, 32/146 participants with golimumab 100
mg, and 35/113 participants with placebo).
Participants received injections of placebo, golimumab 50 mg, or
golimumab 100 mg every 4 weeks until week 20; however, the
efficacy assessment was performed at weeks 14 and 24. At week
14, the number of participants with an improved nail assessment
was significant compared to baseline, and it was almost equal for
both golimumab doses, 47% (43/91 with 50 mg) and 48% (52/
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108 with 100 mg) (P < 0.001), increasing further to 60% (53/89
with 50 mg) and 63% (68/108 with 100 mg) (P < 0.001) at week
24. At week 14, 14% (11/81) of the placebo-treated participants
had nail improvement, which increased to 18% of the participants
(14/79) at week 24. No comparison was reported between the
two treatment groups. It was not possible to analyse ’participants
with at least 50% nail score improvement’ using the data from this
study.
(b) Improvement of nail psoriasis scores (NAS, NAPSI)
Four trials with 731 participants assessed nail psoriasis by NAPSI.
G m el 2011 showed the comparison with methotrexate and
ciclosporin. At week 24, themeanNAPSI (± SD) was 18.0 (±11.5)
in the methotrexate group and 25.8 (±19.2) in the ciclosporin
group. This was not significant between the 2 agents (P = 0.27)
(MD -7.80, 95% CI -18.44 to 2.84; Analysis 9.1). From baseline
to week 24, a relative reduction of 43.3% and 37.2% was reported
for methotrexate and ciclosporin, respectively (P = 0.49).
At week 24, methotrexate had a mean NAPSI improvement of
49.3% for fingernails and 43.1% for toenails. The total nail matrix
score significantly decreased (P = 0.001) at week 24. The total nail
bed showed no significant improvement (P = 0.093) at week 24.
The hand nail matrix, hand nail bed, and toenail matrix reported
a significant improvement: P = 0.002, P = 0.036, and P = 0.031,
respectively. However, no improvement was reported for the nail
bed of the toes (P = 0.070).
At week 24, ciclosporin had a mean NAPSI improvement of
45.2% for fingernails and 32.7% for toenails. The total score of
the nail bed, hand nail bed, and toenail bed reported a significant
improvement: P = 0.001, P = 0.006, and P = 0.02, respectively.
There was no significant changes reported for the matrix scores.
Follow-up
After a follow up of 3 months, the mean NAPSI did not increase
compared to week 24. A mean NAPSI of 18.3 and 25.4 was re-
ported with methotrexate and ciclosporin, respectively. No im-
pairment of nail psoriasis was reported with ciclosporin after fol-
low up if complete improvement was reached at week 24. Both
treatment groups showed a lower mean NAPSI after follow up
compared to the mean score at week 24.
Igarashi 2012 compared ustekinumab 45 mg and 90 mg to
placebo. At week 12, the NAPSI had a mean percentage reduction
of 7.7 ± 95.1 (P = 0.6541) for ustekinumab 45 mg and 10.0 ±
66.1(P=0.4395) for ustekinumab90mg, compared to the placebo
group’s of -2.9 ± 27.8, which was not significant (MD 0.41, 95%
CI -30.94 to 31.76; MD 0.54, 95% CI -23.84 to 24.92, respec-
tively; Analysis 6.1; Analysis 7.1).
There was no significant nail score improvement in the ustek-
inumab 90 mg group versus 45 mg after short-term treatment du-
ration (MD -0.13, 95% CI -35.17 to 34.91; Analysis 8.1).
After 64 weeks of treatment, the NAPSI score had a mean im-
provement of 56.6 ± 43.2% and 67.8 ± 37.5% for the 45 mg
ustekinumab group and 90 mg ustekinumab group (no P value).
In Rich 2008 (nail subgroup from the original study, Reich 2005),
the percentage reduction fromNAPSI at baseline was significantly
greater in infliximab-treated participants than in placebo-treated
participants (26.8% versus -7.7%, respectively) at week 10 and
(57.2% versus -4.1%, respectively) at week 24 (both P < 0.001).
At week 50, the infliximab group maintained nail improvements
achieved at week 24. At week 24, the participants treated with
placebo switched to infliximab and achieved further reductions.
Infliximabwas applied through until week 46; however, theNAPSI
was assessed at week 50.
A different subgroup of participants (original study Reich 2005)
with nail psoriasis who initiated and continued infliximab treat-
ment up to week 46 (n = 186) was conducted by Reich 2010. The
mean NAPSI improvement was 28.3% at week 10, followed by
61.4% at week 24, and 67.8% at week 50. Among participants
with PASI-75 (Psoriasis Area and Severity Index) and PASI-90 skin
psoriasis improvement at week 50, the mean percentage improve-
ments in the NAPSI score were 29.6% and 31.2%, respectively, at
week 10; 63.4% and 65.3% at week 24; and 78.2% and 80.3% at
week 50. Among the PASI-75 and PASI-90 responders, complete
nail clearance was observed in 31.6% and 54% at week 24, and
in 55.8% and 62.0% at week 50, respectively.
Kavanaugh 2009 studied golimumab in different doses (50 mg
and 100 mg) versus placebo. There was a significant improvement
in median NAPSI for golimumab 50 mg and 100 mg: 25% (P =
0.015) and 43% (P < 0.001), respectively, versus 0% in the placebo
group. Further significant improvement was seen through week
24 (1 month after treatment was stopped): 33% for golimumab
50 mg (P < 0.001) and 54% for golimumab 100 mg (P < 0.001).
Placebo-treated participants still had no improvement at week 24.
No comparison was reported between the two treatment doses.
(c) Improvement of nail psoriasis in the participant’s opinion
One trial with 37 participants assessed nail psoriasis in the partic-
ipants’ opinion.
In the study with methotrexate 15 mg/week versus ciclosporin
5 mg/kg/day by G m el 2011, the participants performed a
general evaluation of the nail. At week 24, the mean partici-
pants’ global score showed no significant difference between the
methotrexate and ciclosporin group (P = 0.06). A clinical evalu-
ation using the NAPSI score (participants’ response) was classi-
fied at week 24. Seven (41.1%) of the participants treated with
methotrexate showed a moderate improvement, and 10 (58.8%)
participants, a mild improvement. One (5.8%) participant treated
with ciclosporin showed no improvement; 8 (47%) participants
showed mild improvement; 7 (41.1%) participants showed mod-
erate improvement, and 1 (5.8%) participant showed a complete
improvement.
22Interventions for nail psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Secondary outcomes addressed by the systemic studies
(a) Adverse effects (and serious adverse effects, i.e. serious
enough to require withdrawal of the treatment)
Six trials with 897 participants assessed the adverse effects (AE).
G m el 2011, Igarashi 2012, Mahrle 1995, Levell 1995, Rich
2008, and Kavanaugh 2009 reported adverse effects, which were
in some trials not specified for the nail psoriasis group.
Adverse effects caused by methotrexate were detected in three par-
ticipants (G m el 2011): Two experienced nausea and telogen
effluvium (thinning and shedding of hair) during the study pe-
riod, and one who discontinued the treatment had an elevation of
liver transaminase.
Five participants demonstrated adverse effects caused by ci-
closporin in the control group: One developed hypercholestero-
laemia; one, hirsutism; another had menstrual abnormalities; and
two had an elevation of creatinine and lipids, therefore, discontin-
uing treatment.
None of the participants in the methotrexate or ciclosporin group
experienced adverse effects on the nails, except for 1 participant
treated with ciclosporin, who reported on the distal part of the
nail a mild pain after 10 weeks.
During the first 12 weeks of administration of 45mg ustekinumab
and 90 mg ustekinumab (Igarashi 2012), the adverse effects re-
ported were mostly mild. This did not result in discontinuation
of the therapy. In the placebo group, 25% experienced an exac-
erbation of psoriasis as the most common adverse effect. In the
ustekinumab groups, nasopharyngitis (45 mg = 15.6%, 90 mg =
16.1%) was the most commonly-reported adverse effect. The pro-
portion of participants reporting serious adverse effects was low
(placebo = 6.3%, ustekinumab 45 mg = 0%, ustekinumab 90 mg
= 4.8%). Infections were mentioned in 18.8% of the participants
in the placebo group, 20.3% of the 45 mg ustekinumab group,
and 24.2% of the 90 mg ustekinumab group. Up to week 72, the
most common adverse effects reported were nasopharyngitis, in-
creased blood triglycerides and increased creatine phosphokinase,
and seasonal allergies, including allergic rhinitis.
The most common adverse effects in the ciclosporin group in
the study by Mahrle 1995 were gastrointestinal, skin and mucous
membrane symptoms, nervous system and psychiatric disorders,
and general adverse reactions. The percentage of participants with
adverse effects was higher in the etretinate (control) group com-
pared to the (intervention) ciclosporin group. In the etretinate
group, cheilitis (inflammation of the lip), dry mouth, and skin
exfoliation were reported.
The study by Levell 1995 assessed minimal toxicity in the ci-
closporin group. A 25% dose reduction of ciclosporin was needed
because of high blood pressure (150/100 mmHg) in 1 partici-
pant. The blood pressure subsequently returned to normal. In one
participant, the serum creatinine increased when on ciclosporin
by > 30% after 8 weeks’ treatment, but this reversed after a 25%
dose reduction. Besides this, both groups reported an increasing
serum urate and fall in serum magnesium. The group adminis-
tered dithranol with salicylic acid, and UVB also reported a burn-
ing sensation of the skin.
In the study by Rich 2008, 82% of participants with infliximab 5
mg/kg experienced at least 1 adverse effect at week 24, compared
to 71% in the placebo group. Kavanaugh 2009 reported adverse
effects for participants with psoriatic arthritis who were given goli-
mumab (50 and 100 mg) compared to the placebo group: 65%
(222/343) of participants with golimumab had adverse effects
(mostly nasopharyngitis and upper respiratory tract infections) at
the week-24 measurement compared to 59% (67/113) of those in
the placebo group. Most infections were reported for those in the
100 mg golimumab group (33% in the 50 mg group, 41% in the
100 mg group, 24% in the placebo group).
Table 5 shows the weighted average of adverse effects for systemic
therapy: 69.8% in the intervention group and 60.3% in the com-
parison group. Systemic therapy showed the highest weighted av-
erage of adverse effects, compared to topical and radiotherapy.
The study by Mahrle 1995 (RR 1.78, 95% CI 1.30 to 2.44)
showed that significantly more participants experienced adverse
effects in the control than in the intervention group. In the studies
by Igarashi 2012, G m el 2011, Kavanaugh 2009, and Rich
2008, there was no significant difference in adverse effects experi-
enced by the participants in either group (Analysis 4.1, see Anal-
ysis 4.1.2).
(b) Effects on quality of life
None of the systemic studies addressed this outcome.
(c) Improvement in nail features, pain score, nail thickness,
thickness of subungual hyperkeratosis, number of affected
nails, and nail growth
One trial with 305 participants assessed separate nail features (Rich
2008).
In this study, participants on infliximab showed an improvement
of nail features. At week 24, the nail matrix had a mean improve-
ment from baseline of 52.9% compared to a worsening of -1.9%
for placebo (P < 0.001), and the nail bed had amean improvement
of 69.2% compared to 18.4% for placebo (P < 0.001).
Infliximab improved the nail score for most of the nail features
measured at weeks 10, 24, and 50. In the placebo group, the score
was unchanged or only modestly decreased. After cross-over from
placebo to infliximab at week 24, the nail score for all of the nail
features further decreased.
At baseline, the most frequent nail matrix feature was pitting
(70%), and subsequently leuconychia, nail plate crumbling, and
red spots in the lunula. Red spots in the lunula reported the fastest
reduction. Only 33.3% (9/77) of the infliximab participants had
persistent red spots in the lunula at week 10. By week 24, the in-
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fliximab group showed significant (P < 0.001) improvement com-
pared to the placebo group for participants with persistent pitting
(57% versus 93%) and leuconychia (26.2% versus 77.3%) fea-
tures.
The most common nail bed feature was onycholysis (70%), and
subsequently oil drop discolourations, nail bed hyperkeratosis, and
splinter haemorrhages. By week 24, the infliximab group showed
significant improvement (P < 0.001) compared to placebo: Of
those participants receiving infliximab, 25.9% had persistent ony-
cholysis compared to 79.1% receiving placebo, and 26.5% on in-
fliximab had persistent oil drop discolourations compared to 69%
receiving placebo.
Radiotherapy (three studies)
Three trials studied the effect of radiotherapy versus placebo on
nail dystrophy (Kwang 1995; Lindelof 1989; Yu 1992). Lindelof
1989 studied 5 Gy of grenz rays (ultrasoft X-rays) on 10 occasions
at intervals of 1 week. Yu 1992 studied superficial radiotherapy
(SRT) given as 3 fractionated doses of 150 cGy, which were ad-
ministered every 2 weeks to a total of 450 cGy per fortnight (90
kV, 5 mA, 1.00 mm aluminium filter), and Kwang 1995 used
electron beam, with a total of 6 Gy given in 8 fractions over 8
weeks.
Primary outcomes addressed by the radiotherapy studies
(a) Global improvement of nail psoriasis as rated by a
clinician
In all 3 trials, with a total of 46 participants, a clinician assessed
nail psoriasis.
After 10 weeks, Lindelof 1989 (internally-controlled study)
showed a significantly better effect on psoriatic nails with grenz ray
therapy compared to placebo (P < 0.05). However, the response
was moderate. Of the 24 included participants, 2 withdrew be-
cause of illness in their families. Of the 22 remaining, 1 partici-
pant showed almost complete recovery; however, 14 participants
showed no improvement at all.
Follow-up
During the follow-up period of 6 months, there were no clear
signs of further improvements (18 participants were unchanged; 2
improved moderately; 2 became slightly worse). All the nails that
responded were of normal thickness; hyperkeratotic nails did not
respond.
In Yu 1992, the superficial radiotherapy-treated group demon-
strated a significant fall in the nail score compared to baseline.
This was measured at 10 weeks (score = 5.5 ± 0.4 to 4.4 ± 0.3
(20%)) (P < 0.0001) and at 15 weeks (score = 5.5 ± 0.4 to 4.6 ±
0.4 (16%)) (P = 0.046) after therapy. The control group showed
no score improvement compared to baseline at week 10 (score =
5.4 ± 0.4 to 5.4 ± 0.6 (0%) and even worsening at week 15 (score
= 5.4 ± 0.4 to 5.5 ± 0.4 (-1.85%)) (no P value). At weeks 10 and
15, a significant improvement was shown for the treated group
compared to the untreated group (P = 0.03 and P = 0.047, respec-
tively). At week 20, the nail score remained 4.6 (16% improve-
ment from baseline) in the treated group. In the untreated group,
the nail score reduced to 4.8 (11% improvement from baseline)
(not significant) at week 20.
The efficacy of electron beamwith eight fractions over eight weeks
was studied in an internally-controlled trial by Kwang 1995 where
treatment was administered to the affected nails of one hand; the
other hand was used as control. Assessment was performed at 3,
6, and 12 months after treatment. Three months after treatment,
electron beam showed a significant reduction (P < 0.05) compared
to the other hand; however, not at 6months (P > 0.5) or 1 year (P >
0.5). Compared to week 0, the treated hands showed a significant
improvement at 3 months (P < 0.05) and 6 months (P < 0.05)
after treatment, but this was not shown at 1 year (P > 0.5).
(b) Improvement of nail psoriasis scores (NAS, NAPSI)
None of the radiotherapy studies addressed this outcome.
(c) Improvement of nail psoriasis in the participant’s opinion
None of the radiotherapy studies addressed this outcome.
Secondary outcomes
(a) Adverse effects (and serious adverse effects, i.e. serious
enough to require withdrawal of the treatment)
Three trials with 46 participants assessed adverse effects.
• Grenz rays (Lindelof 1989): 5 out of 22 participants
showed slight pigmentation of the grenz ray-treated nail fold.
• Superficial radiotherapy (Yu 1992): This assessed adverse
effects, but did not report any.
• Electron beam (Kwang 1995): The only local adverse effect
was short-lasting brownish-black discolourations of all the nails
treated with electron beam.
Table 5 shows the weighted average of adverse effects for radiother-
apy: 40.5% in the intervention group and 0% in the comparison
group.
Analysis 4.1 shows the number of participants with adverse effects
of any treatment. The study from Kwang 1995 showed signifi-
cantly more adverse effects in the intervention group compared
to the control group (RR 0.04, 95% CI 0.00 to 0.61). Lindelof
1989 showed no significant difference in adverse effects reported
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in the treatment group compared to the placebo group (RR 0.09,
95% CI 0.01 to 1.55).
(b) Effects on quality of life
None of the radiotherapy studies addressed this outcome.
(c) Improvement in nail features, pain score, nail thickness,
thickness of subungual hyperkeratosis, number of affected
nails, and nail growth
One trial with 12 participants assessed separate nail features
(Kwang 1995). One trial with 10 participants assessed nail growth
and thickness (Yu 1992). These studies were both internally-con-
trolled.
A decrease in subungual hyperkeratosiswas themain improvement
noted after eight fractions with electron beam, followed by pitting
andonycholysis.No assessmentwas reported directly after 8weeks’
treatment, but at 3, 6, and 12 months after treatment (Kwang
1995). No P values or underlying data were available.
At 10, 15, and 20 weeks post-treatment, the rate of linear nail
growth by Yu 1992 slightly diminished in the superficial radio-
therapy (SRT)-treated nails compared with the control nails (not
statistically significant). At week 15, treated nails demonstrated a
significant reduction in mean nail thickness (1.10 mm ± 0.08 to
0.75 mm ± 0.03) compared to the placebo group (1.20 ± 0.09 to
0.88 ± 0.04) (P = 0.005). This difference was not significant after
20 weeks of treatment.
Additional: Nail features
We evaluated the efficacy of interventions on nail features (nail
matrix and nail bed features) and reported this separately per fea-
ture instead of per intervention. Eleven included trials assessed the
following nail features: onycholysis, pitting, subungual hyperker-
atosis, leuconychia, red spots in the lunula, salmon patches, splin-
ter haemorrhages, ridging, furrows, transverse grooves, Beau lines,
onychomadesis, periungual psoriasis, crumbling, oil drop, nail fold
involvement, the extent of nail pitting, onychorrhexis, onicoressi,
nail plate discolourations, nail thickness, and nail growth.
Table 7 presents the most common nail features in the nail matrix
and nail bed. Figure 5 shows some pictures of nail features.
Figure 5. Some nail features: onycholysis, splinter haemorrhages, pitting, and oil drop or salmon patches
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Nail matrix
Pitting
Pitting was studied separately in seven trials: Cannavo 2003, Flori
1994, de Jong 1999, Rich 2008, Rigopoulos 2007, Scher 2001,
and Tzung 2008.
The best improvement in pitting was seen with topical ciclosporin
70% in maize oil twice daily for 12 weeks (Cannavo 2003). The
median severity score changed from 0.5 before treatment to 0.0
after treatment, an improvement of 100% (P = 0.086).
Tazarotene 0.1% cream once daily for 12 weeks under occlusion
showed a 75.2% nail score improvement after treatment (from
score 1.13 to 0.28) (Rigopoulos 2007). The clobetasol group saw
a nail score improvement of 67% in pitting (from 1.09 to 0.36).
Although there was no significant difference between these 2 in-
terventions, there was a significant improvement over time (P <
0.001) for both agents.
Infliximab 5 mg/kg gave a complete clearance to 56.4% (84/149)
in the participants with pitting after 50 weeks (Rich 2008). At
week 24, the placebo group crossed over to infliximab and showed
for 67.5% (27/40) of the participants complete clearance at week
50.
After 90 days of treatment with hyaluronic acid and chondroitin
sulphates (Flori 1994), there was an improvement of 41.4% (sever-
ity score from 1.9 ± 0.88 to 1.1 ± 0.74). This was significant com-
pared to baseline (P = 0.003), but not significant compared to
placebo.
After 24 weeks of tazarotene 0.1% gel under occlusion, an im-
provement of 33.3% was shown (this was significant versus vehi-
cle, P ≤ 0.05) (Scher 2001).
Treatment with 1% 5-fluorouracil (de Jong 1999) gave a 28% im-
provement in the nail pit area (score = 2.9 to 2.1). The improve-
ment of the number of nail pits was not significant (P > 0.05).
Treatment with calcipotriol 0.005% failed to show significant im-
provement (P ≥ 0.131) in pitting after 12 weeks (Tzung 2008).
Red spots in the lunula
Rich 2008 and Tzung 2008 described red spots in the lunula.
Treatment with infliximab 5 mg/kg showed a complete clearance
in 24 participants after 50 weeks (96% (24/25)) (Rich 2008). At
week 24, the placebo group switched to infliximab and showed
complete clearance in all (3/3) participants atweek 50.Calcipotriol
0.005% failed to show significant improvement of the red spots
in the lunula (P ≥ 0.131) after 12 weeks (Tzung 2008).
Leukonychia
Three trials (Rich 2008, Scher 2001, and Tzung 2008) studied
leuconychia as a separate nail feature.
After 50 weeks, clearance was seen both in 82% of the participants
treated with infliximab (82/100) and also in the group who were
initially given placebo (18/22) (Rich 2008).
Treatment with calcipotriol (P ≥ 0.131) or tazarotene gel failed
to show a significant improvement of leuconychia (Scher 2001;
Tzung 2008).
Crumbling
Cannavo 2003, Rich 2008, Scher 2001, and Tzung 2008 studied
nail crumbling as a separate nail feature.
Treatment with topical ciclosporin 70% inmaize oil gave amedian
improvement of 100% for crumbling (score = 1.5 to 0.0, P <
0.05) after 12 weeks (Cannavo 2003). Also, 66.7% (50/75) of the
participants treated with infliximab showed a complete clearance
after 50 weeks (Rich 2008).
Tazarotene 0.1% gel showed no significant difference for nail
crumbling between the treated and placebo group (no underlying
data) (Scher 2001). Calcipotriol 0.005% showed a worsening of
nail crumbling after 12 weeks (P ≥ 0.131; no further data were
available) (Tzung 2008).
Nail bed
Onycholysis
Seven trials (Cannavo 2003; Flori 1994; de Jong 1999; Rich 2008;
Rigopoulos 2007; Scher 2001; Tzung 2008) studied onycholysis.
The best improvement was seen with topical ciclosporin 70% in
maize oil (Cannavo 2003) and infliximab (Rich 2008). After 12
weeks, topical ciclosporin 70% in maize oil showed a 100% im-
provement of the onycholysis (median severity score before treat-
ment was 3.0, whereas after treatment it was 0.0, P < 0.001).
Infliximab 5 mg/kg reported complete clearance in 73.2% (104/
142) of the participants after 50 weeks (Rich 2008). At week 24,
the group who were initially given placebo switched to infliximab.
After 50 weeks of treatment, 78% of these participants showed
clearance (32/41).
After 90 days, hyaluronic acid and chondroitin sulphate showed
a score improvement of 68.8% (score = 2.1 to 0.7) compared to
baseline for onycholysis (Flori 1994). Rigopoulos 2007 studied ei-
ther tazarotene 0.1% cream or clobetasol propionate 0.05% once
daily under occlusion for 12 weeks. Tazarotene 0.1% cream once
daily under occlusion showed an improvement of 58.4% (severity
score from 1.97 to 0.82) for onycholysis after 12 weeks, which
was decreased to 21.8% (severity score = 1.54) in the follow-up
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period at 24 weeks. Clobetasol showed a total of 56.8% score
improvement after 12 weeks (severity score from 1.90 to 0.82),
which decreased to 8.9% (severity score = 1.73) after 24 weeks. Al-
though there was no significant difference between the 2 interven-
tions in terms of onycholysis, there was a significant improvement
over time (P < 0.001) for both agents. In the non-occluded nails,
tazarotene 0.1% gel showed an improvement of 33% compared
to vehicle (which was statistically significant, P ≤ 0.05) after 24
weeks (Scher 2001). For the occluded nails, the study reported
significant improvement compared to vehicle (P ≤ 0.05) without
underlying data. de Jong 1999 treated onycholysis with 1% 5-flu-
orouracil for 12 weeks and reported a score improvement of 19%
(score = 1.6 to 1.3), which was not significant (P > 0.05).
Calcipotriol studied as monotherapy or in combination with be-
tamethasone dipropionate failed to show significant improvement
(P ≥ 0.131) in onycholysis (Tzung 2008).
Splinter haemorrhages
Rich 2008, Scher 2001, and Tzung 2008 separately described
splinter haemorrhages. The only improvement was seen with in-
fliximab 5 mg/kg (Rich 2008). After 50 weeks, 88% (44/50) of
the participants showed a complete clearance. Ninety per cent
(9/10) of the placebo group that switched to infliximab after 24
weeks of treatment showed a complete clearance after 50 weeks.
Treatment with tazarotene 0.1% gel and calcipotriol 0.005% (P
≥ 0.131) failed to show a significant improvement (Scher 2001;
Tzung 2008).
Salmon patches and oil drop discolourations
The terms ’salmon patches’ and ’oil drop discolourations’ are used
interchangeably in the literature. The following described the
features: Rigopoulos 2007 (salmon patches), Cannavo 2003 (oil
drop), de Jong 1999 (oil spots), Rich 2008 (oil drop), and Tzung
2008 (oil drop).
Rich 2008 showed the best results with infliximab, andRigopoulos
2007 showed the best results with tazarotene 0.1% cream or clo-
betasol 0.05%. Infliximab showed a complete clearance in 81.2%
(78/96) of the participants after 50 weeks. Tazarotene 0.1% cream
once daily under occlusion showed a score improvement of 85.2%
(score = 1.15 to 0.17) after 12 weeks (P < 0.001 to baseline). Clo-
betasol 0.05% once daily under occlusion showed a 82.2% (score
= 1.07 to 0.19) score improvement (P < 0.001 to baseline). There
was no significant difference between these two interventions in
terms of salmon patches.
1% 5-fluorouracil showed 63% score improvement (score = 0.8
to 0.3) after 12 weeks (de Jong 1999).
Participants who were treated twice daily with topical ciclosporin
70% inmaize oil showed a 75% score improvement (median score
at baseline was 2.0 to 0.5 after treatment, P = 0.07) after 12 weeks
(Cannavo 2003).
Calcipotriol as monotherapy and as combination therapy with
betamethasone dipropionate both showed efficacy in improving
oil drop discolourations (P < 0.039) (Tzung 2008). The study did
not provide further underlying data.
Subungual hyperkeratosis and nail thickness
Eight studies (Cannavo 2003; de Jong 1999; Flori 1994; Rich
2008; Rigopoulos 2007; Scher 2001; Tzung 2008; Tosti 1998)
described subungual hyperkeratosis as a separate nail feature. Yu
1992 assessed nail thickness.
A complete clearance was shown in 78.7% (70/89) of the partic-
ipants treated with infliximab after 50 weeks (Rich 2008). Top-
ical ciclosporin 70% in maize oil presented an improvement of
83% (median baseline score = 3.0 to 0.50 after treatment, P <
0.005) after 12 weeks (Cannavo 2003). Tazarotene 0.1% cream
showed an improvement of 80% (score = 1.8 to 0.36), while clo-
betasol reported 66% improvement (score = 1.70 to 0.58) after 12
weeks; both were significant to baseline (P < 0.001), with no sig-
nificance between agents (Rigopoulos 2007). Twelve weeks after
the end of treatment hyperkeratosis seemed to retain significant
improvement for participants applying tazarotene (score = 0.97,
P < 0.001). Treatment with hyaluronic acid and chondroitin sul-
phates showed a mean score changed from 1.3 (at baseline) to 0.4
(after 90 days); this was an improvement of 70% (Flori 1994).
Tazarotene 0.1% gel showed no significant difference between the
treated group and the placebo group after 24 weeks (Scher 2001).
After 12 weeks with 1% 5-fluorouracil once daily, de Jong 1999
reported a 47% score improvement (score changed from 1.9 to
1.0).
Tzung 2008 failed to show significant improvement (P ≥ 0.131)
with calcipotriol 0.005% as well as treatment with calcipotriol in
combination with betamethasone dipropionate .
Tosti 1998 studied calcipotriol 50ug/g, which showed an improve-
ment of 26.5% (score = 2.3 to 1.5 mm) of the fingernail thickness
and 20.1% (score 2.6 to 2.1 mm) of the toenail thickness after 3
months. The comparison group given betamethasone and salicylic
acid had an improvement of 30.4% (score = 2.3 to 1.6mm) of their
fingernails and 22.9% (score = 3.0 to 2.3 mm) improvement of
their toenails. Responders (more than 50% improvement in base-
line hyperkeratosis in 1 or more nails at 3 months) were offered
a continuation of the initially-applied treatment for 2 additional
months. After 5 months’ treatment with calcipotriol, subungual
hyperkeratosis of the fingernails showed a 49.2% reduction (from
2.8 to 1.4 mm) and the toenails showed a 40.7% (to 1.2 mm)
reduction. The betamethasone and salicylic acid group reported a
51.7% (score = 2.1 to 1.0 mm) and 51.9% (to 1.3 mm) decrease
of subungual hyperkeratosis in fingers and toenails, respectively.
Superficial radiotherapy demonstrated a significant reduction in
mean nail thickness of 31.8% (1.10 ± 0.08 to 0.75 ± 0.03) com-
pared to the sham-treated group (P = 0.005) at week 15 (Yu 1992).
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Other
Beau lines and onicoressi
Flori 1994 assessed these two nail features separately after treat-
ment with hyaluronic acid and chondroitin sulphates. After 90
days of treatment, there was an improvement of 31.8% of the
Beau lines (score = 1.5 ± 0.83 to 1.0 ± 0.65), which was significant
compared to baseline (P = 0.018) but not significant compared to
placebo, and a 65% improvement of onicoressi (score = 1.3 ± 1.11
to 0.5 ± 0.64), which was significant compared to baseline (P =
0.018) and placebo (P = 0.039).
Nail growth
Scher 2001 and Yu 1992 described nail growth. In both studies,
there was no significant difference in nail growth between the
treated group (respectively, tazarotene gel 0.1% and superificial
radiotherapy) and the placebo group.
D I S C U S S I O N
In this review, we provided a summary of the best available evi-
dence for several types of treatments for nail psoriasis: topical, sys-
temic, and radiotherapy. This will be useful for producing guide-
lines and identifying future research.
Summary of main results
Of the 212 retrieved references, we could only include 18 trials,
with a total of 1266 participants.
The quality of the studies was generally poor as assessed by the risk
of bias of the studies (see Figure 3, ’Methodological quality graph:
review authors’ judgements about each methodological quality
item presented as percentages across all included studies’), and
the evidence of the efficacy and safety of treatment options for
nail psoriasis was based on only one study per treatment for most
therapies.
We assessed and compared between treatments the primary out-
comes ’Global improvement of nail psoriasis as rated by a clin-
ician’ and ’Improvement of nail psoriasis scores’. Two biologic
and three radiotherapy studies showed significant results for the
improvement of nail psoriasis compared to placebo (Kavanaugh
2009; Kwang 1995; Lindelof 1989; Rich 2008; Yu 1992). Inflix-
imab 5 mg/kg showed 57.2% nail score improvement versus -
4.1% for placebo; golimumab 50 mg and 100 mg showed 33%
and 54%, respectively, versus 0% for placebo, both after medium-
term treatment (Kavanaugh 2009; Rich 2008). From the 3 radio-
therapy studies, only the superficial radiotherapy study showed
underlying data: 20% versus 0% score improvement after short-
term treatment (Yu 1992).
Seven studies using 5-fluorouracil 1% in Belanyx® lotion (for
both fingers and toenails), ciclosporin 2.5mg/kg, tazarotene 0.1%
cream, calcipotriol 50 ug/g, calcipotriol 0.005%, methotrexate,
and ustekinumab showed no statistically significant results com-
pared to, respectively, belanyx lotion, etretinate, clobetasol propi-
onate, betamethasone dipropionate with salicylic acid, betametha-
sone dipropionate alone, ciclosporin, and placebo when assessed
by a clinician and by nail scores.
Not all of the included studies assessed nail improvement com-
pared to the control group. This reflects the lower quality of these
trials. Data on improvement compared to baseline was given in 7
studies, which reported significant nail improvement compared to
baseline, of which topical ciclosporin 70% in maize oil (Cannavo
2003), tazarotene 0.1% cream, and clobetasol 0.05% (Rigopoulos
2007) showed > 75% nail improvement after short-term treat-
ment. The percentage score improvement of fingernail psoriasis,
regardless of the outcome measures used, are presented in Table
4 with or without significant improvement to the comparison
group and with or without significant improvement to baseline
after short- and medium-term treatment.
Topical drugs are mostly formulated to treat skin disease, so they
are not optimised for penetrating in and through the nail plate. To
improve penetration, some of the topical therapies were applied
with an enhancer or under occlusion with varying results (de Jong
1999; Rigopoulos 2007; Scher 2001). With regard to the penetra-
tion of radiotherapy through the nail bed, Kwang 1995 stated that
an electron beam could penetrate to the nail bed, unlike grenz rays,
which treat only the surface of the nail. Nails treated with grenz
rays reported no improvement in hyperkeratotic nails. When nails
are of normal thickness, the results of applied radiotherapy might
be different.
Five studies (Cannavo 2003; de Jong 1999; G m el 2011; Tosti
1998; Tzung 2008) assessed our primary outcome ’Improvement
of nail psoriasis in the participant’s opinion’. The participants pre-
ferred topical 70% ciclosporin treatment compared to the placebo
(Cannavo 2003). The participants assessed a mainly ’good’ ac-
ceptability for calcipotriol and betamethasone in Tosti 1998. The
studies by Tzung 2008 and de Jong 1999 showed similar trends for
the participant’s assessment compared to the Investigator’s Global
Assessment.
The secondary outcome ’Adverse effects’ is shown per interven-
tion in Table 5. The percentage of adverse events in the control
groups consist of adverse effects due to placebo or active treat-
ment. Furthermore, in studies about skin psoriasis (Igarashi 2012;
Kavanaugh 2009; Levell 1995; Mahrle 1995; Rich 2008), data on
adverse events were often not presented separately for participants
with or without nail involvement.
In theory, for the internally-controlled trials, there could be a
carry-over effect related to effects and adverse effects. In this re-
view, we did not include internally-controlled trials with systemic
treatment. The trials with topical treatment and radiotherapy are
assumed to be a local treatment, with no or minimal carry-over
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effect.
We did not include studies with systemic therapy solely for nail
psoriasis in this review. For nail psoriasis, when considering sys-
temic therapy the risk and burden of adverse effects must be taken
into account.
Only one study (Cannavo 2003) reported our secondary outcome
’Effects on quality of life’. The topical 70% ciclosporin group
reported more improvement on the ’impact on every day life’ and
’positively experienced social interactions’ of their nail pathology
compared to the control group.
Eleven studies showed separate data on nail features (secondary
outcome parameter), of which 3 (hyaluronic acid + chondroitin
sulphates (Flori 1994), tazarotene 0.1% gel (Scher 2001), and
calcipotriol 0.005% (Tzung 2008)) showed significance in some
features. One study (infliximab (Rich 2008)) showed a significant
decrease in the occurrence of individual features over time. Three
studies showed no significance between the treatments (de Jong
1999; Rigopoulos 2007; Tosti 1998), and four studies reported no
compared data (Baran 1999; Baran 1999a; Cannavo 2003; Kwang
1995). Two trials (Scher 2001; Yu 1992) reported the outcome
parameter nail growth effect.
Table 6, ’Nail features with ≥ 50% improvement’, gives an im-
pression of possible treatment options for each affected feature.
Nevertheless, we should be cautious interpreting these data. Some
studies assessed the improvement of all eight nail features; others
assessed just one feature during the trial. Topical intervention trials
mostly performed separate assessments of the nail features. Trials
with systemic treatments concerning cutaneous psoriasis including
nail psoriasis mainly assessed the global nail feature improvement.
Therefore, it is difficult to compare the efficacy of the different
interventions on the separate nail features. This table shows the
high variability of reporting on nail features in the studies, which
makes comparison impossible.
Overall completeness and applicability of
evidence
The objective of our Cochrane review was to assess the best avail-
able evidence of the efficacy and safety of the treatments for nail
psoriasis.
Psoriasis of the nail bed and nail matrix presents different nail fea-
tures: four in the nail bed and four in the nail matrix, as described
in detail above. These features are assessed separately in nail scores
like NAPSI and NAS, but only a few studies used such specific
scores. Most included studies reported the efficacy according to
point scales of nail features assessed by the physician. Some studies
assessed only a few nail features, according to a nail score or point
scale. Therefore, studies were difficult to compare.
The question is whether the evidence from trials using treatments
on participants with cutaneous psoriasis with nail psoriasis may
be applied to those people with nail psoriasis only.
The systemic-intervention studies Igarashi 2012, Kavanaugh
2009, Levell 1995, Mahrle 1995, and Rich 2008 treated partici-
pants for their plaque psoriasis or psoriatic arthritis, with an effect
on nail psoriasis as a secondary outcome. Therefore, information
such as adverse effects and dropouts was often related to the to-
tal group of participants with psoriasis and not specifically to the
participants with nail psoriasis.
Short-term adverse effects were mainly investigated. Two studies
presented no data on adverse effects in their trial (Baran 1999;
Baran 1999a).
The included studies mainly focused on fingernail, rather than
toenail, psoriasis. The latter was assessed only by Flori 1994,
G m el 2011, and Tosti 1998, of which G m el 2011 eval-
uated nail matrix and nail bed scores in toes only before and after
treatment, and Flori 1994 presented no data at all. Therefore, in
this review, we had insufficient data to report on treatments for
toenail psoriasis.
The applicability of some of the treatments found in our included
studies, such as electron beam therapy, may be disputable and of
limited use in current practice. We identified some ongoing stud-
ies; these may eventually help to fill in the gaps in the evidence for
the efficacy of, for example, adalimumab, etanercept, and topical
methotrexate (see the ’Characteristics of ongoing studies’ tables
and the ’Characteristics of studies awaiting classification’ tables).
Quality of the evidence
It was not possible to pool data because of methodological and
clinical heterogeneity between the studies. There was considerable
variation in how well the studies were reported, which created
difficulties in making accurate assessments of the risk of bias.
We included 18 trials, of which 13 studies reported the method
used to randomise participants. We assumed the study by Baran
1999a was randomised, although the method was unclear because
the comparable trial in the same publication (Baran 1999) was
indeed randomised.
Only 5 trials adequately concealed treatment allocation; in the
other 13 studies, this was not clearly reported. Twelve trials had
a double-blind design; 2 were single-blind; 1 was an open trial;
and 3 were unclear about blinding. Three out of 18 studies were
not free of selective reporting. Six studies were judged to be free of
other bias; eight were unclear; and four were judged to be at high
risk of other biases.
Point-scale measurements (ordinal) were themost commonly used
outcomes for assessing nail psoriasis. Because of the clinical and
methodological heterogeneity of the studies, missing statistical
data, or limitations in study reports, we could not perform meta-
analysis (pooling) and sensitivity analyses.
We could not express numbers needed to treat.
Four cross-over trials (Igarashi 2012; Kavanaugh 2009; Lindelof
1989; Rich 2008) had no carry-over effect because there was a
cross-over from placebo to an intervention treatment. Participants
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treated with ciclosporin and etretinate in Mahrle 1995 crossed
over to topical dithranol after 10 weeks (to phase 2). Because of
no required wash-out, there might have been a carry-over effect in
the second phase. Therefore, we only reported the first 10 weeks
(phase 1) of the study.
There was too much clinical heterogeneity in the studies, for ex-
ample, different populations, disease severity, doses, frequency and
durations of treatment, time points of assessments, including fol-
low up, different outcome measurements used, and type of nail
psoriasis (isolated nail psoriasis or with skin involvement). The
number of participants included in the individual studies varied
widely, from 10 to 305 participants (1 study had 102 participants
(Igarashi 2012); 1, 137 participants (Mahrle 1995); and 1 trial by
Rich 2008 studied 305 participants), but with between 10 and
60 representing the most common sample size. Most comparison
studies compared active treatment with placebo. The treatment
duration ranged between 2 weeks and 64 weeks. The follow-up
duration was variable, with a range of between 4 weeks and 12
months; 5 out of the 18 included studies had no follow-up pe-
riod. Seven studies used standard outcome measures like NAPSI
or NAS. In 14 studies, the physicians assessed the nails according
to point scales. In order to compare the outcome measurements
used, we incorporated as end point ’no/worse’, ’moderate’, and
’good’ improvement. This approach was not ideal; therefore, the
end points should be seen as indicative rather than definitive. Of
the 18 studies assessed, 14 reported losses to follow-up or drop-
outs.
Five studies (Cannavo 2003; de Jong 1999; G m el 2011; Tosti
1998; Tzung 2008) assessed one of our primary outcomes: ’Im-
provement of nail psoriasis in the participant’s opinion’. Only one
study (Cannavo 2003) reported on quality of life as a question-
naire. Eleven studies showed separate data on nail features, and 2
trials (Scher 2001; Yu 1992) reported the outcome parameter nail
growth.
Studies on cutaneous psoriasis that reported the effect on nail pso-
riasis as a secondary outcome of the trial did not mention differ-
ences in outcomes between participants with or without nail pso-
riasis. The outcome of internally-controlled studies (i.e. studies in
which a lesion on one side is compared to another control lesion)
measuring Patient’s Global Assessment (PAGA) score, adverse ef-
fects, and dropouts could be influenced by the treatments of both
sides.
Levell 1995 showed a discrepancy between the data reported in
the figure and text of the original study. In this review, we reported
the data presented in the text.
Potential biases in the review process
We performed our review according to theCochrane Handbook for
Systematic Reviews of Interventions. Although it was not possible
to assess the likelihood of publication bias by using funnel plots,
we searched for ongoing studies in the trial registers. However, we
did not identify unpublished results.
The incompleteness of some of the included studies and our in-
ability to obtain clarification of certain trial details or to resolve
ambiguities in the reports may have contributed to some bias in
their assessment.
Agreements and disagreements with other
studies or reviews
Reich 2009 reviewed the management of nail psoriasis, also show-
ing the efficacy of topical glucocorticosteroids andVitamin D ana-
logues, such as calcipotriol, in improving the signs and symptoms
of nail psoriasis. We agree, as suggested by Jiaravuthisan 2007,
that systemic treatments for nail psoriasis may be used in cases
where cutaneous psoriasis also needs systemic intervention. Sys-
temic treatment could be an option for those whose nail psoria-
sis has shown resistance to topical or radiotherapy treatment, for
those with very severely affected nails, and if the condition has an
adverse impact on the quality of life.
de Berker 2000, de Berker 2009, and Reich 2009 discussed the
penetration of the nail treatment through the nail bed and matrix
as a factor limiting efficacy. Therefore, the site of application is
important to where the nail pathology lies. Treatment for the nail
matrix can be administered to the nail fold. For treatment of the
nail bed features, onycholytic nails must be trimmed back to the
hyponychium (the area between the nail plate and the fingertip)
before administering the therapy as near as possible to the nail bed.
Jiaravuthisan 2007 reported that different intralesional treatment
seems to be efficacious in treating the nail matrix. The burden of
intralesional treatment could be pain, subungual haematomas, and
short-term paraesthesia. The most common intralesional treat-
ment for nail psoriasis is triamcinolone acetonide 2.5% to 10%
(de Berker 2009). In our review, we did not include RCT evidence
of intralesional treatments.
An abstract from Baerveldt 2010 reported a prospective, double-
blind, randomised, placebo internally-controlled trial, which as-
sessed the efficacy of topically-applied ciclosporin solution 100
mg/ml in maize oil versus maize oil twice daily. The duration of
the treatment was until the achievement of complete cure or for a
maximum of 16 weeks, and for the control group for a maximum
of 28 weeks. The results reported no direct therapeutic efficacy
for ciclosporin after 28 weeks. This is in contrast to the good im-
provement of Cannavo 2003 with topical ciclosporin.
The long-term use of topical glucocorticosteroids and calcipotriol
are associated with adverse events like atrophy and skin irritation
(de Berker 2009; Reich 2009). Occlusion of the topical therapy
will enhance the intensity but may develop an increased risk for
adverse effects (de Berker 2009). Tazarotene 0.1% gel has been
demonstrated to provide some benefit when used under occlusion
(Scher 2001). For long-term treatment, occlusion is not desirable
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because long-term management might be inconvenient for the
participant and will result in poor compliance.
The data from the RCTs that used systemic ciclosporin were con-
flicting. Levell 1995 reported a 82% score improvement (not sig-
nificant compared to baseline) (median baseline score = 5.5, with
a median decrease in severity score of 4.5 (95.1%CI 0 to 8) within
12 weeks of ciclosporin 5.0 mg/kg treatment; however, in this
study, we found a discrepancy in improvement between the pre-
sented figure and the text. Mahrle 1995 showed a mild improve-
ment of 17.5% of the 90 participants with nail involvement, out
of 137 skin psoriasis participants treated with ciclosporin 2.5 to
5.0 mg/kg for 10 weeks. The study reported a final mean dosage
of 3.4 mg/kg/day and a mean daily dose of 3.02 mg/kg/day for
the 137 participants with skin psoriasis (of whom 90 had nail
involvement). After 24 weeks, G m el 2011 showed a relative
reduction inNAPSI score of 37.2% with ciclosporin 5mg/kg/day,
reduced to 2.5 to 3.5 mg/kg/day after 12 weeks if side-effects were
absent. Feliciani 2004 reported in a cohort study after 3months an
improvement in 47% of 21 participants with ciclosporin 3.5 mg/
kg compared with an improvement of 79% of 33 participants with
the same dosage plus topical calcipotriol. The review byGregoriou
2008 suggested, “Systemic ciclosporin should be considered a sec-
ond-line treatment for nail psoriasis”. For the other conventional
systemic therapies, there were no randomised controlled trials ful-
filling our inclusion criteria available. However, some of the con-
ventional systemic therapies would be expected to be efficacious.
The guidelines for biologic interventions from the British Asso-
ciation of Dermatologists (Smith 2009) and the review by Reich
2009 referred to infliximab as an intervention for nail psoriasis.
Noiles 2009 reviewed clinical trials with infliximab for nail pso-
riasis. The review reported the significant improvement of inflix-
imab for nail psoriasis as the most efficacious biologic treatment.
For the other biologic agents, there was no high level of evidence,
being derived from case studies or in open-label prospective trials
as secondary outcomes with plaque psoriasis or psoriatic arthritis.
However, the efficacy of other biologics would be expected, but
comparative evidence is lacking.
The systematic review from Cassell 2006 emphasised again the
difficulties in comparing and interpreting data from studies with
small participant numbers, lacking appropriate controls, and with
no standard outcome measures.
To heal the nail, an important factor is the growth of the nail.
According to de Jong 1999, a treatment period of 12 weeks is too
short to obtain an improvement of more than 50% of most of the
nail signs in nail psoriasis. It takes about 6 months to regrow a
fingernail completely; therefore, a treatment period of at least 24
weeks is necessary to obtain a justified impression of efficacy.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The included studies in this review often showed a lot of hetero-
geneity and very limited evidence per treatment type (often only
one study per treatment), so meta-analysis of the data was not
possible. The quality of studies was low.
Clinical decision-making on the choice of intervention for nail
psoriasis should be based on high-level evidence if it is available. In
the absence of such high-level evidence for use of an intervention,
decisions should be based on the best available evidence. This is
sometimes clinical experience and may be based on an individual
person’s characteristics and preferences.
The studies on the biologicals infliximab 5 mg/kg (Rich 2008),
golimumab 50 mg, and golimumab 100 mg (Kavanaugh 2009)
reported significant results compared to placebo with regard to
the primary outcome ’Improvement of nail psoriasis’. This was
after short- (until 12 weeks) and medium-term (12 to 24 weeks)
treatment. After 24 weeks of treatment, infliximab 5 mg/kg and
golimumab 100 mg reported greater than 50% nail score im-
provement compared to placebo, which was significant. Electron
beam (Kwang 1995), grenz rays (Lindelof 1989), and superficial
radiotherapy (Yu 1992) reported significant results compared to
placebo with regard to the primary outcome ’Improvement of nail
psoriasis’ after short-term treatment.
The studies with topical ciclosporin 70% in maize oil (applied
twice daily for 12 weeks, Cannavo 2003) and tazarotene cream
compared to clobetasol (once daily under occlusion for 12 weeks,
Rigopoulos 2007) showed > 75% nail improvement compared
to baseline after short-term treatment. These data were all based
on one study per treatment. These studies did not use standard
outcome measures to assess nail psoriasis.
Unfortunately, the medium-term studies (12 to 24 weeks of treat-
ment) (e.g. systemic therapy) had no measure points on the short-
term (up to 12 weeks of treatment), which made comparison with
the short-term studies impossible. The treatments for psoriasis nail
features were also difficult to compare because the included trials
often did not assess the same nail features during treatment. Fur-
thermore, trials with systemic interventions were primarily for cu-
taneous psoriasis trials, where nail features were mostly not speci-
fied.
Eleven studies reported separate data on nail features (our sec-
ondary outcome parameter), of which 3 of the 4 studies dis-
cussed here showed significant results. After 90 days’ treatment
with hyaluronic acid and chondroitin sulphate, there was a signif-
icant improvement in onychorrhexis (P = 0.039), onycholysis (P
= 0.041), and hyperkeratosis (P = 0.041) in the participants (Flori
1994). After treatment with tazarotene gel, there was a significant
improvement in those with onycholysis and pitting. Onycholysis
improved after treatment under occlusion at weeks 4 and 12 (P <
0.05), and at week 24 without occlusion (P < 0.05). Pitting im-
proved under occlusion at week 24 (P < 0.05) (Scher 2001). Oil
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drop discolourations significantly improved after 12 weeks’ treat-
ment with calcipotriol 0.005% (P < 0.039) (Tzung 2008). One
study (infliximab (Rich 2008)) showed a significant decrease in
the occurrence of individual features over time.
The benefits of systemic interventions should be balanced against
their possible harms. Powerful systemic treatments have been
shown to be beneficial, but they may often not be a realistic op-
tion for people troubled with nail psoriasis because of side-effects,
unless they are candidates for these systemic treatments because of
their cutaneous psoriasis. Current RCTs generally do not pick up
serious side-effects because of their timescale and design, which
is probably why this review was only able to report mild adverse
effects for systemic treatment. Some topical therapies were shown
to be beneficial and seemed to cause fewer adverse effects. Radio-
therapy treatments for psoriasis are not generally used in common
practice.
Randomised controlled trials for psoriasis treatments that include
the assessment of nail psoriasis are lacking, for example, other top-
ical corticosteroids, acitretin, UV therapy, laser, and biologics like
adalimumab and etanercept that need further research. The lack
of evidence for these interventions does not mean the treatments
don’t improve nail psoriasis. In particular, evidence for topical
treatment should be further investigated as these play a major role
in common prescribing practice. Also, treatments with conflicting
results need further research.
Implications for research
More RCTs on nail psoriasis are needed, assessing the efficacy and
safety of possible treatments, e.g. topical treatments compared to
each other, topical versus systemic therapy, conventional systemic
therapy compared to biologics, biologics head-to-head.
The quality of studies should be improved. To compare studies,
clinical homogeneity should be reached by clear descriptions of the
populations, e.g. isolated nail psoriasis or with skin involvement,
type of nail psoriasis (nail matrix and nail bed psoriasis), disease
severity, treatment dosage and frequency, durations of treatment
(long enough), outcome measurements (like point scales and nail
scores (NAPSI, NAS); participants’ reported outcomes, such as
quality of life; and adverse effects), and time points of assessments,
including long enough follow up to be meaningful.
Participants with nail psoriasis could have a solitary nail psoriasis
problem or have psoriasis of the skin, joints with nail involvement,
or both. Studies dealing with the overall impact of systemic treat-
ments for psoriasis may report on nail psoriasis as a secondary out-
come. In the future, separate trials including participants with only
nail psoriasis would be welcome. These studies should describe
participants’ characteristics, results (with validated nail scores), ad-
verse effects, and separate information on dropouts for those with
nail psoriasis. Patient-reported outcomes, such as ’quality of life’,
are important outcomes because of the great impact nail psoriasis
can have on daily life.
The RCTs in our review included treatment durations of 12 to
64 weeks. The duration of treatment in the included studies was
often short. To regrow a nail completely takes at least six months
(de Jong 1999), so to obtain clear evidence for the efficacy of an
intervention, a trial with a duration of at least six months is nec-
essary. These studies may have obtained better results if the dura-
tion had been appropriate. As shown by Igarashi 2012 and Rich
2008, at 64 weeks and 46 weeks of treatment, respectively, the nail
score improvement was considerably increased compared to the
short-termmeasure point, and it was maintained compared to the
medium-term measurement. Therefore, future trials must be per-
formed with sufficient duration to report the efficacy of the inter-
vention. In addition, the follow up must be long enough, because
follow up and the rate of relapse after treatment discontinuation
is also of clinical importance.
Harmonised and validated outcome measures are necessary for
evaluating nail psoriasis. There are some validation studies for
the NAPSI. Aktan 2007 investigated the interobserver reliability
of the NAPSI, graded by 3 dermatologists looking at 25 partic-
ipants. They found a moderate to good scoring agreement with
the NAPSI. Cassell 2007 showed in participants with psoriatic
arthritis, a modified NAPSI (mNAPSI), with an inter-rater relia-
bility and construct validity. A nail score (like NAPSI, mNAPSI,
or NAS) is required to assess and compare the improvements
of different trials. For quality criteria for outcome measures, the
COSMIN (consensus-based standards for the selection of health
measurement instruments) checklist canbe used (Mokkink 2010).
Also, studies reported methodological heterogeneity, e.g. incom-
plete data about the internal validity. Future trials need to be rigor-
ous in design, which reduces bias. High-quality descriptions of all
aspects of methodology will improve the interpretation of results.
This could be achieved by following the Consolidated Standards
of Reporting Trials (CONSORT) statement checklist in future
trials (Schulz 2010). For internally-controlled trials with topical
treatments, one should be aware of the systemic impact of the
carry-over effect on the compared finger or toenail.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Baran 1999
Methods This was a randomised, double-blind, internally placebo-controlled study
It was unclear if intention-to-treat analysis was conducted.
Participants Inclusion criteria of the trial
• The trial included 27 consecutive participants with nail psoriasis (8 women, 19
men: age range = 22 to 79 years; average age = 47.0 years).
Each participant was treated randomly with either the active formulation or the placebo
lacquer. 1 participant dropped out, and 26 participants were evaluable
Interventions • 8% clobetasol-17-propionate in a colourless nail lacquer vehicle
• Placebo lacquer.
The participants applied the placebo lacquer to one hand and the clobetasol lacquer to
the other hand once daily until the end of treatment. The nail lacquer film was removed
with a cosmetic nail varnish remover once weekly before a new application
The duration of treatment ranged between 1.2 and 6.6 months (average duration = 2.5
months)
Outcomes Outcomes of the trial
1. Therapeutic results on a 4-point scale: cured, improved, failure, or worsened
2. Observed features: onycholysis. pitting, subungual hyperkeratosis, salmon
patches, splinter haemorrhages, ridging, transverse grooves, onychomadesis, and
periungual psoriasis
Notes There was a 1-month wash-out period for participants who had been treated with cal-
cipotriol or steroid cream
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Each participant was treated ran-
domly.”
Allocation concealment (selection bias) Unclear risk Comment: The paper provided insufficient
details.
Blinding (performance bias and detection
bias)
Clinician/ Investigator
Low risk Quote: “...double-blind study.”
Blinding (performance bias and detection
bias)
Participants
Low risk Quote: “...double-blind study.”
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Baran 1999 (Continued)
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Quote: “...double-blind study.”
Comment: The blinded clinicianwas prob-
ably the assessor.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “27 consecutive participants with
nail psoriasis were included, one dropped
out during the study. At the end of the
study, 26 participants were evaluable.”
Selective reporting (reporting bias) Low risk Comment: The trial reported all prespeci-
fied outcomes.
Other bias Low risk Comment: This was free of other sources
of bias.
Baran 1999a
Methods This was a double-blind, internally placebo-controlled study. In the methods of the
trial, no randomisation is mentioned. We assume the study was randomised because the
comparable trial in the same publication (Baran 1999) was randomised.
It was unclear if intention-to-treat analysis was conducted.
Participants Inclusion criteria of the trial
• The trial included 18 participants who had fingernail psoriasis affecting both
hands (all of the participants were men; age range = 22 to 79 years; average age = 53.7
years).
During the study, 3 participants dropped out, and 15 participants were evaluable
Interventions • 8% clobetasol-17-propionate in a colourless nail lacquer vehicle
• Placebo lacquer
The participants applied the placebo lacquer to 1 hand and the clobetasol lacquer to the
other hand once daily in the first week and from the second week onwards twice or 3
times weekly. The nail lacquer film was removed with a cosmetic nail varnish remover
once weekly before a new application
The duration of treatment ranged between 5.1 and 8.9 months (average duration = 7
months)
Outcomes Outcomes of the trial
1. Therapeutic results on a 4-point scale: cured, improved, failure, or worsened
2. Observed features: onycholysis. pitting, subungual hyperkeratosis, salmon
patches, splinter haemorrhages, ridging, transverse grooves, onychomadesis, and
periungual psoriasis
Notes The trial required participants who had been treated with intralesional steroids to have
a wash-out period of more than 2 months
Risk of bias
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Baran 1999a (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Each participant was treated ran-
domly.”
Allocation concealment (selection bias) Unclear risk Comment: The paper provided insufficient
details.
Blinding (performance bias and detection
bias)
Clinician/ Investigator
Low risk Quote: “...double-blind study.”
Blinding (performance bias and detection
bias)
Participants
Low risk Quote: “...double-blind study.”
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Quote: “...double-blind study.”
Comment: The blinded clinicianwas prob-
ably the assessor.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “18 participants who had finger-
nail psoriasis affecting both hands were in-
cluded, three dropped out during the study.
At the endof the study, 15participantswere
evaluable.”
Selective reporting (reporting bias) Low risk Comment: All of the outcomes were re-
ported.
Other bias Low risk Comment: This was free of other sources
of bias.
Cannavo 2003
Methods This was a randomised, placebo-controlled study.
The blinding was unclear.
It was unclear if intention-to-treat analysis was conducted.
Participants Inclusion criteria of the trial
• The study enrolled 16 men affected by moderate plaque-type psoriasis and
involvement of at least 4 nails of the hands (pitting, onycholysis, crumbling of the nail
plate, subungual hyperkeratosis, and oil drop change). The age range was 46 to 80 years
(mean age = 61.06 ± 10.08). 4 to 10 nails per participant were affected (median = 7).
Themean age of participants in group Awas 62.88 ± 10.53. Themean age of participants
in group B was 59.25 ± 9.95
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Cannavo 2003 (Continued)
Interventions • Oil solution containing 70% of an oral preparation of ciclosporin (Sandimmun
Neoral® oral solution) (total 70 mg/100 ml) and 30% of maize oil, which was applied
on the nails twice daily for a period of 12 weeks
• The control group were treated with maize oil only, which was applied twice daily
for a period of 12 weeks
8 weeks after the last visit, a follow-up visit was performed to evidence the presence of
relapses
Outcomes Outcomes of the trial
1. Clinical severity score (0 = absent, 3 = severe) for onycholysis, hyperkeratosis,
pitting, crumbling, and oil drop
2. Participants’ severity score: ’minimal’, ’moderate’, ’severe’, or ’very severe’
3. Participants’ assessment of lesions bothering them: ’not at all’, ’a little’,
’moderately’, or ’very much’
4. PAGA (global therapeutic efficacy): ’excellent’, ’good’, ’moderate’, ’no
improvement’, or ’aggravation’
Notes There was a wash-out period of 12 weeks for participants allocated systemic therapy
No local or systemic side-effect was detectable, and the compliance was excellent
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...dividing into two groups using
block randomisation. In each block of four,
two participants were randomly assigned to
a group and two to the other.”
Allocation concealment (selection bias) Unclear risk Comment: The paper provided insufficient
details. They used a block randomisation of
small blocks (4) in a, probably, unblinded
trial
Blinding (performance bias and detection
bias)
Clinician/ Investigator
Unclear risk Quote: “All participants were evaluated by
the same dermatologists.”
Comment: The paper provided insufficient
details about blinding of dermatologists
Blinding (performance bias and detection
bias)
Participants
Unclear risk Comment: The paper provided insufficient
details about the blinding of participants
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Comment: The paper provided insufficient
details about blinding
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Cannavo 2003 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: There was no mention of miss-
ing outcome data.
Selective reporting (reporting bias) Low risk Comment: The trial reported all of the ex-
pected outcomes.
Other bias Low risk Comment: This was free of other sources
of bias.
de Jong 1999
Methods This was a randomised, double-blind, internally-controlled study
Intention-to-treat analysis was performed.
Participants Inclusion criteria of the trial
• The trial included 57 adult participants (2 x 57 hands) with dystrophic fingernail
psoriasis. (There were 36 men and 21 women; age range = 21 to 77 years; mean age =
45.8 years). The duration of fingernail psoriasis had a mean of 9.9 years (range = 0 to
46 years).
• A minimum NAS score of 5 was required for inclusion.
Exclusion criteria of the trial
• The trial tested participants for onychomycosis by means of a KOH test and
mycological culture, and they were excluded if positive.
Interventions Left hand versus right hand treated with either of the following:
• 1% 5-fluorouracil in Belanyx lotion; or
• Vehicle Belanyx lotion
The intervention was applied once daily and covered with a plaster for 12 weeks, with a
follow-up period of 4 weeks
Outcomes Outcomes of the trial
1. Changes in NAS scores of a comparable target nail of each hand, according to a 5-
point rating scale (0 = none, 4 = very severe). Assessed NAS parameter were as follows:
extent of the nail pitting area (0% to 100%), in steps of 25% + number of pits (0 to >
15), the average of which was defined as nail pitting; subungual keratosis (0 to > 3 mm:
measured from nail bed to thickest part); onycholysis (0% to 100%); and oil spots (0%
to 100%)
2. Changes in severity score, investigators’ opinion: 5-point rating scale (0 = none, 4
= very severe)
3. Changes in severity score, participants’ opinion: 5-point rating scale (0 = none, 4
= very severe)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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de Jong 1999 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “...randomised trial.”
Allocation concealment (selection bias) Unclear risk Comment: The paper provided insufficient
details.
Blinding (performance bias and detection
bias)
Clinician/ Investigator
Low risk Quote: “...double-blind study.”
Blinding (performance bias and detection
bias)
Participants
Low risk Quote: “...double-blind study.”
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Quote: “...double-blind study.”
Comment: The blinded investigator was
probably the assessor.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: Therewere nomissing outcome
data.
Selective reporting (reporting bias) Low risk Comment: The trial reported all the ex-
pected outcomes.
Other bias Low risk Comment: This was free of other sources
of bias.
Flori 1994
Methods This was a randomised, double-blind, placebo-controlled study
It was unclear if intention-to-treat analysis was conducted.
Participants Inclusion criteria of the trial
• The trial included 30 participants in total, who were divided into 2 groups of 15
participants. (There were 16 men and 14 women; age range = 18 to 74 years. The
active treatment group contained 10 men and 5 women, with a mean age of 42.5 years.
The placebo group contained 6 men and 9 women, with a mean age of 41.8 years.)
There were no dropouts or withdrawals during the study.
Exclusion criteria of the trial
• Participants were tested for onychomycosis at first visit and excluded if positive.
• The trial excluded participants treated with steroids, retinoids, or PUVA/UVB in
the previous months.
Interventions • Hyaluronic acid with chondroitin sulphate (containing also vitamin A, vitamin
B6, and vitamin E (Kevis nails))
• Placebo
Both active and placebo treatment were applied as a gel and micro-emulsion. The gel
was applied in the morning and the micro-emulsion in the evening, 100 mg by finger,
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Flori 1994 (Continued)
during 90 days. Every application was preceded with topical creme, which contained
betamethasone 0.2% and 2% aminoglycoside antibiotic
Outcomes Outcomes of the trial
1. Pitting, onicoressi, Beau’s lines, onycholysis, and subungual hyperkeratosis
assessed with a 4-point-scale: 0 = no lesion, 1 = light lesion, 2 = medium lesion, and 3 =
serious lesion
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Participants were sequenced in a
randomisation scheme.”
Allocation concealment (selection bias) Unclear risk Comment: The paper provided insufficient
details.
Blinding (performance bias and detection
bias)
Clinician/ Investigator
Low risk Quote: “...double-blind study.”
Blinding (performance bias and detection
bias)
Participants
Low risk Quote: “...double-blind study.”
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Quote: “...double-blind study.”
Comment: The blinded investigator was
probably the assessor.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “All participants completed the en-
tire treatment course.”
Comment: The study reported no drop-
outs.
Selective reporting (reporting bias) High risk Onychodystrophy toenails were reported
in the placebo group. The treated group re-
ported no toenails. There were no results
for the placebo toenails
Other bias Unclear risk Puropharma supplied the Kevis nails deliv-
ery.
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G m el 2011
Methods This was a randomised, single-blind, actively-controlled study
Intention-to-treat analysis was not performed.
Participants Inclusion criteria of the trial
• The study included 37 consecutive psoriatic participants with nail involvement
aged between 25 and 68 years of either gender.
34 participants completed the 6-month study. Diagnosis of psoriatic nail was based on
the presence of diagnostic psoriatic nail signs on fingernails. Psoriatic participants with
nail involvement had psoriatic lesions on more than 10% of their total body surface area
(BSA), a minimum PASI of 10, and a NAPSI score of 10 or greater
Participants had stopped all topical therapy at least 4 weeks before and all systemic
therapies for at least 6 months before initiating the study protocol
Exclusion criteria of the trial
• The study excluded participants with positive findings from native or culture for
fungi.
Interventions • Methotrexate was administered at 15 mg single dose weekly (subcutaneously)
with folic acid 5 mg daily except on the days of administration of methotrexate. If no
side-effects occurred, it was applied for the first 3 months. In the second 3 months, the
dose was planned to be decreased to 10 mg/week.
• Ciclosporin 5 mg/kg daily (divided into 2 doses) was applied. In case of absence
of side-effects, it was planned to apply this dose for the first 3 months. In the second 3
months, the dose was planned to be decreased to 2.5 to 3.5 mg/kg/day. The treatment
period lasted 24 weeks, and follow up was for at least 3 months after the end of
treatment.
Outcomes Outcomemeasures were evaluated at baseline and at weeks 4, 8, 12, 16, 20, and 24 using
the NAPSI. In addition, nail matrix and bed scores in hand and foot were evaluated
separately before and after the treatment in the 2 groups
Outcomes of the trial
1. Using the NAPSI score, the participants’ responses were classified at the end of
the treatments as no improvement (< 5% improvement), mild improvement (> 5% to
50% improvement), moderate improvement (> 50% to 99%), and complete
improvement (100% improvement).
2. At each visit, the physician performed a global assessment, which is a general
evaluation of a psoriatic nail, using a scale of 0 to 10, with a score of 0 indicating the
worst involvement of nail and a score of 10 for the absence of nail involvement. Similar
evaluation was performed by the participants as the participant’s global score.
3. All participants were monitored for adverse effects at each visit using a
standardised questionnaire and followed up for at least 3 months after the end of
treatment.
Notes During the study and the follow-up period, additional therapy was restricted to the use
of emollients that were applied once daily in the evening
Risk of bias
Bias Authors’ judgement Support for judgement
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G m el 2011 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “Randomized assignment of either
of the two treatments was performed by
asking the patients to throw a dice.”
Allocation concealment (selection bias) Low risk Randomised assignment of either of the
2 treatments was performed by asking the
participants to throw a dice without know-
ing the underlying allocation criteria (num-
bers 1 to 3 = ciclosporin; numbers 4 to 6 =
methotrexate)
Blinding (performance bias and detection
bias)
Clinician/ Investigator
Unclear risk Quote: “...a one-blind study. Outcome
measureswere evaluated by an independent
observer (MÖ). At each visit, the physician
(MÖ) performed a global assessment.”
Comment: It was unclear if the physician
was blinded. It was unclear if the physician
was the same person as the independent/
blinded observer
Blinding (performance bias and detection
bias)
Participants
High risk Quote: “...a one-blind study.”
Comment: The participants were not
blinded for the treatment
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Quote: “...a one-blind study. The scores
were determined by a blinded observer.
Outcome measures were evaluated by an
independent observer (MÖ). At each visit,
the physician (MÖ) performed a global as-
sessment.”
Comment: It was unclear if the indepen-
dent/blinded observer was the physician,
who probably was not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Of the 37 participants, 34 com-
pleted the study. 1 participant discontin-
ued treatment before the end of the treat-
ment in the methotrexate group because
of elevation of liver transaminase. Of the
ciclosporin withdrawals, 2 participants de-
veloped elevation in serum creatinine and
lipids. These 3 participants were excluded
from the statistical analysis.”
Comment: These dropouts were < 20%
and present in both study arms
Selective reporting (reporting bias) Low risk Comment: The expected outcomes were
reported.
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G m el 2011 (Continued)
Other bias Low risk Baseline demographics and disease features
were similar to that of the groups
There was no conflict of interest
Igarashi 2012
Methods This was a randomised, double-blind, placebo-controlled study
It was unclear if intention-to-treat analysis was conducted.
Participants Inclusion criteria of the trial
• A total of 160 participants with moderate-to-severe plaque-type psoriasis (at least
6 months, with PASI of 12 or higher) entered the study. 158 participants were
randomly assigned, of whom 102 (64.6%) participants had nail psoriasis. (There were
83% men and 17% women; mean age = 46 years.)
Interventions • Participants were randomised 2:2:1 to receive ustekinumab 45 mg or 90 mg by
subcutaneous injection at weeks 0 and 4, and every 12 weeks, or placebo at weeks 0
and 4, with a cross-over to ustekinumab 45 or 90 mg at week 12, and treatment at
weeks 16, 28, 40, and 52. At week 28, participants with less than 50% improvement in
PASI discontinued the study agent. The study consisted of a placebo-controlled period
(weeks 0 to 12), an active treatment period (weeks 12 to 64), and a follow-up period
(week 64 to 72).
Outcomes Outcomes of the trial
1. Efficacy parameters were analysed through week 64 and safety parameters,
through week 72.
2. The Nail Psoriasis Severity Index (NAPSI) was assessed using a target nail. This
was a secondary end point including improvement from baseline to weeks 12 through
64 (in participants who had psoriatic nails at baseline).
3. Other outcomes used the PASI score, which measures the severity of psoriasis; the
Physician’s Global Assessment (PGA) of a participant’s psoriasis (cleared (0), minimal
(1), mild (2), marked (3), or severe (4)); the Dermatology Life Quality Index (DLQI)
measuring the effect of psoriasis on quality of life (0 (not at all) to 30 (very much)); the
Visual Analog Scale (VAS) measures patient-assessed joint pain; the patient-reported
36-item Short Form Health Survey (SF-36); and the Psoriasis Disability Index (PDI),
which is a disease-specific assessment of the effect of psoriasis on participants’ quality of
life.
4. Safety was assessed by adverse effects reporting throughout the study and through
laboratory tests (e.g. haematology, urinalysis) and physical examination.
Notes Adverse effects and other used outcomes were reported for the whole group, not specif-
ically for nail psoriasis
Participants had not received systemic therapies or phototherapies within the previous
4 weeks or topical therapies within the previous 2 weeks. Participants with latent TB
diagnosed during screening could be treated with an anti-TB agent (i.e. isoniazid (INH)
) for at least 3 weeks prior to randomisation
Risk of bias
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Igarashi 2012 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...double blind study, participants
were randomised 2:2:1.”
Comment: This was probably done.
Allocation concealment (selection bias) Unclear risk Comment: The paper provided insufficient
details.
Blinding (performance bias and detection
bias)
Clinician/ Investigator
Low risk Quote: “...double blind study.”
Blinding (performance bias and detection
bias)
Participants
Low risk Quote: “...double blind study.”
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Quote: “...double blind study.”
Comment: The blinded investigator was
probably the assessor.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “Of the 193 participants screened,
160 participants were randomised and 158
were treated. Two participants [were] with-
drawn before treatment. The primary pop-
ulation for the efficacy analysis consisted of
157 participants, as 1 patient was excluded
due to lack of any efficacy data after receiv-
ing a single dose of placebo. During treat-
ment and follow up, 21 participants dis-
continued the study, of whom 12 partici-
pants discontinued because of adverse ef-
fects.”
Comment: Specific data about the discon-
tinuation of psoriasis participants with nail
symptoms were not reported. There were
dropouts reported of the total randomised
participants
Selective reporting (reporting bias) Low risk Comment: The expected outcomes were
reported.
Other bias Unclear risk Sponsor: The study was supported by
Janssen Pharmaceutical K.K., a part of the
Johnson& Johnson family companies. The
authors reported conflict of interest
Baseline participant demographics and
disease characteristics were comparable
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Igarashi 2012 (Continued)
among the treatment groups
Kavanaugh 2009
Methods This was a randomised, double-blind, placebo-controlled study
Intention-to-treat analysis was performed.
Participants Inclusion criteria of the trial
• 405 participants were randomised.
• Participants enrolled in the study had active psoriatic arthritis, from whom 287
had nail psoriasis.
Interventions • Participants were randomised in a blinded manner (1:1.3:1.3) to receive
subcutaneous injections of placebo, golimumab 50 mg, or golimumab 100 mg at
weeks 0, 4, 8, 12, 16, and 20. Randomisation was stratified by baseline methotrexate
use (in the placebo group 48% used methotrexate, 49% from the 50 mg Golimumab
group, and 47% from the 100 mg Golimumab group. These percentages are from the
whole group (405 participants)). At week 16, participants with < 10% improvement
from baseline in both the swollen and tender joints counts entered early escape, with
dose escalation from placebo to golimumab 50 mg or from golimumab 50 mg to
golimumab 100 mg (no specific numbers for nail psoriasis; 79 participants had a dose
escalation). Follow up began at week 24; all participants received golimumab (no
information about the dose) and continued to receive subcutaneous treatment every 4
weeks. The last evaluation was performed at week 24.
Outcomes Outcomes of the trial
1. The Nail Psoriasis severity index (NAPSI) was used to assess the severity of a
target fingernail, representing the worst nail psoriasis at baseline.
2. Fingernail psoriasis was also evaluated using the physician’s global assessment of
psoriatic nail disease, where 1 = absent and 5 = very severe.
3. Comparisons were made for individual golimumab dose groups versus placebo.
No comparisons between golimumab 50 mg and golimumab 100 mg were made.
4. Safety evaluations included adverse events, routine laboratory analysis, and the
presence of antibodies to golimumab.
Notes Stable doses of methotrexate, NSAIDs, and corticosteroids were allowed
Adverse events were reported for the whole group, not specifically for nail psoriasis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Participants were randomised in a
blinded manner (1:1.3:1.3).”
Comment: This was probably done.
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Allocation concealment (selection bias) Low risk Quote: “...by a centralized interactive voice
response system.”
Comment: This was probably done.
Blinding (performance bias and detection
bias)
Clinician/ Investigator
Low risk Quote: “...double blind study.”
Blinding (performance bias and detection
bias)
Participants
Low risk Quote: “...double-blind study.”
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Quote: “...double blind study.”
Comment: The blinded investigator was
probably the assessor.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “16 weeks: 10/113 participants
in placebo group discontinued treatment
(four due to adverse events, two had un-
satisfactory efficacy, one lost to follow up
and three other). 9/292 participants in the
golimumab group discontinued treatment
(four had adverse events, one unsatisfac-
tory efficacy, one lost to follow up and three
other)
24 weeks: two out of 103 participants in
placebo group discontinued (no reason is
given). Four out of 283 participants in the
golimumab group discontinued (two be-
cause of adverse events, two no reason is
given).”
Comment: Specific data about the drop-
outs of psoriasis participants with nail
symptoms were not reported. There were
dropouts reported of the total randomised
participants with psoriatic arthritis
Selective reporting (reporting bias) Low risk All of the expected outcomeswere reported.
Other bias High risk Centocor Research & Development Inc.
and Schering-Plough were involved in the
study design and the interpretation of data
Stable doses of methotrexate, NSAIDs, and
corticosteroids were allowed
There were no relevant differences between
the groups.
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Kwang 1995
Methods This was a randomised, internally placebo-controlled study.
Blinding was unclear.
It was unclear if intention-to-treat analysis was conducted.
Participants Inclusion criteria of the trial
• 12 participants with symmetrical nail psoriasis were enrolled in the study.
Interventions • Active treatment was randomly allocated to the affected nails of 1 hand, while the
other 1 served as control.
The nails and nailbeds were treated with an electron beam (7 mega electron volts). A
total of 6 Gy was given in 8 fractions over 8 weeks (1 fraction of 0.75 per week)
Follow-up assessment was performed 3, 6, and 12 months after treatment
Outcomes Outcomes of the trial
1. Photographs of the involved nails of both hands were obtained prior to electron
beam therapy and at each follow-up visit. Each of the nails were graded as follows:
grade 1: pits, furrows, transverse depressions, onycholysis; grade 2: subungual
hyperkeratosis, thickening and crumbling of nail plate, oil drop, discolourations, and
splinter haemorrhages; and grade 3: proximal nail fold involvement, distal arthropathy.
2. At each follow up, the nails were graded and scored as follows: cured without
residual nail abnormalities, markedly improved with residual lesions, moderately
improved, slightly improved, and no change.
Notes None of the participants received systemic treatment and did not apply any topical
medication or clip their nail while on follow up
The only local side-effect was a temporary deep brownish-black discolouration of all the
electron beam-treated nails
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Active treatment was randomly al-
located to the affected nails of one hand,
while the other one served as control.”
Comment: This was probably done.
Allocation concealment (selection bias) Unclear risk Comment: The paper provided insufficient
details.
Blinding (performance bias and detection
bias)
Clinician/ Investigator
Unclear risk Comment: There was no information
about blinding of the clinician
Blinding (performance bias and detection
bias)
Participants
Unclear risk Comment: There was no information
about blinding of the participants
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Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Comment: There was no information
about blinding of the outcome assessor
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no missing outcome data.
Selective reporting (reporting bias) Low risk All of the expected outcomes were reported
Other bias Unclear risk There was no information about the base-
line characteristics.
Levell 1995
Methods This was a randomised, actively-controlled study.
The trial was not blinded.
It was unclear if intention-to-treat analysis was conducted.
Participants Inclusion criteria of the trial
• A total of 60 participants with plaque psoriasis entered the study (33 women, 27
men: age range = 18 to 67 years; age range for ciclosporin = 18 to 61 years; age range
for dithranol = 20 to 67 years). Of them, 29 participants had psoriatic nail disease.
Exclusion criteria of the trial
• Systematic treatment for psoriasis taken less than 2 weeks before the study
Interventions • Oral ciclosporin was given as 2 daily doses of 2.5 mg/kg until 2 weeks after the
psoriasis had cleared.
• After a suberythemal dose of UVB, dithranol (2% to 8% with 0.5% salicylic acid
in emulsifying ointment) was applied daily for 15 minutes and then washed off.
The Ingram regimen, using dithranol in Lassar’s paste, was used for participants not
improving on the short contact regime. Treatment was considered a failure and stopped
if there were any residual lesions after 16 weeks of either treatment
Participants were treated for 16 weeks until clear (the complete absence of visible or
palpable lesions of psoriasis). All participants who cleared were followed up until relapse
or until 8months had elapsed. Visits for assessment weremade twice before the treatment
began and every 2weeks thereafter until the rash was cleared and, after clearance,monthly
until relapse or for 8 months
Outcomes Outcomes of the trial
1. Severity score from 0 to 2 points for individual nail involvement
2. Psoriasis of the nails was assessed as improved, unchanged, or worsened.
Notes Systematic treatment for psoriasis was not allowed for the last 2 weeks before starting
the treatment
Adverse events included minimal toxicity (ciclosporin), burning (dithranol with sal-
icylic acid and UVB), high blood pressure (ciclosporin), increasing serum creatinine
(ciclosporin), increasing serum urate (ciclosporin and dithranol with salicylic acid and
UVB), and increasing serum magnesium (ciclosporin)
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Levell 1995 (Continued)
There was a wash-out period of 2 weeks for systematic therapy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The participants were randomised
by a code.”
Comment: This was probably done.
Allocation concealment (selection bias) Low risk Quote: “...the code being available only to
a hospital pharmacist who was otherwise
uninvolved with the study.”
Blinding (performance bias and detection
bias)
Clinician/ Investigator
High risk Quote: “The study was an open ran-
domised comparison.”
Comment: The trial did not use blinding.
Blinding (performance bias and detection
bias)
Participants
High risk Quote: “The study was an open ran-
domised comparison.”
Comment: The trial did not use blinding.
Blinding (performance bias and detection
bias)
Outcome assessor
High risk Quote: “The study was an open ran-
domised comparison.”
Comment: The trial did not use blinding.
Incomplete outcome data (attrition bias)
All outcomes
High risk Of the participantswith nail psoriasis, 3 out
of 13 participants in the ciclosporin group
and 1 out of 16 participants in the dithra-
nol with salicylic acid and UVB group
withdrew before further assessment (rea-
sons were difficulty in attending daily, ob-
jecting to the frequent assessment, and dys-
pepsia)
There was little information about the nail
psoriasis group and scoring
Selective reporting (reporting bias) High risk Quote: “The Ingram regimen, using
dithranol in Lassar’s paste, was used for par-
ticipants not improving on the short con-
tact regimen.”
Comment: No information was given
about the number of participants and re-
sults regarding who needed this cross-over
There was a discrepancy in the article be-
tween the improvement score showed in
the figure and the text
53Interventions for nail psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Levell 1995 (Continued)
Other bias High risk Sandoz Pharmaceuticals sponsored the
study.
Ciclosporin was given until 2 weeks after
the psoriasis had cleared
Lindelof 1989
Methods This was a randomised, double-blind, internally-controlled study. There was cross-over
to active treatment for the placebo-treated group after 10 weeks
It was unclear if intention-to-treat analysis was conducted.
Participants Inclusion criteria of the trial
• 24 participants with psoriasis of the nails of both hands; age range = 29 to 75
years. The psoriatic nails had various degrees of severity, ranging from nails of normal
thickness with pits to very thickened hyperkeratotic nails.
Interventions • Each participant received 5 Gy of grenz rays given on 10 occasions at intervals of
1 week. The psoriatic nail of 1 hand received active treatment; the other hand was
treated with placebo (the apparatus hummed without irradiation).
The grenz ray machine factors were 10 kV, 10 mA, half-value layer 0.02 mm Al, half-
value depth in tissue 0.5 mm, focus skin distance 10 cm. Active treatment was given to
the former placebo-treated hands after 10 weeks. The participants were then followed
for 6 months
Outcomes Outcomes of the trial
1. Clinical evaluation was done before the grenz ray therapy and after the 10th
treatment. Photographs of the involved nails of both hands were obtained prior to the
grenz ray treatment. The nails were examined for signs of psoriasis, i.e. pitting,
onycholysis, oil drops, subungual hyperkeratosis, onychorrhexis, and psoriatic
involvement of the proximal nail fold. After 10 weeks, the improvement of each of the
psoriatic nail signs was judged, and an overall improvement was scored for each hand.
The nails were scored as follows: almost complete recovery, moderate improvement,
slight improvement, and no improvement. No carry-over effect was present at cross-
over from placebo to active treatment.
Notes The participant had been untreated for at least 6 months before the start of the study
5 participants showed slight pigmentation of the grenz ray treated nail fold. No other
local or systematic adverse reactions were noted
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ’...double blind trial, participants
were randomly allocated.”
Comment: This was probably done.
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Lindelof 1989 (Continued)
Allocation concealment (selection bias) Unclear risk Comment: No information about ran-
domisation of the hands was available
Blinding (performance bias and detection
bias)
Clinician/ Investigator
Low risk Quote: “...double blind trial, neither the
participant nor the evaluating doctor knew
which side had received active grenz ray
therapy.”
Blinding (performance bias and detection
bias)
Participants
Low risk Quote: “...double blind study, neither the
participant nor the evaluating doctor knew
which side had received active grenz ray
therapy.”
Comment: Placebowas administered by al-
lowing the apparatus to hum without irra-
diation
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Quote: “...double blind study, neither the
participant nor the evaluating doctor knew
which side had received active grenz ray
therapy.”
Comment: The blinded doctor was the
outcome assessor.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 participants failed to participate through-
out the study, because of illness in their
families
Selective reporting (reporting bias) High risk The nail signs were not separately discussed
in the results.
Other bias Unclear risk There was no information about the base-
line characteristics.
Mahrle 1995
Methods This was a randomised (2 ciclosporin, 1 etretinate), active controlled, cross-over study
The blinding was unclear.
It was unclear if intention-to-treat analysis was conducted.
Participants Inclusion criteria of the trial
• 210 participants with moderate to severe chronic plaque type psoriasis were
randomised, of whom a total of 137 participants had nail symptoms. There were 90
nail psoriasis participants in the ciclosporin group, and 47 participants in the etretinate
group. There were no data available for the number of nail psoriasis participants
assigned to which groups in which phases (after cross-over).
• Specific data about the age and sex of the psoriasis participants with nail
involvements were not reported separately, even for the dropouts and adverse events
data.
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Interventions • Ciclosporin
• Etretinate
The initial dosage for ciclosporin was 2.5 mg/kg/day and 0.5 mg/kg/day for etretinate,
which could be individually adjusted to 5.0 and 0.75 mg/kg/day, respectively, depending
on the response reduction of the PASI score during the first 10 weeks (phase 1). The
daily dose was administered in divided doses in the morning and evening
After 10 weeks (phase 1), the study continued with a cross-over (phase 2). Because no
wash-out was required, there was a carry-over effect in the second phase. That is why we
only analysed the first 10 weeks (phase 1)
Outcomes Outcomes of the trial
1. 4-point scale nail involvement (there was no definition of the 4-point scale
assessment of nail psoriasis)
Notes There was 4 weeks’ wash-out for systemic therapy and 1 week for topical treatment
before entering the study
With regard to concomitant medication, only salicylic acid-containing emollients were
allowed during the study. During the follow-up weeks, any antipsoriatic therapy except
ciclosporin was allowed
There was a carry-over effect from phase 1 to 2; it was unclear if a wash-out was applied
between these phases. Even after contacting the author about the missing data, we did
not receive any more information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...randomly allocated (2:1); after
the first phase (10 weeks) ciclosporin group
were again randomly (1:1) allocated.”
Allocation concealment (selection bias) Unclear risk Comment: The paper provided insufficient
details.
Blinding (performance bias and detection
bias)
Clinician/ Investigator
Unclear risk Comment: The paper provided insufficient
details about the blinding of the clinician
Blinding (performance bias and detection
bias)
Participants
Unclear risk Comment: The paper provided insufficient
details about the blinding of the partici-
pants
Blinding (performance bias and detection
bias)
Outcome assessor
Unclear risk Comment: The paper provided insufficient
details about the blinding of the outcome
assessor
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: Specific data about the drop-
outs of psoriasis participants with nail
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Mahrle 1995 (Continued)
symptoms were not reported. There were
dropouts reported of the total randomised
psoriasis participants. There were no data
about the participants’ cross-over to the
other therapy
Selective reporting (reporting bias) Low risk Comment: The expected outcomes were
reported.
Other bias High risk Sandoz AG sponsored the study.
With regard to concomitant medication,
salicylic acid-containing emollientswere al-
lowed during the study
Rich 2008
Methods This was a randomised, double-blind study, placebo-controlled study (data came from
the EXPRESS study)
It was unclear if intention-to-treat analysis was conducted.
Participants Inclusion criteria of the trial
• Of 378 enrolled participants with moderate to severe psoriasis, 305 had nails
involved (217 men and 88 women).
• Participants were eligible if they had a diagnosis of at least 6 months, PASI > 12,
and psoriasis > 10% of body surface area.
Interventions • Infliximab 5 mg/kg iv at weeks 0, 2, and 6, and every 8 weeks through to week 46
• Placebo at weeks 0, 2, and 6, and every 8 weeks through to week 24, crossing over
in a double-blind fashion to infliximab 5 mg/kg at weeks 24, 26, and 30, and every 8
weeks through week 46
Eligible participants were allocated in a 4:1 ratio to receive infliximab 5mg/kg or placebo.
The follow-up period was 4 weeks
Outcomes Outcomes of the trial
1. Nail psoriasis was assessed at weeks 10, 24, 38, and 50 with the Nail Psoriasis
Severity Index (NAPSI). A target nail that represented the most severe nail psoriasis at
baseline was scored with the NAPSI; no carry-over effect was present at cross-over from
placebo to active treatment.
Notes All systematic treatments and phototherapies were stopped a month before treatment;
topical treatment was stopped 2 weeks before starting the study treatment
Adverse events were not specifically reported for nail psoriasis
Risk of bias
Bias Authors’ judgement Support for judgement
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Rich 2008 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “Participants were randomly allo-
cated in a 4:1 ratio using a minimisation
algorithm with biased coin assignment by
means of an interactive voice response sys-
tem.”
Comment: This was probably done.
Allocation concealment (selection bias) Low risk Quote: “This information was distributed
to the unblindedpharmacist, who thenpre-
pared the study drug.”
Comment: This was probably done.
Blinding (performance bias and detection
bias)
Clinician/ Investigator
Low risk Quote: “...double blind study. The inves-
tigators, study site personnel and partici-
pants remained blinded until the database
lock at week 50.”
Blinding (performance bias and detection
bias)
Participants
Low risk Quote: “...double blind study, the inves-
tigators, study site personnel and partici-
pants remained blinded until the database
lock at week 50.”
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Quote: “...double blind study, the inves-
tigators, study site personnel and partici-
pants remained blinded until the database
lock at week 50.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 3/305 participants with nail psoriasis were
missing: The study did not provide reasons
for missing data
Selective reporting (reporting bias) Low risk All of the expected outcomeswere reported.
Other bias Unclear risk Centocor Inc, Malvern, Pa, and Schering-
plough, and Kenilworth, NJ supported the
study
The 2 groups were homogeneous for all pa-
rameters.
Rigopoulos 2007
Methods This was a randomised, double-blind, actively-controlled study
It was unclear if intention-to-treat analysis was conducted.
Participants Inclusion criteria of the trial
• The study included 46 psoriatic participants with nail symptoms.
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Interventions • The first group applied tazarotene 0.1% cream (Zorac®) to the affected nail
plates, surrounding nail folds, and periungual skin under occlusion at bed time for 12
weeks.
• The second group applied clobetasol propionate 0.05% cream (Butavate) in the
same way.
Occlusion was performed after application of the cream using common transparent
membrane obtained through general stores
Outcomes Outcomes of the trial
1. Outcome measures were assessed at baseline and at weeks 4, 8, and 12 using the
Nail Psoriasis Severity Index (NAPSI) to grade the following parameters
independently: pitting, onycholysis, subungual hyperkeratosis, and salmon patches.
Follow-up evaluation was performed 12 weeks after the end of the therapy
Notes A 12-week wash-out period was allowed for topical and systematic medications
3 of 16 participants in the tazarotene group reported adverse events: desquamation and
erythema of nail fold skin, periungual irritation, paronychia, and irritation of the skin
of the toe or finger distanced from the nail area. 1 of 14 participants in the clobetasol
group reported a sensation of burning on the nail fold skin
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The participants were randomly
assigned by a computer.”
Comment: This was probably done.
Allocation concealment (selection bias) Low risk Quote: “...assignment by a computer.”
Comment: This was probably done.
Blinding (performance bias and detection
bias)
Clinician/ Investigator
Low risk Quote: “...double blind study, investigators
were blinded regarding the agent applied
by each participant.”
Blinding (performance bias and detection
bias)
Participants
Low risk Quote: “...double blind study.”
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Quote: “...double blind study.”
Comment: The blinded investigator was
probably the outcome assessor
Incomplete outcome data (attrition bias)
All outcomes
High risk Therewere 16dropouts (7 in the tazarotene
group, and 9 in the clobetasol group): 10/
16 had urgent need for systemic therapy; 4
of 16 failed to keep to the follow-up sched-
ule; and 2 had missing outcome data
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Selective reporting (reporting bias) Low risk All of the expected outcomeswere reported.
Other bias Unclear risk There was no information about baseline
characteristics.
Both agents were given in identical con-
tainers.
Scher 2001
Methods This was a randomised, double-blind, vehicle-controlled study
It was unclear if intention-to-treat analysis was conducted.
Participants Inclusion criteria of the trial
• The trial included a total of 31 adults (71% men, 29% women) with at least 2
fingernails that had at least 3 of the following characteristics: pitting, onycholysis,
subungual hyperkeratosis, leuconychia, nail plate crumbling/loss, splinter
haemorrhages, or nail bed discolourations. The mean age of the participant was 43
years old.
21 participants received tazarotene, and 10 participants received vehicle. Most partici-
pants were Caucasian (25)
Exlusion criteria of the trial
• Participants were excluded if either of their 2 target fingernails had positive results
with a potassium hydroxide stain or dermatophyte/fungal culture. During the study,
there were no dropouts or losses to follow up.
Interventions • Tazarotene 0.1% gel
• Vehicle gel
Participants were randomised to receive either of the above, which they applied each
evening for up to 24 weeks to 2 target fingernails: 1 under occlusion and 1 unoccluded
Outcomes Outcomes of the trial
1. Pitting, onycholysis, subungual hyperkeratosis, leuconychia, nail plate crumbling/
loss, splinter haemorrhages, or nail bed discolourations were assessed on a 7-point scale
(0 = none, 1 = mild, 2 = mild to moderate, 3 = moderate, 4 = moderate to severe, 5 =
severe, 6 = very severe) for 24 weeks.
2. Nail growth: by marking each target fingernail each visit with a transverse groove
parallel to the lunula, measured using an electronic calliper
Notes Occlusion was with polyethylene film/sheeting.
No other medications were allowed on the fingernails.
There was a wash-out period of 4 weeks for topical fingernail medications and investi-
gational drugs, 6 weeks for intralesional corticosteroids and UVB or psoralen plus UVA
phototherapy, and 12 weeks for systemic antipsoriatic medications
Risk of bias
Bias Authors’ judgement Support for judgement
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Scher 2001 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: “...randomised trial.”
Allocation concealment (selection bias) Unclear risk Comment: The paper provided insufficient
details.
Blinding (performance bias and detection
bias)
Clinician/ Investigator
Low risk Quote: “...double blind study.”
Blinding (performance bias and detection
bias)
Participants
Low risk Quote: “...double blind study.”
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Quote: “...double blind study.”
Comment: The blinded investigator was
probably the outcome assessor
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: There were no dropouts.
Selective reporting (reporting bias) Low risk The trial reported all of the expected out-
comes.
Other bias Unclear risk Allergan, Inc provided financial support.
Tosti 1998
Methods This was a randomised, double-blind actively-controlled study
It was unclear if intention-to-treat analysis was conducted.
Participants Inclusion criteria of the trial
• Participants were eligible if over 18 years of age, of either sex, with severe
subungual hyperkeratosis (> 1 mm for fingernails, > 2.5 mm for toenails).
• A total of 58 participants were enrolled. (There were 35 men and 23 women;
mean age = 51.8 years.) 29 participants received topical calcipotriol - 16 men and 13
women; mean age = 50.7 years - of whom 13 participants (47 nails) had fingernail
psoriasis, and 20 participants (109 nails) had toenail psoriasis. The mean duration of
nail psoriasis in these participants was 8.3 years. 29 participants (19 men and 10
women; mean age = 53 years) received topical betamethasone dipropionate and
salicylic acid, of whom 16 participants (82 nails) had fingernail psoriasis, and 24
participants (161 nails) had toenail psoriasis. The mean duration of nail psoriasis in
these participants was 7.1 years.
• A total of 29 participants had psoriasis of the fingernails, and 44 participants had
toenail psoriasis.
• 2 participants assigned to receive calcipotriol presented exclusion criteria and were
not considered in the assessment of efficacy; 12 (4 with calcipotriol and 8 with
betamethasone) failed to attend the visit and were considered as dropouts.
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Exclusion criteria of the trial
• Onychomycosis
• Pregnant or breast-feeding women
• Known hypersensitivity to the study molecule
• Receiving vitamin D-based therapies or other topical or systemic treatments
• Severe renal or hepatic insufficiency
Interventions • Calcipotriol ointment (50 µg/g) or betamethasone dipropionate (64 mg/g) and
salicylic acid (0.03 g/g) ointment, twice daily for at last 3 months. Participants who
showed a 50% or more reduction in the baseline hyperkeratotic thickness at least in 1
nail (responders) were offered continuation of treatment for 2 further months.
Participants who completed the 5 months of treatment were then followed for 1 month
after discontinuation.
Outcomes Outcomes of the trial
1. Nail thickness (nail plate + hyperkeratotic nail bed) in mm using a calliper
2. Responders (≥ 50% reduction after 3 months, further treatment for 2 months
and 1 month follow up)
3. Participant’s opinion about acceptability of treatment using a 5-point scale: 0 =
nil, 1 = poor, 2 = fair, 3 = good, 4 = excellent
Notes The trial was conducted in accordance with the principles of the Declaration of Helsinki
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “...randomised study.”
Allocation concealment (selection bias) Unclear risk Comment: The paper provided insufficient
details.
Blinding (performance bias and detection
bias)
Clinician/ Investigator
Low risk Quote: “...double blind study.”
Blinding (performance bias and detection
bias)
Participants
Low risk Quote: “...double blind study.”
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Quote: “...double blind study.”
Comment: The blinded investigator was
probably the outcome assessor
Incomplete outcome data (attrition bias)
All outcomes
High risk 2/29 calcipotriol participants presented ex-
clusion criteria, and 12 participants (4 of
29 calcipotriol-treated participants and 8
of 29 betamethasone + salicylic acid-treated
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participants) failed to attend the visits dur-
ing the trial and were considered as drop-
outs
Responders (≥ 50% reduction after 3
months, further treatment for 2 months
and 1 month follow up); fingernails: 8 (28
nails) calcipotriol, 10 (38 nails) betametha-
sone; toenails: 7 (51 nails) calcipotriol, 12
(58 nails) betamethasone
Selective reporting (reporting bias) Low risk Comment: All of the outcomes were re-
ported.
Other bias High risk Quote: “...partially supported by Prodotti
Formenti SRL, Milan, Italy.”
“The baseline subungual hyperkeratotic
thickness of the responder groups was
not homogeneous for calcipotriol and be-
tamethasone treatment for fingernails as
well as toenails.”
Tzung 2008
Methods This was a randomised, investigator-blinded, actively-controlled study
It was unclear if intention-to-treat analysis was conducted.
Participants Inclusion criteria of the trial
• A total of 40 participants of at least 20 years of age with fingernail psoriasis were
allocated randomly to 2 groups (A and B) for 12 weeks of treatment. 32 participants
completed the study (7 women and 25 men). 5 participants in group A and 3 in group
B dropped out for reasons unrelated to the treatment.
Interventions • Group A: calcipotriol 0.005% plus betamethasone dipropionate 0.05% ointment
(Daivobet®), once daily for 12 weeks
• Group B: calcipotriol 0.005% ointment (Daivonex), twice daily for 12 weeks
Outcomes Outcomes of the trial
1. NAPSI: nail matrix (4) and nail bed (4) involvement. Target nail was evaluated
every 4 weeks (lower score = improvement)
2. Investigator’s Global Assessment (IGA) (0 = worse; 1 = no change; 2, 3, and 4 =
slight, moderate, and marked improvement, respectively; 5 = clearance)
3. PAGA at end of the study (0 = worse; 1 = no change; 2, 3, and 4 = slight,
moderate, and marked improvement, respectively; 5 = clearance)
Notes There were no conflicts of interest.
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “...randomised trial.”
Allocation concealment (selection bias) Unclear risk Comment: The paper provided insufficient
details.
Blinding (performance bias and detection
bias)
Clinician/ Investigator
Low risk Quote: “...an investigator-blinded trial.”
Blinding (performance bias and detection
bias)
Participants
High risk Quote: “...an investigator-blinded trial.”
Comment: The participants were not
blinded to the treatment.
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Quote: “...an investigator-blinded trial.”
Comment: The blinded investigator was
probably the assessor.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 40 participants were randomised; 32 par-
ticipants completed the study. 5 partici-
pants in group A and 3 in group B dropped
out for reasons unrelated to the treatment
Selective reporting (reporting bias) Low risk All of the study’s prespecified (primary and
secondary) outcomes that were of interest
were reported in the prespecified way
Other bias Low risk This was free of other sources of bias.
Yu 1992
Methods This was a randomised, double-blind, internally-controlled study
It was unclear if intention-to-treat analysis was conducted.
Participants Inclusion criteria of the trial
• The trial included 10 participants with severe psoriatic nail dystrophy involving
all fingernails. Of these 10 participants, 2 defaulted and were excluded before
radiotherapy commenced. (There were 7 men and 1 woman; age range = 42 to 68
years; mean age = 55 years.)
Interventions • Superficial radiotherapy was administered to the distal phalanx of each individual
finger of a randomly preselected hand. 3 fractionated doses of 150 cGy were
administered every 2 weeks to a total of 450 cGy per fortnight (90 kV, 5 mA, half-value
layer 1.00 mm, focus skin distance 100 mm).
• The control hand was treated with ’sham’ radiotherapy.
The participants’ nails were assessed at -10, 0, 10, 15, and 20 weeks (total of 30 weeks)
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They intend to keep these participants under review every third month over a period of
2 years in order to watch for a delayed response
Outcomes Outcomes of the trial
1. Visual assessment: each nail was scored using a rating scale (0 = normal, 1 =
slightly affected, 2 = moderately affected, 3 = severely affected) for pitting, onycholysis,
subungual hyperkeratosis, and destruction of the nail plate. Range of scoring points: 0
to 12
2. Rate of nail growth: in mm per week using an electronic calliper
3. Nail thickness using an electronic calliper
Notes None of the participants were receiving active treatment for their nail dystrophy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Superficial radiotherapy was ad-
ministered to a randomly preselected hand.
”
Comment: This was probably done.
Allocation concealment (selection bias) Unclear risk Comment: The paper provided insufficient
details.
Blinding (performance bias and detection
bias)
Clinician/ Investigator
Unclear risk Quote: “...double blind trial, neither the
participants nor the assessor were aware
which side was being active treated until
the end of the trial.”
Comment: It was unclear if the investigator
was the blinded assessor
Blinding (performance bias and detection
bias)
Participants
Low risk Quote: “...double blind trial, neither the
participants nor the assessor were aware
which side was being active treated until
the end of the trial.”
Comment: ’Sham radiotherapy’ was ad-
ministered to the control hand
Blinding (performance bias and detection
bias)
Outcome assessor
Low risk Quote: “...double blind trial, neither the
participants nor the assessor were aware
which side was being active treated until
the end of the trial.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 participants defaulted and were excluded
before radiotherapy
Selective reporting (reporting bias) Low risk The trial reported all of the expected out-
comes.
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Other bias Unclear risk There was no information about the base-
line characteristics.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Camacho 1976 This was not a randomised controlled trial.
Cantoresi 2009 This was not a randomised controlled trial.
Feuerman 1973 No nails or nail psoriasis score were used.
Lassus 1997 Data were missing for primary and secondary outcomes of this review. Extraction of suitable data was not possible
Luger 2009 Participants in the 2 treatment groups were analysed together; there was no specification between them. There was
no adequate control group, and the number of participants was not correct. There were not enough data provided
about which intervention was better
Mrowietz 1991 There were not enough data for nail psoriasis participants on the primary and secondary outcomes of this review
O’Daly 2009 There were no nail psoriasis participants in the study.
Characteristics of studies awaiting assessment [ordered by study ID]
Abesamis-Cubillan 1997
Methods This was a randomised, double-blind, placebo-controlled trial
Participants Inclusion criteria of the trial
• The trial included 14 psoriasis participants with concomitant nail psoriasis. 8 participants with a total of 75
dystrophic nails were assigned to the calcipotriol group; 6 participants with 60 nails involved were given placebo.
Interventions • Topical calcipotriol
• Placebo (white petrolatum)
Outcomes Outcomes of the trial
1. A clinical visual rating scale was devised to grade the severity of the nails (0 = normal, 1 = slightly affected, 2 =
moderately affected, 3 = severely affected) for each of the following features: pitting, grooves, subungual
hyperkeratosis, and onycholysis.
2. Adverse events were assessed in both the treatment group and placebo group.
Notes We emailed the Prinicpal Investigator (PI), but received no response
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Baerveldt 2010
Methods This was a prospective, double-blind, randomised, internally-controlled trial
Participants Inclusion criteria of the trial
• Adults with fingernail psoriasis of both hands for at least 6 months
• A minimum of at least 2 affected nails on the left hand and the right hand, and the number of affected nails
may have differed by 1 nail at the maximum on the left hand compared with those on the right hand
• The dose of oral medication before the start had to have been constant for 8 weeks, and it would be reasonably
expected that the dose would not be altered during the treatment phase of the study.
• The trial evaluated 30 participants with a baseline NAPSI of 18.3 in the ciclosporin group and 16.9 at the
placebo group (with a maximum score of 40).
Interventions • On the left and right fingernails either placebo or 100 mg/ml ciclosporin application, twice daily.
The duration of the treatment was until complete cure or for a maximum of 16 weeks, with the control group treated
for a maximum of 28 weeks. The follow up was for 12 weeks after stopping the treatment
Outcomes Outcomes of the trial
• Nail Psoriasis Severity Index (NAPSI)
Notes 6 participants dropped out because of non-compliance, protocol violation, or the start of systemic therapy
Kavanaugh 2011
Methods This was a randomised, placebo-controlled trial (GO-REVEAL study)
Participants Inclusion criteria of the trial
• Psoriatic arthritis participants with 3 swollen and 3 tender joints and psoriasis.
The trial lasted for 104 weeks, and it included 405 participants
Interventions • Subcutaneous placebo (group 1)
• Golimumab 50 mg (group 2)
• Golimumab 100 mg (group 3)
The interventions were administered every 4 weeks. At week 16, participants with inadequate response entered early
escape. Group 1 crossed over to golimumab 50 mg at week 24. In open-label extension, participants could be dose-
escalated, from golimumab 50 mg to 100 mg
Outcomes Outcomes of the trial
1. Improvement of target fingernail psoriasis
2. Adverse effects
Notes This was a conference publication.
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Kingsley 2009
Methods This was a multicentre, randomised, double-blind, placebo-controlled trial, which lasted 6 months (the MIPA
(methotrexate in active psoriatic arthritis) trial).
The trial conducted intention-to-treat analysis.
Participants Inclusion criteria of the trial
• Participants with active psoriatic arthritis
Interventions • Oral methotrexate (15 mg/week)
• Placebo
Outcomes Outcomes of the trial
1. Improvement of nail score
Notes The trial reported dropouts.
This was a conference publication.
Langley 2011
Methods This was a randomised, placebo-controlled trial. This abstract used data from the 28-week phase IV trial, REACH
(randomized, placebo-controlled evaluation of adalimumab for treatment of adults with moderate to severe chronic
plaque psoriasis involving hands, feet, or both; NCT00735787).
Participants Inclusion criteria of the trial
• Participants with moderate to severe chronic plaque psoriasis involving hands, feet, or both
Interventions • Adalimumab
• Placebo
Participants were randomised 2:1 to adalimumab (80 mg at week 0, 40 mg every other week from weeks 1 to 27) or
placebo (placebo at weeks 1 to 15, 80 mg adalimumab at week 16, 40 mg every other week from weeks 17 to 27)
Outcomes Outcomes of the trial
1. Nail Psoriasis Severity Index (NAPSI)
Notes This was an abstract conference publication.
Leonardi 2011
Methods This was a randomised, placebo-controlled, phase II, double-blind trial
Intention-to-treat analysis was carried out (last observation carried forward)
Participants Inclusion criteria of the trial
• 142 participants with moderate to severe plaque psoriasis
Interventions • Subcutaneous injections of 10, 25, 75, or 150 mg of LY2439821 (LY), a humanized anti-interleukin (IL)-17
monoclonal antibody
• Placebo at weeks 0, 2, 4, 8, 12, and 16
Efficacy measures and safety were monitored through week 20.
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Outcomes Outcomes of the trial
1. Nail Psoriasis Severity Index (NAPSI)
2. Adverse effects
Notes This was a conference publication.
McInnes 2009
Methods This was a randomised, placebo-controlled trial (GO-REVEAL study), with 405 participants
Participants Inclusion criteria of the trial
• Psoriatic arthritis participants with 3 swollen and 3 tender joints and active plaque psoriasis (at least 1 lesion at
least 2 cm in diameter)
Interventions • Subcutaneous placebo
• Golimumab 50 mg
• Golimumab 100 mg
The interventions were administered every 4 weeks.
Outcomes Outcomes of the trial
1. The single worst psoriasis-affected nail (target) was assessed using the Nail Psoriasis Severity Index (NAPSI).
2. The Nail Physician’s Global Assessment (PGA; 1 to 5; 1 = absence of; 5 = very severe) evaluated all fingernails.
Notes This was a conference publication.
Thaci 2010
Methods This was a randomised, vehicle-controlled trial, which lasted 16 weeks
Participants were treated in the phase IIIb, multicentre European study BELIEVE
Participants Inclusion criteria of the trial
• BELIEVE study: Participants with moderate to severe psoriasis who had failed, been intolerant of, or had
contraindications to more than 2 systemic therapies
Interventions • Adalimumab 80 mg at week 0, and 40 mg every other week from weeks 1 to 15
• Either topical vehicle or topical calcipotriol/betamethasone (C/B) (once daily for 4 weeks, and thereafter as
needed (PRN: pro re nata); face, scalp, and nails excluded).
Outcomes Outcomes of the trial
1. Nails were assessed by NAPSI of the hands (range = 0 to 80) at baseline, week 8, and week 16.
Notes This was a poster presentation.
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Characteristics of ongoing studies [ordered by study ID]
EUCTR2004-004825-87-HU
Trial name or title Efficacy and safety of 0.1%, 0.5% and 1% tazarotene nail lacquer formulation versus vehicle in nail psori-
asis. International, multicenter, double-blind, randomized study of four parallel groups. - Dose ranging for
tazarotene nail lacquer
Methods This is a double-blind, randomised study of 4 parallel groups, assessing the application of 0.1%, 0.5%, or
1% tazarotene fingernail lacquer 6-month daily in fingernail psoriasis
Participants Inclusion criteria of the trial
• Participants are aged 18 years or over with a history of cutaneous psoriasis. Participants have at least 4
nails with a minimal severity level defined as onycholysis of at least 25% or subungual hyperkeratosis at least
2 mm.
Interventions • Application of 0.1%, 0.5%, or 1% tazarotene fingernail lacquer for 6 months daily
Outcomes Primary outcomes of the trial
1. Main objective: to assess the efficacy of a 6-month daily application of 0.1%, 0.5%, or 1% tazarotene
fingernail lacquer in fingernail psoriasis, using Expert Physician Global Assesment (EPGA) corresponding to
a blinded assessment of photographs using a 6-point scale
2. Primary end point(s): Blinded Expert Global Assesment (EPGA) from photographs at 6 months on a
6-point scale: 1 = clear, 2 = excellent, 3 = good, 4 = fair, 5 = poor, 6 = worse
Secondary outcomes of the trial
1. To assess the efficacy every 6 weeks using Baran’s Total Clinical Score and Investigator Physician Global
Assessment (IPGA)
2. To assess the efficacy of a 3-month daily application using EPGA
3. To assess relapse at 3 months after the end of the treatment
4. To assess local and general safety of the test product at each visit
5. To collect the participant self-assessment at 3 and 6 months
Starting date 22 April 2005
Contact information Pierre Fabre Dermatology represented by Institut de Recherche Pierre Fabre
Notes Status: not recruiting
EUCTR2006-004453-18-FR
Trial name or title A Randomised, Open-Label Preliminary Study To Assess The Effects Of Etanercept 50 mg OnceWeekly For
24 Weeks And Etanercept 50 mg Twice Weekly For 12 weeks Reducing To Etanercept 50 mg Once Weekly
For 12 weeks On Nail And Skin Symptoms In Patients With Nail Psoriasis And Plaque Psoriasis
Methods This is a randomised, open-label study assessing the effects of etanercept 50 mg once weekly for 24 weeks
and etanercept 50 mg twice weekly for 12 weeks reducing to etanercept 50 mg once weekly for 12 weeks on
nail and skin symptoms in participants with nail psoriasis and plaque psoriasis
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Participants Inclusion criteria of the trial
• Participants are 18 years of age or older at time of consent and have active, stable plaque psoriasis
defined by the following criteria:
◦ Body surface area (BSA) > 10% at screening and baseline;
◦ PASI > 10 at screening and baseline;
◦ PGA of psoriasis status of moderate or worse (moderate, marked, or severe) at screening and
baseline; or
◦ DLQI > 10 at baseline
• Participants have active fingernail psoriasis as defined as target fingernail NAPSI > 2 and overall NAPSI
> 14. The target nail is defined as the nail with most severe overall grading at baseline.
• Participants had failure of at least 1 systemic psoriasis therapy for nail psoriasis, are eligible to receive
biologic therapy for psoriasis in accordance to local guidelines, are able to store injectable test article
between 2° and 8°C, and are able and willing to self-inject test article or have a designee who can do so
Interventions • Etanercept 50 mg once weekly for 24 weeks or etanercept 50 mg twice weekly for 12 weeks reducing to
etanercept 50 mg once weekly for 12 weeks
Outcomes Primary outcomes of the trial
• Main objective: to estimate the Nail Psoriasis Severity Index (NAPSI) in the target fingernail for both
treatment regimens over 24 weeks
• Primary end point(s): change from baseline in NAPSI for target fingernail over 24 weeks
Secondary outcomes of the trial
• To estimate the overall NAPSI for both treatment regimens over 24 weeks
• To estimate the proportion of participants achieving a 50% and 75% improvement in NAPSI in the
target fingernail and overall NAPSI at 12 and 24 weeks
• To estimate the Psoriasis Area and Severity Index (PASI) scores over 24 weeks
• To estimate the proportion of participants achieving a 50% and 75% improvement in PASI scores at
12 and 24 weeks
• To estimate the Physician Global Assessment (PGA) of Psoriasis over 24 weeks
• To estimate patient Dermatology Life Quality Index (DLQI) over 24 weeks
• To estimate Physician and Patient Global Assessment of Nail Psoriasis Disease Activity Visual
Analogue Scale (VAS) over 24 weeks
• To evaluate the safety and tolerability of the treatment regimens over 24 weeks
• To explore the utility of a novel fingernail grading assessment tool over 24 weeks
Starting date 7 June 2007
Contact information Wyeth Pharmaceuticals (France)
Notes Status: Authorised - recruitment may be ongoing or finished
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Trial name or title Efficacy and safety of 8% clobetasol nail lacquer formulation versus vehicle in nail psoriasis
Methods This is a randomised, double-blind, placebo-controlled trial assessing the efficacy of a 6-month daily applica-
tion of 8% clobetasol nail lacquer versus vehicle in fingernail psoriasis using the dynamic physician (blinded
expert) global assessment (EPGA), the dynamic physician (investigator) global assessment (IPGA), and the
patient global self assessment
Participants Inclusion criteria of the trial
• Participants are 18 years or older, men or women, and ambulatory participants. They have a history of
having - for the last 6 months - bilateral fingernail psoriatic involvement on both hands.
• At least 1 fingernail with psoriatic involvement per hand, at least 1 nail per hand (target nail) with an
onycholysis area > 25%, a subungual hyperkeratosis > 2 mm, or both. The target nail should be on the same
finger of each hand.
Interventions • 6-month daily application of 8% clobetasol nail lacquer
• Vehicle
Outcomes Primary outcomes of the trial
• Main objective: to assess the efficacy of a 6-month daily application of 8% clobetasol nail lacquer
versus vehicle in fingernail psoriasis using the dynamic physician (blinded expert) global assessment (EPGA)
, the dynamic physician (investigator) global assessment (IPGA), and the patient global self assessment
• Primary end point(s): dynamic PGA: 1) dEPGA (dynamic expert PGA), 2) dIPGA (dynamic
investigator PGA); Static PGA: 1) sEPGA (static expert PGA), 2) sIPGA (static investigator PGA)
• Total clinical score assessing onycholysis, hyperkeratosis, healthy nail, number of cured nails, healthy
hands, number of cured hands, patients global self assessment, tolerance to clobetasol dosage, plasmatic
clobetasol measurement at baseline and 3 and 6 months
Secondary outcomes of the trial
• To assess local and general safety of 8% clobetasol fingernail lacquer
• To assess systemic exposure of clobetasol after 6 months’ treatment
Starting date 19 January 2007
Contact information Pierre Fabre Dermatology represented by Institut de Recherche Pierre Fabre
Notes Status: Authorised - recruitment may be ongoing or finished
EUCTR2010-019706-16-IT
Trial name or title A randomized, double blind, placebo controlled, parallel groups, pilot study to assess the effects of two new
nail lacquers, cyclosporine 5% and calcipotriol 0.005%, in the treatment of nail psoriasis - ND
Methods This is a randomised, double-blind, placebo-controlled, parallel-group pilot study assessing the application
of 2 new nail lacquers, ciclosporin 5% and calcipotriol 0.005%
Participants Inclusion criteria of the trial
• Participants are men and women aged 18 to 80 years, who have a clinical diagnosis of mild to
moderate psoriasis (BSA involvement = 10% or PASI =10), have nail psoriasis (fingernails) of the nail
matrix, the nail bed affecting at least 1 nail, or both. There is presence of at least 1 clinical sign of nail
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psoriasis of the matrix (pitting, leukonychia, red spots in lunula, nail plate crumbling), of the nail bed
(salmon patch, onycholysis, hyperkeratosis, and splinter haemorrhage), or both in at least 1 nail.
Interventions • Topical ciclosporin 5%
• Calcipotriol 0.005%
Outcomes Primary outcomes of the trial
1. Main objective: to evaluate the changes of clinical signs of nail bed and of the nail matrix of the nails
affected by psoriasis by means of NAPSI score at the end of treatment, at each study visit, and at the follow-
up visit (12 weeks after the end of treatment)
2. To evaluate the changes of nail thickness of the affected nails by means of 20 MHz ultrasound at the
end of treatment, at each study visit, and at the end of the follow-up period (12 weeks after the end of
treatment)
3. Evaluation of the safety profile of P-3072 and P-3073 at the end of treatment and at each study visit by
means of adverse effects monitoring
4. To evaluate the changes in participants’ quality of life at the end of treatment, at each study visit, and at
the end of the follow-up period (12 weeks after the end of treatment)
5. To evaluate the changes in pain due to nail psoriasis
6. To evaluate the changes in discomfort due to nail psoriasis
7. To evaluate participants’ opinion on the product (effectiveness and acceptability) at the end of
treatment
8. Primary end point(s):
◦ Changes in clinical signs of the nail bed (salmon patch, onycholysis, hyperkeratosis, and splinter
haemorrhage) and of the nail matrix (pitting, leukonychia, red spots in lunula, and nail plate crumbling) of
the affected nails evaluated by means of NAPSI score at the end of treatment, at each study visit, and at the
follow-up visit
◦ Changes of nail thickness of the affected nails evaluated by means of 20 MHz ultrasound at the
end of treatment, at each study visit, and at the end of the follow-up period
◦ Evaluation of the safety profile of P-3072 and P-3073 at each study visit by means of adverse
effect monitoring
◦ Changes in participants’ quality of life by means of NPQ10 (Nail Psoriasis Quality of Life) and
DLQI (Dermatology Life Quality Index) questionnaires evaluated at each study visit
◦ Changes of pain due to nail psoriasis by means of a VAS (Visual Analogue Scale)
◦ Changes of discomfort due to nail psoriasis by means of a VAS (Visual Analogue Scale)
◦ Participants’ opinion on the product effectiveness and on its acceptability evaluated at each study
visit by means of participants’ diaries
◦ Blood and nail concentration of ciclosporin and calcipotriol at the end of treatment, at each study
visit, and at the end of the follow-up period
Starting date 27 July 2010
Contact information Polichem
Notes Status: Authorised - recruitment may be ongoing or finished
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NCT00581100
Trial name or title Randomised, Open-label Preliminary Study to Assess the Effects of 2 Regimens of Etanercept on Nail and
Skin Symptoms in Patients With Nail Psoriasis and Plaque Psoriasis
Methods This is an open-label randomised controlled trial.
The study will assess the effects of the 2 etanercept regimens on fingernail psoriasis over 24 weeks among
participants with both skin and fingernail involvement who have previously failed at least 1 therapy for nail
psoriasis
The end point of 24 weeks was chosen to allow sufficient time for normal nail growth
Participants Inclusion criteria of the trial
• Participants of 18 years of age or older with active fingernail psoriasis and failure of at least 1 systemic
psoriasis therapy for nail psoriasis
Interventions • Etanercept
Outcomes Outcomes of the trial
1. Change from baseline in NAPSI for target fingernail over 24 weeks
2. Proportion of subjects achieving NAPSI 50 and NAPSI 75 for target fingernail and an overall NAPSI
at 12 and 24 weeks
3. Change from baseline in the Physician and Patient Assessment of Nail Psoriasis Activity VAS to 24
weeks
4. Change from baseline using novel assessment tool (physician fingernail grading assessment) over 24
weeks
Starting date September 2007
Contact information Medical Monitor, Study Director, Wyeth
Notes Status: Completed
NCT00666354
Trial name or title Phase IIB Dose Response and Safety Study of Topical Formulations of Methotrexate (MQX-5902, MQX-
5904 and MQX-5906) in the Treatment of Fingernail Psoriasis
Methods This is a multicentre, randomised, double-blind, efficacy and safety study evaluating improvements in the
appearance of the target fingernail measured monthly for 4 months. The trial will also assess safety, i.e., the
frequency and severity of adverse events in the treatment of participants with fingernail psoriasis, measured
monthly for 5 months
Participants Inclusion criteria of the trial
• 83 participants, 18 to 75 years of age and either sex
Interventions • Active comparator 1 = methotrexate (other names: MQX-5906)
Dosing: 0.01 g of topical amphimatrix containing 0.05% methotrexate per affected nail and adjacent skin
folds applied daily for 3 months
• Active comparator 2 = methotrexate (other names: MQX-5902)
Dosing: 0.01 g of topical amphimatrix containing 0.25% methotrexate per affected nail and adjacent skin
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folds applied daily for 3 months
• Active comparator 3 = methotrexate (other names: MQX-5904)
Dosing: 0.01 g of topical amphimatrix containing 1.0%methotrexate per affected nail and adjacent skin folds
applied daily for 3 months
The total duration of follow-up is 1 month.
Outcomes Primary outcomes of the trial
1. Evaluate improvements in the appearance of the target fingernail, utilising photography for imaging
and independent photograph evaluators, measured monthly for 4 months
2. Assess safety, i.e., the frequency and severity of adverse events associated with MQX-5902, MQX-5904,
and MQX-5906 in the treatment of participants with fingernail psoriasis, measured monthly for 5 months
Secondary outcomes of the trial
The following will be measured monthly for 4 months.
1. The improvement in the appearance of the control fingernail as determined by independent evaluators
2. The improvement of the target fingernail as measured by the investigator using the mNAPSI (a
modification of the Nail Psoriasis Severity Index)
3. A comparison of the improvement of the mNAPSI of the target and control fingernails
4. Information on the relative changes in nail psoriasis severity of the other affected fingernails
5. A comparison of nail growth of the target and control fingernails as determined from nail notch
movement measured on nail photographs
Starting date 01 October 2007
Contact information Professor Neil McHugh
Royal National Hospital for Rheumatic Diseases
Upper Borough Walls, Bath
United Kingdom
BA1 1RL
MediQuest Therapeutics, Inc. (USA) sponsored the trial (email: info@mqti.com; phone: +1 425 398 9580)
Notes Status: Completed
NCT00999687
Trial name or title Evaluation of the Efficacy and Safety of Indigo Naturalis Oil Extract on Psoriatic Nails
Methods This is a phase II/phase III, randomised, placebo-controlled, single-blind trial
Participants Inclusion criteria of the trial
• Participants aged 18 to 75 years old with fingernail psoriasis
• Failure of topical or systemic Chinese herbal antipsoriasis therapy for fingernail psoriasis, or both
Interventions • Indigo naturalis oil extract
• Placebo
The interventions were administered for 24 weeks.
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NCT00999687 (Continued)
Outcomes Outcomes of the trial
1. Change from baseline in modified NAPSI for target fingernail over 24 weeks
2. Comparison of improvement of modified NAPSI of the indigo naturalis oil agent-treated and control
fingernails
Starting date September 2009
Contact information Yin-Ku Lin, MD, PhD
Principal Investigator
Chang Gung Memorial Hospital
Notes Status: Enrolling by invitation
NCT01107457
Trial name or title A Dose-Ranging And Efficacy Study of LY2439821 (An Anti-IL-17 Antibody) In Patients With Moderate-
To-Severe Psoriasis
Methods This is a randomised, placebo-controlled, double-blind trial
Participants will be evaluated for treatment efficacy at multiple visits, and the primary end point will be
evaluated at week 16. Participants will be followed an additional 16 to 24 weeks (32 to 40 weeks in total) after
the completion of dosing in order to continue safety monitoring and to determine the duration of treatment
efficacy
Participants Inclusion criteria of the trial
• Approximately 125 participants of either gender and over 18 years old will be randomised to 1 of 4
LY2439821 groups or to placebo (approximately 25 participants per group).
• Plaque psoriasis covering at least 10% body surface area and a PASI score of 12
Interventions • LY2439821 10 mg, 25 mg, 75 mg, and 150 mg (biological)
• Placebo (drug)
Outcomes Outcomes of the trial
1. Change from baseline through 32 weeks in Nail Psoriasis Severity Index (NAPSI) in participants with
nail psoriasis
Starting date April 2010
Contact information Eli Lilly & Co.
Study Director: phone CTLILLY (+1 877 285 4559) or phone +1 317 615 4559
Notes Status: This trial is not yet recruiting.
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D A T A A N D A N A L Y S E S
Comparison 1. (Systemic) ciclosporin 2.5 mg/kg vs topical dithranol + salicylic acid + UVB
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participants with at least 50%
nail score improvement after
short-term treatment duration
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
Comparison 2. (Topical) ciclosporin 70% in maize oil vs maize oil
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participants with at least 50%
nail score improvement after
short-term treatment duration
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
Comparison 3. (Topical) calcipotriol 0.005% vs calcipotriol 0.005% + 0.05% betamethasone dipropionate
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participants with at least 50%
nail score improvement after
short-term treatment duration
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
Comparison 4. Topical - Systemic - Radiotherapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participants with adverse effects
(AE)
15 Risk Ratio (M-H, Random, 95% CI) Totals not selected
1.1 Topical therapy 7 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Systemic therapy 5 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 Radiotherapy 3 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Comparison 5. (Topical) calcipotriol 50 ug/g vs betamethasone dipropionate 64 mg/g + salicylic acid 0.03 g/g
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participants with at least 50%
nail score improvement after
short-term treatment duration
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2 Nail score improvement after
short-term treatment duration
1 Mean Difference (IV, Random, 95% CI) Subtotals only
Comparison 6. (Systemic) ustekinumab 45 mg versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Nail score improvement after
short-term treatment duration
1 Mean Difference (IV, Random, 95% CI) Subtotals only
Comparison 7. (Systemic) ustekinumab 90 mg versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Nail score improvement after
short-term treatment duration
1 Mean Difference (IV, Random, 95% CI) Subtotals only
Comparison 8. (Systemic) ustekinumab 45 mg versus 90 mg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Nail score improvement after
short-term treatment duration
1 Mean Difference (IV, Random, 95% CI) Subtotals only
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Comparison 9. (Systemic) methotrexate versus ciclosporin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Nail score improvement after
medium-term treatment
duration
1 Mean Difference (IV, Random, 95% CI) Subtotals only
Analysis 1.1. Comparison 1 (Systemic) ciclosporin 2.5 mg/kg vs topical dithranol + salicylic acid + UVB,
Outcome 1 Participants with at least 50% nail score improvement after short-term treatment duration.
Review: Interventions for nail psoriasis
Comparison: 1 (Systemic) ciclosporin 2.5 mg/kg vs topical dithranol + salicylic acid + UVB
Outcome: 1 Participants with at least 50% nail score improvement after short-term treatment duration
Study or subgroup Oral ciclosporin Dithranol Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Levell 1995 8/10 8/15 1.50 [ 0.85, 2.64 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 8 (Oral ciclosporin), 8 (Dithranol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.1 0.2 0.5 1 2 5 10
Favours dithranol Favours ciclosporin
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Analysis 2.1. Comparison 2 (Topical) ciclosporin 70% in maize oil vs maize oil, Outcome 1 Participants with
at least 50% nail score improvement after short-term treatment duration.
Review: Interventions for nail psoriasis
Comparison: 2 (Topical) ciclosporin 70% in maize oil vs maize oil
Outcome: 1 Participants with at least 50% nail score improvement after short-term treatment duration
Study or subgroup Top ciclosporin 70% Maize oil Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cannavo 2003 8/8 0/8 17.00 [ 1.14, 252.54 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 8 (Top ciclosporin 70%), 0 (Maize oil)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.02 0.1 1 10 50
Favours maize oil Favours top. ciclosporin
Analysis 3.1. Comparison 3 (Topical) calcipotriol 0.005% vs calcipotriol 0.005% + 0.05% betamethasone
dipropionate, Outcome 1 Participants with at least 50% nail score improvement after short-term treatment
duration.
Review: Interventions for nail psoriasis
Comparison: 3 (Topical) calcipotriol 0.005% vs calcipotriol 0.005% + 0.05% betamethasone dipropionate
Outcome: 1 Participants with at least 50% nail score improvement after short-term treatment duration
Study or subgroup Calcipotriol Calcipotriol+betamethason Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Tzung 2008 9/17 8/15 0.99 [ 0.52, 1.91 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 9 (Calcipotriol), 8 (Calcipotriol+betamethason)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.5 0.7 1 1.5 2
Favours calcipotriol+beta Favours calcipotriol
80Interventions for nail psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.1. Comparison 4 Topical - Systemic - Radiotherapy, Outcome 1 Participants with adverse effects
(AE).
Review: Interventions for nail psoriasis
Comparison: 4 Topical - Systemic - Radiotherapy
Outcome: 1 Participants with adverse effects (AE)
Study or subgroup Control Intervention Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Topical therapy
Cannavo 2003 0/8 0/8 0.0 [ 0.0, 0.0 ]
de Jong 1999 0/57 6/57 0.08 [ 0.00, 1.33 ]
Flori 1994 0/15 0/15 0.0 [ 0.0, 0.0 ]
Rigopoulos 2007 1/14 3/16 0.38 [ 0.04, 3.26 ]
Scher 2001 0/10 5/21 0.18 [ 0.01, 3.00 ]
Tosti 1998 3/21 3/25 1.19 [ 0.27, 5.29 ]
Tzung 2008 0/15 0/17 0.0 [ 0.0, 0.0 ]
2 Systemic therapy
G m el 2011 5/19 4/18 1.18 [ 0.38, 3.72 ]
Igarashi 2012 21/32 79/126 1.05 [ 0.79, 1.39 ]
Kavanaugh 2009 67/113 222/343 0.92 [ 0.77, 1.09 ]
Mahrle 1995 40/70 45/140 1.78 [ 1.30, 2.44 ]
Rich 2008 54/76 244/298 0.87 [ 0.74, 1.01 ]
3 Radiotherapy
Kwang 1995 0/12 12/12 0.04 [ 0.00, 0.61 ]
Lindelof 1989 0/22 5/22 0.09 [ 0.01, 1.55 ]
Yu 1992 0/8 0/8 0.0 [ 0.0, 0.0 ]
0.2 0.5 1 2 5
AE in interv grp AE in control grp
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Analysis 5.1. Comparison 5 (Topical) calcipotriol 50 ug/g vs betamethasone dipropionate 64 mg/g + salicylic
acid 0.03 g/g, Outcome 1 Participants with at least 50% nail score improvement after short-term treatment
duration.
Review: Interventions for nail psoriasis
Comparison: 5 (Topical) calcipotriol 50 ug/g vs betamethasone dipropionate 64 mg/g + salicylic acid 0.03 g/g
Outcome: 1 Participants with at least 50% nail score improvement after short-term treatment duration
Study or subgroup Calcipotriol
Betamethasone
+ salicylic Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Tosti 1998 8/13 10/16 0.98 [ 0.55, 1.75 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 8 (Calcipotriol), 10 (Betamethasone + salicylic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.5 0.7 1 1.5 2
Favours betamethasone Favours calcipotriol
Analysis 5.2. Comparison 5 (Topical) calcipotriol 50 ug/g vs betamethasone dipropionate 64 mg/g + salicylic
acid 0.03 g/g, Outcome 2 Nail score improvement after short-term treatment duration.
Review: Interventions for nail psoriasis
Comparison: 5 (Topical) calcipotriol 50 ug/g vs betamethasone dipropionate 64 mg/g + salicylic acid 0.03 g/g
Outcome: 2 Nail score improvement after short-term treatment duration
Study or subgroup Calcipotriol
Betamethasone
+ salicylic
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Tosti 1998 8 1.4 (0.57) 10 1.1 (0.32) 0.30 [ -0.14, 0.74 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-1 -0.5 0 0.5 1
Favours betamethasone Favours calcipotriol
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Analysis 6.1. Comparison 6 (Systemic) ustekinumab 45 mg versus placebo, Outcome 1 Nail score
improvement after short-term treatment duration.
Review: Interventions for nail psoriasis
Comparison: 6 (Systemic) ustekinumab 45 mg versus placebo
Outcome: 1 Nail score improvement after short-term treatment duration
Study or subgroup Ustekinumab 45 mg Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Igarashi 2012 43 0.28 (95.1) 17 -0.13 (27.8) 0.41 [ -30.94, 31.76 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-1 -0.5 0 0.5 1
Favours placebo Favours ustekinumab 45 mg
Analysis 7.1. Comparison 7 (Systemic) ustekinumab 90 mg versus placebo, Outcome 1 Nail score
improvement after short-term treatment duration.
Review: Interventions for nail psoriasis
Comparison: 7 (Systemic) ustekinumab 90 mg versus placebo
Outcome: 1 Nail score improvement after short-term treatment duration
Study or subgroup Ustekinumab 90 mg Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Igarashi 2012 40 0.41 (66.1) 17 -0.13 (27.8) 0.54 [ -23.84, 24.92 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours placebo Favours ustekinumab 90 mg
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Analysis 8.1. Comparison 8 (Systemic) ustekinumab 45 mg versus 90 mg, Outcome 1 Nail score
improvement after short-term treatment duration.
Review: Interventions for nail psoriasis
Comparison: 8 (Systemic) ustekinumab 45 mg versus 90 mg
Outcome: 1 Nail score improvement after short-term treatment duration
Study or subgroup Ustekinumab 45 mg Ustekinumab 90 mg
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Igarashi 2012 43 0.28 (95.1) 40 0.41 (66.1) -0.13 [ -35.17, 34.91 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-0.2 -0.1 0 0.1 0.2
Favours ustekinumab 90 mg Favours ustekinumab 45 mg
Analysis 9.1. Comparison 9 (Systemic) methotrexate versus ciclosporin, Outcome 1 Nail score
improvement after medium-term treatment duration.
Review: Interventions for nail psoriasis
Comparison: 9 (Systemic) methotrexate versus ciclosporin
Outcome: 1 Nail score improvement after medium-term treatment duration
Study or subgroup Methotrexate (MTX) Ciclosporin (CsA)
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
G m el 2011 17 18 (11.5) 17 25.8 (19.2) -7.80 [ -18.44, 2.84 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Favours CsA Favours MTX
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A D D I T I O N A L T A B L E S
Table 1. Glossary of terms
Term Definition
Arthritis-psoriatica Inflammation of 1 or more joints (oligo- or poly-arthritis) closely
associated with skin psoriasis, nail changes, or both
Carry-over effect The treatment effect will be affected, depending upon the order
in which they were received. Carry-over treatment effect across
periods
Distal portion of the nail matrix The closest part of the nail matrix (ground substance of the nail)
to the body
Erythematous Flushing of the skin due to dilatation of the blood capillaries
Exocytosis The appearance of migrating inflammatory cells in the epidermis
Koebner phenomenon Lesions appearing on lines of trauma or other triggers
Lunula Nail moon
Nail dystrophy Destruction of the nail plate
Onicolisi/Onycholysis Separation or loosening of part or all of a nail from its bed
Onicoressi Fragile nails with thin longitudinal tracks
Onycholysis Separation or loosening of part or all of a nail from its bed
Onychomadesis Loosening of the nail from the nail bed
Onychorrhexis Longitudinal grooves that can split to the nail bed
Parakeratotic foci Parts of the horny layer of the upper skin inwhich cells still contain
nuclei
Parakeratosis pustulosa, acropustulosis keratotica, acroder-
matitis continua of Hallopeau
Other nail diseases partly resembling nail psoriasis
Paronychia An inflamed swelling of the nail fold
Psoriasis A chronic inflammatory skin disease characterised by thickened
patches, inflamed, red skin covered with thick, silvery scales
Salmon patches A dyschromia/discolouration of the nails resembling an oil patch
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Table 1. Glossary of terms (Continued)
Subungal hyperkeratosis or subungual keratosis Thickening of the outer horny layer of the skin underneath the
nail
Table 2. Abbreviations
Abbreviation Term
5-FU 5-fluorouracil
AE Adverse event
cGy centiGray
CsA Ciclosporin A
DMSO2 Methylsulphonylmethane
Gy Gray (relating to the amount of grenz
rays used in a type of
radiotherapy treatment)
HPCH Hydroxypropyl chitosan
IGA Investigator’s Global Assessment
MTX Methotrexate
NAPSI Nail Psoriasis Severity Index
NAS Nail Area Severity
NS Not-significant
P P value
PAGA Patient’s Global Assessment
PASI Psoriasis Area and Severity Index
PGA Physician Global Assessment
RCT Randomised controlled trial
S. Significant
SRT Superficial radiotherapy
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Table 2. Abbreviations (Continued)
VS Versus
Table 3. Basic characteristics
Author Year Inter-
vention
Com-
parison
Applica-
tion
Treat-
ment
dura-
tion
Follow-
up
N Inter-
nally-
con-
trolled
study
Primary
outcome
Sec-
ondary
outcome
Level of
evidence
Topical therapy
Baran 1999 Topical
8% clo-
betasol
Placebo
lacquer
Once
daily
1, 2 to 6,
6
months,
aver-
age 2, 5
months
No 18 Yes 1 3 B
Baran 1999a Topical
8% clo-
betasol
Placebo
lacquer
1st week
once
daily,
onwards
2 or 3
times
weekly
5,
1 to 8, 9
months,
aver-
age 7, 0
months
No 27 Yes 1 3 B
Can-
navo
2003 Topical
ci-
closporin
70% in
maize oil
Maisoil Twice
daily
12 weeks
(3
months)
8 weeks 16 No 1, 3 1, 2, 3 A2
de Jong 1999 1% 5-
fluo-
rouracil
in Be-
lanyx®
lotion
Be-
lanyx®
lotion
Once
daily,
under
occlu-
sion
12 weeks
(3
months)
4 weeks 57 Yes 1, 2, 3 1, 3 A2
Flori 1994
Hyaluronic
acid +
chon-
droitin
sul-
phates
Placebo Gel in
the
morn-
ing, mi-
cro
emul-
sion at
night
90 days
(3
months)
No 30 No 1 1, 3 A2/B
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Table 3. Basic characteristics (Continued)
Rigopou-
los
2007
Tazarotene
0.1%
cream
Clobeta-
sol pro-
pionate
0.05%
Once
daily un-
der oc-
clusion
12 weeks
(3
months)
12 weeks 46 No 2 1, 3 A2
Scher 2001
Tazarotene
0.1% gel
Vehicle
gel
Once
daily,
one tar-
get
nail un-
der oc-
clusion
24 weeks
(6
months)
No 31 No 1 1, 3 A2/B
Tosti 1998 Cal-
cipotriol
50 ug/g
Be-
tametha-
son
dipropi-
onate 64
mg/
g + sali-
cylic acid
0.03 g/g
Twice
daily
3 to 5
months
1 month 58 No 3 1, 3 B
Tzung 2008 Cal-
cipotriol
0.005%
Cal-
cipotriol
0.005%
+ be-
tametha-
sone
dipropi-
onate 0.
05%
Cal-
cipotriol
twice
daily
with be-
tametha-
sone
once
daily
12 weeks
(3
months)
No 40 No 1, 2, 3 1, 3 B
Systemic therapy
G m
el
2011
Methotrex-
ate 15
mg
Ci-
closporin
5 mg/kg
MTX:
sin-
gle dose
weekly
subcuta-
neous.
After 3
months
de-
crease to
10 mg/
week
CsA:
24 weeks 12 weeks 37 No 1 ,2, 3 1 A2
88Interventions for nail psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 3. Basic characteristics (Continued)
daily (di-
vided
into
2 doses)
, after 3
months
de-
crease to
2.5 to 3.
5mg/kg/
day
Levell 1995 Systemic
ci-
closporin
2.5 mg/
kg
Topical
dithra-
nol 2%
to 8% +
0.
5% sali-
cylic acid
+ UVB
CsA: 2
daily
doses.
Dith:
once
daily for
15 min-
utes pre-
ceded by
UVB
Up to 16
weeks (4
months)
until
clear
Up to 8
months
29 No 1 1 A2/B
Mahrle 1995 Systemic
ci-
closporin
2.5 mg/
kg
Etreti-
nate 0.5
mg/kg
Once
daily
22 weeks
(5, 5
months)
4 weeks 137 No 1 1 B
Biological therapy
Igarashi 2012 Ustek-
inumab
45 mg or
90 mg
Placebo Subcuta-
neous in-
jection
week 0,
4, every
12 weeks
64 weeks 8 weeks 102 No 2 1 A2
Ka-
vanaugh
2009 Goli-
mumab
50 mg or
100 mg
Placebo Subcuta-
neous in-
jection
every 4
weeks
20 weeks
(5
months)
4 weeks 287 No 1, 2 1 B
Rich 2008 Inflix-
imab 5
mg/kg
Placebo In-
fusion at
week 0,
2, 6 and
every
46 weeks
(11, 5
months)
4 weeks 305 No 2 1, 3 A2
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Table 3. Basic characteristics (Continued)
8 weeks
onward
Radiotherapy
Kwang 1995 Electron
beam 0.
75 Gy
Placebo 0.75 Gy
per week
(total 6
Gy)
8
weeks (2
months)
12
months
12 Yes 1 1, 3 B
Linde-
lof
1989 Grenz
rays 5Gy
Placebo 5
Gy once
a week
10 weeks
(2, 5
months)
6
months
24 Yes 1 1 A2/B
Yu 1992 Super-
ficial ra-
diother-
apy 450
cGy
’Sham
radio-
therapy’
Fort-
nightly
14
days (1/2
month)
18 weeks 10 Yes 1 1, 3 B
Primary outcomes
(a) Global improvement of nail psoriasis as rated by a clinician
(b) Improvement of nail psoriasis scores (NAS, NAPSI)
(c) Improvement of nail psoriasis in the participant’s opinion
Secondary outcomes
(a) Adverse effects (and serious adverse effects, i.e. serious enough to require withdrawal of the treatment)
(b) Effects on quality of life
(c) Improvement in nail features, pain score, nail thickness, thickness of subungual hyperkeratosis, number of affected nails, and nail
growth
Level of evidence
A2: Randomised controlled trial of good quality (adequate control group, good study design, size of the study, consistence)
B: Randomised clinical trial of low quality
Table 4. Finger nail severity and improvement
Mean % score improvement after treatment
Baseline
score
Short-term treatment Medium-term treatment Time of
assess-
ment
Moderate Good Moderate Good
Study Year Inter-
vention
Com-
parison
Inter-
vention
Com-
parison
Inter-
vention
Com-
parison
Inter-
vention
Com-
parison
Topical
therapy
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Table 4. Finger nail severity and improvement (Continued)
Baran:
Topical
clobe-
tasol vs
placebo
lacquer
1999 No score 61.5 (n =
16)
7.7 (n =
2)
- - - - - - Av-
erage 2,5
months
(1.2 to 6.
6
months)
Baran:
Topical
clobe-
tasol vs
placebo
lacquer
1999a No score - - - - 53.3 (n =
8)
26.7 (n =
4)
- - Average
7
months
(5.1 to 8.
9
months)
Can-
navo:
Topical
ci-
closporin
70% in
maize
oil vs
maize
oil
2003 Both 8 - - 77.0 (n =
8)sb
12.0 (n =
8)nsb
- - - - 12 weeks
de Jong:
5-fluo-
rouracil
in Be-
lanyx®
lotion
vs Be-
lanyx®
lotion
1999 7.1 vs 7.
1
32.0 (n =
57)ns,sb
39.0 (n =
57)ns,sb
- - - - - - 12 weeks
Flori:
Hyaluronic
acid +
chon-
droitin
sul-
phates
vs
placebo
1994 1.6 vs 1.
6
55.4 (n =
15)
23.9 (n =
15)
- - - - - - 90 days
Rigopou-
los:
2007 1.5 vs 1.
4
- - 75.0 (n =
16)ns,sb
68.0 (n =
14)ns,sb
- - - - 12 weeks
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Table 4. Finger nail severity and improvement (Continued)
Tazarotene
cream
vs clo-
betasol
propi-
onate
Scher:
Tazarotene
gel vs
vehicle
gel
2001 No score - - - - Not enough information of total improve-
ment for both groups
24 weeks
Tosti:
Cal-
cipotriol
vs be-
tametha-
son
dipropi-
onate +
salicylic
acid
1998 Both 2.3 26.5 (n =
13)ns
30.4 (n =
16)ns
49.2 (n =
8)ns,sb
51.7 (n =
10)ns,sb
- - 12 and
20 weeks
(respon-
ders
at week
12 con-
tinued to
week 20)
Tzung:
Cal-
cipotriol
vs cal-
cipotriol
+ be-
tametha-
sone
dipropi-
onate
2008 No score Both reduction in total score (n = 32)ns,sb - - - - 12 weeks
Sys-
temic
therapy
G m
el:
Methotrex-
ate vs ci-
closporin
2011 39.1 vs
42.1
- - - - 43.3 (n =
17)
ns+nsb
37.2 (n =
17)
ns+nsb
- - 24 weeks
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Table 4. Finger nail severity and improvement (Continued)
Levell:
Sys-
temic
ci-
closporin
vs
topical
dithra-
nol +
salicylic
acid +
UVB
1995 5.5 vs 5.
0
- - 82.0 (n =
10)nsb
0.0 (n =
15)nsb
- - - - Median
6 weeks
CsA
median
8 weeks
dithra-
nol
Mahrle:
Sys-
temic
ci-
closporin
vs
Etreti-
nate
1995 No score No significant changes < 25%, in nail in-
volvement for both groupsns
- - - - 10 weeks
Biologi-
cal ther-
apy
Igarashi:
Ustek-
inumab
45
mg vs
placebo
2012 3.7 vs 4.
6
No significant changes < 25%, in nail in-
volvement for both groupsns
- - - - 12 weeks
Igarashi:
Ustek-
inumab
90
mg vs
placebo
2012 4.1 vs 4.
6
No significant changes < 25%, in nail in-
volvement for both groupsns
- - - - 12 weeks
Ka-
vanaugh:
Goli-
mumab
50 mg
vs
placebo
2009 4.7 vs 4.
4
25.0 (n
= 95)s
0.0 (n =
83)
- - 33.0 (n =
95)s
0.0 (n =
83)
- - 14 and
24 weeks
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Table 4. Finger nail severity and improvement (Continued)
Ka-
vanaugh:
Goli-
mumab
100 mg
vs
placebo
2009 4.6 vs 4.
4
43.0 (n
= 109)s
0.0 (n =
83)
- - 54.0 (n =
109)s
0.0 (n =
83)
- - 14 and
24 weeks
Rich:
Inflix-
imab vs
placebo
2008 4.6 vs 4.
3
26.8 (n =
240)s
-7.7 (n =
65)s
- - 57.2s -4.1s - - 10 and
24 weeks
Radio-
therapy
Kwang:
Elec-
tron
beam vs
placebo
1995 No score Statistical improvement at 3 months after 8
weeks’ therapys+sb
No separate data between intervention and
comparison groups were given
- - - - 12 weeks
Linde-
lof:
Grenz
rays vs
placebo
1989 No score Moderate therapeutic responses.
No separate data between intervention and
comparison groups were given
- - - - 10 weeks
Yu:
Super-
ficial ra-
diother-
apy vs
’Sham
radio-
therapy’
1992 5.5 vs 5.
4
< 25% (20%) (no/worse) improvement for
both groups after 2 weeks’ treatment (n = 8)
s+sb , measure point at week 10
- - - - 10 weeks
This table shows the mean % score improvement of fingernail severity in time. Outcomes are divided into moderate and good
improvement after short-term, medium-term, or both treatment, regardless of the outcome measure used and the number of nail
features assessed. The baseline score therefore consists of different kind of scores, e.g. NAPSI, NAS, point scales. We didn’t show
improvement less than 25% (no/worse group) for a better overview of relevant data. Also, the follow up is not reported in this figure.
Responses of more than 50% after short-term treatment and of more than 25% after medium-term treatment are shown in graphs
in Figure 4.
If possible, the data of significance compared to the other treatment was shown. If this was not reported in the studies, the significance
compared to baseline was shown.
s: significant between the two treatment groups; ns: not significant between the two treatment groups; sb: significant to baseline; nsb:
not significant to baseline.
Definitions:
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No/worse improvement = no improvement, worse, very severe, severe, no change; < 25% improvement of the NAPSI (we have omitted
this group)
Moderate improvement = moderate, mild-moderate, medium, moderately; 25% to 75% improvement of the NAPSI
Good improvement = mild, slightly, marked, almost complete recovery, no lesion, absent, cured, normal, clearance; 75% to 100%
improvement of the NAPSI
Table 5. ’% participants with adverse effects’
Intervention and control
group
Adverse effects % participants (numbers/to-
tal)
Topical therapy
I: Weighted average 10.7%*
C: Weighted average 2.9%*
I: Clobetasol (Baran 1999;
Baran 1999a)
C: Placebo lacquer
Not assessed -
I: Topical ciclosporin (Cannavo
2003)
C: Maisoil
I: No adverse events were found
C: No adverse events were
found
I: 0.0% (0/8)
C: 0.0% (0/8)
I: 5-Fluorouracil (de Jong
1999)
C: Belanyx® lotion
I: Pain, swelling, discoloura-
tions, inflammation, onycholy-
sis, perforation
C: No adverse events were
found
I: 10.5% (6/57)
C: 0.0% (0/57)
I: Hyaluronic acid and chon-
droitin sulphates (Flori 1994)
C: Placebo
I: No adverse events were found
C: No adverse events were
found
I: 0.0% (0/15)
C: 0.0% (0/15)
I: Tazarotene 0.1% cream (
Rigopoulos 2007)
C: Clobetasol propionate 0.
05% (Rigopoulos 2007)
I: Desquamation, erythema, ir-
ritation
C: Burning on the nail fold skin
I: 18.8% (3/16)
C: 7.1% (1/14)
I: Tazarotene 0.1% gel (Scher
2001)
C: Vehicle gel
I: Peeling, irritation, parony-
chia, and erythema of the prox-
imal nail fold
C: No adverse events were
found
I: 23.8% (5/21)
C: 0.0% (0/10)
I: Calcipotriol (Tzung 2008)
C: Calcipotriol + betametha-
sone dipropionate (Tzung
2008)
I: No adverse events were found
C: No adverse events were
found
I: 0.0% (0/17)
C: 0.0% (0/15)
I: Calcipotriol (Tosti 1998)
C: Betamethasone + salicylic
acid (Tosti 1998)
I: Erythema, irritation, burn-
ing, urticaria
C: Erythema
I: 12.0% (3/25)
C: 14.3% (3/21)
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Table 5. ’% participants with adverse effects’ (Continued)
Systemic therapy
I: Weighted average
(excl Levell 1995) 69.8%*
C: Weighted average
(excl Levell 1995) 60.3%*
I: Methotrexate 15 mg/week (
G m el 2011)
C: Ciclosporin 5 mg/kg (
G m el 2011)
I: Nausea, telogen effluvium.
One had an elevation of liver
transaminase and therefore dis-
continuation of treatment
C: Hypercholesterolaemia, hir-
sutism, menstrual abnormali-
ties, mild pain on the distal part
of nail. Two had an elevation of
creatinine and lipids and there-
fore discontinuation of treat-
ment
I: 22.2% (4/18)
C: 26.3% (5/19)
I: Ustekinumab 45 or 90 mg (
Igarashi 2012)
C: Placebo
I: Such as: nasopharyngitis, in-
creased triglycerides, increased
creatine phosphokinase, sea-
sonal allergy, infections
C: Exacerbation of skin psoria-
sis, infections
I: 97.4% not specific for nail
psoriasis (150/154)
C: 65.6% not specific for nail
psoriasis (21/32)
I: Golimumab 50 and 100 mg
(Kavanaugh 2009)
C: Placebo
I: Mostly infections: upper res-
piratory tract infections, na-
sopharyngitis
C: Mostly upper respiratory
tract infections, headache, and
serious adverse events (not spec-
ified)
I: 65% not specific for nail pso-
riasis (222/343)
C: 59%not specific for nail pso-
riasis (67/113)
I: Ciclosporin (Levell 1995)
C: Topical dithranol 2% to 8%
+ 0.5% salicylic acid + UVB
I: Minimal toxicity
C: Burning
I: Some participants, not spe-
cific for nail psoriasis
C: Some participants, not spe-
cific for nail psoriasis
I: Ciclosporin (Mahrle 1995)
C: Etretinate
I: Mostly gastrointestinal, skin
and mucous membrane symp-
toms, nervous system and psy-
chiatric disorders, general ad-
verse reactions
C: Mostly skin and mucous
membrane symptoms, and gen-
eral adverse reactions
I: 32.1%, not specific for nail
psoriasis (45/140)
C: 57.1%, not specific for nail
psoriasis (40/70)
I: Infliximab (Rich 2008)
C: Placebo
I: Infections, headache, in-
creased hepatic enzymes, fa-
tigue
C: Infections, headache, psori-
asis, pharyngitis
I: 82.0%, not specific for nail
psoriasis (244/298)
C: 71%, not specific for nail
psoriasis (54/76)
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Table 5. ’% participants with adverse effects’ (Continued)
Radiotherapy
I: Weighted average 40.5%*
C: Weighted average 0.0%*
I: Electron beam (Kwang 1995)
C: Placebo
I: Temporary brownish-black
discolourations
C: No adverse events were
found
I: 100.0% (12/12)
C: 0.0% (0/12)
I: Grenz rays (Lindelof 1989)
C: Placebo
I: Slight pigmentation of the
nail fold
C: No adverse events were
found
I: 22.7% (5/22)
C: 0.0% (0/22)
I: Superficial radiotherapy (Yu
1992)
C: ’Sham radiotherapy’
I: No adverse events were found
C: No adverse events were
found
I: 0.0% (0/8)
C: 0.0% (0/8)
*: These are the weighted average of participants with adverse effects with this type of intervention group. The control group consists
of a placebo or active comparison.
I = intervention
C = control
The analysis corresponding to these data are shown in Analysis 4.1.
Table 6. Mean improvement of nail features ≥ 50%
Study Interven-
tion
and con-
trol group
Features
not speci-
fied
Pitting Leukony-
chia
Red spots
lunula
Crum-
bling
Onychol-
ysis
Splin-
ter haem-
orrhages
Oil
drop dis-
coloura-
tions
Subun-
gual hy-
perker-
atosis
Short-term treatment
Cannavo I: Topical
ci-
closporin
70% in
maize oil
(median)
C:
Maisoil
- 100%nsb
no data
- - 100%sb
no data
100%sb
no data
- 75%nsb
no data
83%sb
no data
De Jong I:
1% 5-flu-
orouracil
in Be-
lanyx®
lotion
C: Be-
lanyx®
lotion
- - - - - - - 63%ns,sb
57%ns,sb
-
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Table 6. Mean improvement of nail features ≥ 50% (Continued)
Igarashi I: Ustek-
inumab
45 or 90
mg
C:
Placebo
#
#
- - - - - - - -
Kwang I:
Electron
beam 0.
75 Gy
C:
Placebo
- - - - - - - - X
X
Levell I: Sys-
temic ci-
closporin
2.5 mg/
kg
C: Topi-
cal
dithra-
nol 2% to
8% + 0.
5% sali-
cylic acid
+ UVB
#
#
- - - - - - - -
Lindelof I: Grenz
rays 5Gy
C:
Placebo
#
#
- - - - - - - -
Mahrle I: Sys-
temic ci-
closporin
2.5 mg/
kg
C: Etreti-
nate
#
#
- - - - - - - -
Rigopou-
los
I:
Tazarotene
0.1%
cream
C: Clobe-
tasol pro-
pionate 0.
05%
- 75%ns,sb
67%ns,sb
- - - 58%ns,sb
57%ns,sb
- 85%ns,sb
82%ns,sb
80%ns,sb
66%ns,sb
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Table 6. Mean improvement of nail features ≥ 50% (Continued)
Tosti I: Cal-
cipotriol
C: Be-
tametha-
son
dipropi-
onate 64
mg/g
+ salicylic
acid 0.03
g/g
- - - - - - - - < 50%ns∗
< 50%ns∗
Tzung I: Cal-
cipotriol
0.005%
C: Cal-
cipotriol
0.005% +
be-
tametha-
sone
dipro-
pionate 0.
05%
- - - - - - - Xs
Xs
-
Yu I: Superfi-
cial radio-
therapy
450 cGy
C: ’Sham
radio-
therapy’
#
#
- - - - - - - -
Medium and long-term treatment
Baran
1999
I: Topical
8%
clobetasol
C:
Placebo
lacquer
- - - - - X
no data
- - -
Baran
1999a
I: Topical
8%
clobetasol
C:
Placebo
lacquer
- - - - - X
no data
- - -
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Table 6. Mean improvement of nail features ≥ 50% (Continued)
Flori I:
Hyaluronic
acid +
chon-
droitin
sulphates
C:
Placebo
- - - - - 68.8%
s,sb
< 50%
sb**
- - 70%s,sb
< 50%
sb**
G m
el
I:
Methotrex-
ate 15 mg
C: Ci-
closporin
5 mg/kg
#
#
- - - - - - - -
Igarashi I: Ustek-
inumab
45 or 90
mg
C:
Placebo
#
#
- - - - - - - -
Ka-
vanaugh
I: Goli-
mumab
50 or 100
mg
C:
Placebo
#
#
- - - - - - - -
Rich
∗∗∗(%participantswithcompleteclearance)
I: In-
fliximab5
mg/kg
C:
Placebo/
inflix-
imab
- 56%s
68%s
82%s
82%s
96%s
100%s
67%s
76%s
73%s
78%s
88%s
90%s
81%s
86%s
79%s
84%s
Scher I:
Tazarotene
gel 0.1%
C: Vehi-
cle gel
- Xs
no data
- - - Xs
no data
- - -
This table contains the eight nail features used in the NAPSI score. The percentages are score improvements compared to baseline
at the end of treatment duration. Comparison between studies is difficult, because not all studies assessed all eight features of the
NAPSI. It is unclear if this is an improvement of more or less than 50%.
I = intervention
C = control
S = significant between the two treatment groups
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ns = not significant between the two treatment groups
sb = significant to baseline
nsb = not significant to baseline
# = nail feature was not specified in the trial
X = most improved nail feature in this study, but unknown percentage
*: After 3 months, there was a response of 26.5%ns in the calcipotriol group vs 30.4%ns in the betamethasone group.
**: After 90 days, there was a response of 35.5%sb for onycholysis and 23.8%sb for hyperkeratosis.
*** Rich reported percentage of participants with complete clearance at week 50, not a percentage of score improvement. We have no
data about the improvement of the remaining percentage of participants.
Table 7. Most common nail psoriasis features
Nail matrix Nail bed
Pitting
(Small depressions in surface of the nail plate)
Subungual hyperkeratosis
(Thickening of the nail bed)
Leukonychia
(White areas in the nail plate)
Onycholysis
(Separation of the nail plate from the underlying nail bed)
Red spots in the lunula
(White half-moon area of the nail)
Splinter haemorrhages
(Thin longitudinal dark brown streaks under the nail plate)
Nail plate crumbling
(White depressed (rough) areas of the nail plate)
Oildrop or salmon patch
(Red-brown discolourations under the nail plate)
A P P E N D I C E S
Appendix 1. CENTRAL (Cochrane Library) search strategy
#1 (psoriasis)
#2 MeSH descriptor Psoriasis explode all trees
#3 (#1 OR #2)
#4 (nail*) or (toenail*) or (fingernail*) or (thumbnail*)
#5 MeSH descriptor Nail Diseases explode all trees
#6 MeSH descriptor Nails explode all trees
#7 (ungual or ungueal or unguium ) or (onycholysis) or (paronychia) or (subungual hyperkeratosis)
#8 MeSH descriptor Paronychia explode all trees
#9 (pitting) or (punctate) or (onych* or anonych* or leukonych* or paronych* or pachyonychia)
#10 (#4 OR #5 OR #6 OR #7 OR #8 OR #9)
#11 (#3 AND #10)
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Appendix 2. MEDLINE (OVID) search strategy
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. clinical trials as topic.sh.
6. randomly.ab.
7. trial.ti.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. (animals not (humans and animals)).sh.
10. 8 not 9
11. psoriasis.mp. or exp Psoriasis/
12. psoria$.mp.
13. 11 or 12
14. nail$.mp. or exp Nails/
15. (toenail$ or fingernail$ or thumbnail$).tw.
16. onycholysis.mp.
17. (ungual or ungueal or unguium).mp.
18. paronychia.mp. or exp Paronychia/
19. subungual hyperkeratosis.mp.
20. (pitting or punctate).mp.
21. leukonychia.mp.
22. onych$.mp.
23. (onych$ or anonych$ or leukonych$ or paronych$ or pachyonychia).tw.
24. 21 or 17 or 20 or 15 or 14 or 22 or 18 or 23 or 16 or 19
25. 24 and 13 and 10
Appendix 3. EMBASE (OVID) search strategy
1. random$.mp.
2. factorial$.mp.
3. (crossover$ or cross-over$).mp.
4. placebo$.mp. or PLACEBO/
5. (doubl$ adj blind$).mp.
6. (singl$ adj blind$).mp.
7. (assign$ or allocat$).mp.
8. volunteer$.mp. or VOLUNTEER/
9. Crossover Procedure/
10. Double Blind Procedure/
11. Randomized Controlled Trial/
12. Single Blind Procedure/
13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14. psoriasis.mp. or exp Psoriasis/
15. psoria$.mp. ]
16. 14 or 15
17. nail$.mp. or exp Nails/
18. (toenail$ or fingernail$ or thumbnail$).tw.
19. onycholysis.mp.
20. (ungual or ungueal or unguium).mp.
21. paronychia.mp. or exp Paronychia/
22. subungual hyperkeratosis.mp.
23. (pitting or punctate).mp.
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24. leukonychia.mp.
25. onych$.mp.
26. (onych$ or anonych$ or leukonych$ or paronych$ or pachyonychia).tw.
27. 25 or 21 or 26 or 17 or 20 or 22 or 18 or 24 or 19 or 23
28. 27 and 16 and 13
Appendix 4. LILACS search strategy
((Pt RANDOMIZED CONTROLLED TRIAL OR Pt CONTROLLED CLINICAL TRIAL OR Mh RANDOMIZED CON-
TROLLED TRIALS OR Mh RANDOM ALLOCATION OR Mh DOUBLE-BLIND METHOD OR Mh SINGLE-BLIND
METHOD OR Pt MULTICENTER STUDY) OR ((tw ensaio or tw ensayo or tw trial) and (tw azar or tw acaso or tw placebo or
tw control$ or tw aleat$ or tw random$ or (tw duplo and tw cego) or (tw doble and tw ciego) or (tw double and tw blind)) and tw
clinic$)) ANDNOT ((CT ANIMALS ORMH ANIMALS OR CT RABBITS OR CTMICE ORMH RATS ORMH PRIMATES
OR MH DOGS OR MH RABBITS OR MH SWINE) AND NOT (CT HUMAN AND CT ANIMALS)) [Palavras] and psoriasis
or psoria$ [Palavras]
C O N T R I B U T I O N S O F A U T H O R S
Link with editorial base and co-ordinate contributions from co-authors (PS)
Draft protocol (MV and PS)
Design of search strategies (PS, MV, and AV)
Identify relevant titles and abstracts from searches (AV, NB, and MV)
Obtain copies of trials (AV and NB)
Selection of trials (AV, NB, and MV)
Extract data from trials (AV and NB)
Enter data into RevMan (AV and NB)
Carry out analysis (AV, NB, LH, and PS)
Interpret data (AV, NB, PS, LH, ML, and MP)
Draft final review (AV, NB, PS, LH, ML, and MP)
Update review (AV and PS)
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the Background section, we changed our goal. Instead of creating a ’guideline’ based on the best available evidence, we decided to
review the available evidence, possibly for others to compile guidelines.
In the Methods section, we changed the primary outcome ’Improvement of nail psoriasis in the clinician’s opinion’ to ’Global improve-
ment of nail psoriasis as rated by a clinician’ to make it more readable.
Because of insufficient data and the lack of information required to implement the Methods, we changed the methods of the review. In
our protocol, we had stated our intention to perform a meta-analysis and pool the data. However, we could not fulfil these intentions
because of too much clinical and methodological heterogeneity between the studies. We decided to report the data as qualitative
descriptions, presented in three intervention groups (topical, systemic, and radiotherapy), in accordance with the primary and secondary
outcomes of this review, instead of classification by outcome, as we believe that this is more useful in clinical practice. We presented a
table per treatment with the extracted data of fingernail severity and improvements reported in the studies (Table 4).
In the Types of outcome measures section, to conclude something about the efficacy of the treatment of these heterogeneous trials, we
decided to dichotomise the participants with less, equal, or more than 50% improvement, regardless of which score measurement was
used. Therefore, we proportionally converted the scores to percentage improvement.
We added the following assessments to the Risk of bias in included studies section: selective reporting (reporting bias) and other bias.
In the Measures of treatment effect section, we revised the protocol text where we planned to express the results as risk ratio (RR)
and 95% confidence intervals (CI) for dichotomous outcomes and standardised mean differences (MD) and 95% CI for continuous
outcomes. It was impossible to extract or calculate all relevant data, like the 95% CI or standard deviation (SD). The diversity of study
outcome and design made it impossible to do so.
In the Unit of analysis issues section, we made major changes to make it more readable. We adjusted the protocol text to a more
appropriate one according to the extracted low quality data. Unfortunately, it was not possible to perform meta-analysis. No data of
any proposed analysis was given in the original studies. Therefore, we only focused on the ’internally controlled studies’, ’cross-over
trials’, and ’repeated measurements’. The rest of the protocol text was omitted.
In the Data synthesis section, we decided to dichotomise the variables for a better overview if meta-analysis was not possible. Therefore,
we collected and analysed, where possible, the available data reporting participants with at least 50% nail score improvement and
the ’mean nail score improvement’ per intervention after short- and medium-term treatment duration. We analysed participants with
adverse effects for any treatment.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Antibodies, Monoclonal [therapeutic use]; Cyclosporine [therapeutic use]; Dermatologic Agents [∗therapeutic use]; Methotrexate
[therapeutic use]; Nail Diseases [∗drug therapy; ∗radiotherapy]; Psoriasis [∗drug therapy; ∗radiotherapy]; Quality of Life; Randomized
Controlled Trials as Topic
MeSH check words
Humans
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